U.S. patent application number 14/876345 was filed with the patent office on 2016-01-28 for mlk inhibitors and methods of use.
The applicant listed for this patent is The University of Rochester. Invention is credited to Stephen Dewhurst, Harris A. Gelbard, Val S. Goodfellow, Colin J. Loweth, Torsten Wiemann.
Application Number | 20160024087 14/876345 |
Document ID | / |
Family ID | 42243278 |
Filed Date | 2016-01-28 |
United States Patent
Application |
20160024087 |
Kind Code |
A1 |
Gelbard; Harris A. ; et
al. |
January 28, 2016 |
MLK INHIBITORS AND METHODS OF USE
Abstract
Provided are compounds having an inhibitory effect on Mixed
Lineage Kinases. Also provided are pharmaceutical compositions,
methods of preparing the compounds, synthetic intermediates, and
methods of using the compounds, independently or in combination
with other therapeutic agents, for treating diseases and conditions
which are affected by Mixed Lineage Kinase inhibition. Also
provided are methods of treatment of neuropsychiatric disorders
which comprise the inhibition of Mixed Lineage Kinases.
Inventors: |
Gelbard; Harris A.;
(Pittsford, NY) ; Dewhurst; Stephen; (Rochester,
NY) ; Goodfellow; Val S.; (Encinitas, CA) ;
Loweth; Colin J.; (San Marcos, CA) ; Wiemann;
Torsten; (Encinitas, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The University of Rochester |
Rochester |
NY |
US |
|
|
Family ID: |
42243278 |
Appl. No.: |
14/876345 |
Filed: |
October 6, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14508566 |
Oct 7, 2014 |
9181247 |
|
|
14876345 |
|
|
|
|
13131193 |
Sep 13, 2011 |
8877772 |
|
|
PCT/US2009/065878 |
Nov 25, 2009 |
|
|
|
14508566 |
|
|
|
|
61117950 |
Nov 25, 2008 |
|
|
|
61148755 |
Jan 30, 2009 |
|
|
|
61148778 |
Jan 30, 2009 |
|
|
|
Current U.S.
Class: |
514/211.08 ;
514/234.2; 514/249; 514/253.04; 514/275; 514/278; 514/300; 514/303;
544/117; 544/118; 544/296; 544/331; 544/350; 544/362; 546/113;
546/118; 546/15 |
Current CPC
Class: |
A61P 3/00 20180101; C07D
471/04 20130101; A61P 27/16 20180101; C07D 487/04 20130101; A61P
43/00 20180101; A61P 3/10 20180101; A61P 9/00 20180101; A61P 9/04
20180101; A61P 3/06 20180101; A61P 3/08 20180101; A61K 31/496
20130101; C07D 471/10 20130101; A61K 31/5377 20130101; A61P 25/28
20180101; A61P 3/04 20180101; A61K 31/437 20130101; A61P 13/12
20180101; A61P 27/02 20180101; A61K 31/553 20130101; A61P 5/50
20180101; A61P 7/10 20180101; A61P 1/04 20180101; A61P 25/00
20180101; A61P 1/16 20180101; A61P 19/02 20180101; A61P 9/14
20180101; A61P 25/16 20180101; A61K 31/438 20130101; A61K 45/06
20130101; A61P 19/06 20180101; A61P 25/04 20180101; A61P 25/24
20180101; A61P 35/00 20180101; A61K 31/444 20130101; A61P 9/10
20180101; A61P 25/18 20180101; A61K 31/506 20130101; A61P 19/08
20180101; A61P 9/12 20180101; A61P 37/02 20180101; A61P 29/00
20180101; A61K 31/4985 20130101; A61K 31/437 20130101; A61K 2300/00
20130101 |
International
Class: |
C07D 471/04 20060101
C07D471/04; A61K 31/553 20060101 A61K031/553; A61K 31/496 20060101
A61K031/496; A61K 31/438 20060101 A61K031/438; C07D 487/04 20060101
C07D487/04; A61K 31/4985 20060101 A61K031/4985; A61K 31/5377
20060101 A61K031/5377; C07D 471/10 20060101 C07D471/10; A61K 31/437
20060101 A61K031/437; A61K 31/506 20060101 A61K031/506 |
Goverment Interests
[0002] This research has been funded in part by NIH Grant No: NIH
P01 3MH64570.
Claims
1. A compound of structural Formula II ##STR00224## or a salt
thereof, wherein: dashed lines indicate that a second bond may
alternatively be present or absent; X.sub.1 is chosen from CH and
N; X.sub.2 is chosen from C and N; Y.sub.1, Y.sub.2, and Y.sub.3
are independently chosen from a bond, lower alkyl, lower carboxyl,
and lower heteroalkyl; Y.sub.4 is chosen from --(CH.sub.2).sub.m,
C(O), --(CH.sub.2).sub.mO--, and --(CH.sub.2).sub.mN--; m is an
integer from 0 to 2; R.sub.1, R.sub.2, and R.sub.3 are
independently chosen from lower alkyl, lower alkenyl, lower
alkynyl, lower haloalkyl, lower cycloalkyl, heterocycloalkyl, aryl,
heteroaryl, acyl, amido, amino, alkoxy, hydroxy, cyano, and nitro,
any of which may be optionally substituted; or R.sub.1 and R.sub.2
may each additionally be heteroalkyl, and may be joined together
such that R.sub.1 and R.sub.2 together form an alkylene,
alkenylene, or heteroalkyl bridge comprising from 3 to 5 atoms,
which may be optionally substituted; R.sub.4 is chosen from
hydrogen, (O), and (S); R.sub.5 is chosen from hydrogen, hydroxy,
cyano, lower alkyl, lower cycloalkyl, and lower alkoxy, any of
which may be optionally substituted; R.sub.13 is chosen from
hydrogen, halogen, hydroxy, cyano, nitro, lower alkyl, lower
cycloalkyl, lower cycloalkylalkyl, and lower alkoxy, any of which
may be optionally substituted; and additionally, R.sub.13 and
R.sub.3 may be joined together to form a lower spiro-cycloalkyl or
spiro-phenyl comprising from 3 to 6 atoms, which may be optionally
substituted; and R.sub.14 is chosen from null, lower cycloalkyl,
lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which
may be optionally substituted.
2. The compound as recited in claim 1, wherein R.sub.4 is (O), the
second bond linking R.sub.4 and the fused bicyclic core is present,
and the second bond in the five-membered portion of the fused
bicyclic core is absent.
3. The compound as recited in claim 1, wherein R.sub.4 is hydrogen,
the second bond linking R.sub.4 and the fused bicyclic core is
absent, and the second bond in the five-membered portion of the
fused bicyclic core is present.
4. The compound as recited in claim 1, wherein compounds have
structural Formula III ##STR00225## wherein: dashed lines indicate
that a second bond may alternatively be present or absent; X.sub.1
and X.sub.2 are independently chosen from CH and N; Y.sub.3 is
chosen from a bond, lower alkyl, lower carboxyl, and lower
heteroalkyl; Y.sub.4 is chosen from C(O), --(CH.sub.2).sub.m--,
--(CH.sub.2).sub.mO--, and --(CH.sub.2).sub.mN--; m is an integer
from 0 to 1; R.sub.2 and R.sub.3 are independently chosen from
lower cycloalkyl, heterocycloalkyl, lower aryl, and lower
heteroaryl, any of which may be optionally substituted; R.sub.4 is
chosen from hydrogen, (O), and (S); R.sub.14 is chosen from null,
lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower
heteroaryl, any of which may be optionally substituted.
5. The compound as recited in claim 4, having a structural Formula
chosen from Formula IV and Formula V: ##STR00226## or a salt
thereof, wherein X.sub.1 and X.sub.2 are independently chosen from
CH and N; Y.sub.3 is chosen from a bond, lower alkyl, lower
carboxyl, and lower heteroalkyl; Y.sub.4 is chosen from C(O),
--(CH.sub.2).sub.m--, --(CH.sub.2).sub.mO--, and
--(CH.sub.2).sub.mN--; m is an integer from 0 to 1; R.sub.2 and
R.sub.3 are independently chosen from lower cycloalkyl, lower
heterocycloalkyl, lower aryl, and lower heteroaryl, any of which
may be optionally substituted; and R.sub.14 is chosen from null,
lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower
heteroaryl, any of which may be optionally substituted.
6. The compound as recited in claim 5, wherein Y.sub.3 is chosen
from a bond, C(O), and lower alkyl.
7. The compound as recited in claim 6, wherein R.sub.3 is chosen
from lower cycloalkyl, phenyl, and lower heteroaryl, any of which
may be optionally substituted.
8. The compound as recited in claim 7, wherein R.sub.2 is chosen
from phenyl and lower heteroaryl, any of which may be optionally
substituted.
9. The compound as recited in claim 7, wherein R.sub.2 is chosen
from phenyl, 6-membered monocyclic heteroaryl, and 5/6-fused
bicyclic heteroaryl, any of which may be optionally
substituted.
10. The compound as recited in claim 9, wherein R.sub.2 is chosen
from phenyl, pyridinyl, pyrimidinyl, and indolyl, any of which may
be optionally substituted.
11. The compound as recited in claim 10, wherein R.sub.2 is
substituted with one or more substituents chosen from halogen,
hydroxy, lower amino, C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3
alkyl.
12. The compound as recited in claim 11, wherein R.sub.2 is
substituted with one or more substituents chosen from fluorine,
hydroxy, NH.sub.3, NH(CH.sub.3), N(CH.sub.3).sub.2, methoxy, and
methyl.
13. The compound as recited in claim 9, wherein compounds have a
structural Formula chosen from Formula VI, Formula VII, Formula
VIII, and Formula IX: ##STR00227## or a salt thereof, wherein
Y.sub.3 is chosen from a bond, lower alkyl, lower carboxyl, and
lower heteroalkyl; Y.sub.4 is chosen from C(O),
--(CH.sub.2).sub.m--, --(CH.sub.2).sub.mO--, and
--(CH.sub.2).sub.mN--; m is an integer from 0 to 1; R.sub.2 is
chosen from phenyl, 6-membered monocyclic heteroaryl, and 5/6-fused
bicyclic heteroaryl, any of which may be optionally substituted;
R.sub.3 is chosen from lower cycloalkyl, phenyl, and lower
heteroaryl, any of which may be optionally substituted; R.sub.14 is
chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl,
and lower heteroaryl, any of which may be optionally
substituted.
14. The compound as recited in claim 13, wherein R.sub.2 is chosen
from phenyl, pyridinyl, pyrimidinyl, and indolyl, any of which may
be optionally substituted.
15. The compound as recited in claim 14, wherein Y.sub.4 is chosen
from C(O), O, N, and --CH.sub.2--.
16. The compound as recited in claim 13, wherein R.sub.2 is chosen
from ##STR00228## wherein u is an integer from 0 to 3; Y.sub.4 is
chosen from C(O), --(CH.sub.2).sub.m--, --(CH.sub.2).sub.mO--, and
--(CH.sub.2).sub.mN--; m is an integer from 0 to 1; R.sub.14 is
chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl,
and lower heteroaryl, any of which may be optionally substituted;
and each R.sub.15 is independently chosen from halogen, hydroxy,
cyano, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl,
C.sub.2-C.sub.4 alkynyl, C.sub.1-C.sub.4 haloalkyl, C.sub.1-C.sub.3
alkoxy, C.sub.1-C.sub.3 haloalkoxy, lower amino, lower amido, lower
sulfonamido, and lower sulfonyl.
17. The compound as recited in claim 16, wherein R.sub.14 is chosen
from null, lower heterocycloalkyl, phenyl, and monocyclic lower
heteroaryl, any of which may be optionally substituted.
18. The compound as recited in claim 17, wherein Y.sub.4 is
--(CH.sub.2).sub.m--; m is 0; R.sub.14 is null; u is an integer
from 1 to 3; and each R.sub.15 is independently chosen from
fluorine, hydroxy, NH.sub.2, NH(CH.sub.3), N(CH.sub.3).sub.2,
NS(O).sub.2CH.sub.3, methoxy, and methyl.
19. The compound as recited in claim 17, wherein Y.sub.4 is
--(CH.sub.2).sub.m--; m is 1; R.sub.14 is chosen from null, lower
cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl,
any of which may be optionally substituted; u is an integer from 0
to 2; and each R.sub.15 is independently chosen from fluorine,
hydroxy, NH.sub.2, NH(CH.sub.3), N(CH.sub.3).sub.2,
NS(O).sub.2CH.sub.3, methoxy, and methyl.
20. The compound as recited in claim 17, wherein each R.sub.15 is
independently chosen from halogen, hydroxy, lower amino
C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3 alkyl.
21. The compound as recited in claim 20, wherein Y.sub.4 is chosen
from C(O), O, N, and --CH.sub.2--.
22. The compound as recited in claim 21, wherein Y.sub.3 is chosen
from a bond and lower alkyl.
23. The compound as recited in claim 22, wherein R.sub.14 is chosen
from null and lower heterocycloalkyl, either of which may be
optionally substituted.
24. The compound as recited in claim 23, wherein Y.sub.3 is chosen
from a bond and methyl.
25. The compound as recited in claim 24, wherein R.sub.3 is
substituted with one or more substituents chosen from halogen,
hydroxy, lower amino, lower amido, lower phenylamido, lower
phenylalkylamido, lower heterocycloalkyl, lowerheterocycloalkyl,
loweralkylheterocycloalkyl, C.sub.1-C.sub.3 alkoxy and
C.sub.1-C.sub.3 alkyl.
26. The compound as recited in claim 25, wherein Y.sub.4 is
--CH.sub.2--.
27. The compound as recited in claim 26, wherein R.sub.3 is chosen
from benzothiazolyl, pyrrolopyridinyl, indanyl, cyclopropyl,
cyclopentyl, phenyl, pyridinyl, pyrimidinyl, and indolyl, any of
which may be optionally substituted.
28. The compound as recited in claim 27, wherein Y.sub.3 is a
bond.
29. The compound as recited in claim 28, each R.sub.15 is
independently chosen from fluorine, hydroxy, NH.sub.2,
NH(CH.sub.3), N(CH.sub.3).sub.2, methoxy, and methyl.
30. The compound as recited in claim 29, wherein R.sub.3 is
substituted with one or more substituents chosen from fluorine,
chlorine, hydroxy, NH.sub.2, NH(CH.sub.3), N(CH.sub.3).sub.2,
C(O)NH.sub.2, C(O)NHCH.sub.3, morpholino, piperazinyl,
methylpiperazinyl, acetamido, methylacetamido, methylpropionamido,
phenylacetamidomethylene, benzamidomethylene,
phenylpropanamidomethylene, methoxy and methyl.
31. A compound of structural Formula III ##STR00229## or a salt
thereof, wherein: dashed lines indicate that a second bond may
alternatively be present or absent; X.sub.1 and X.sub.2 are
independently chosen from CH and N; Y.sub.3 is a bond; Y.sub.4 is
chosen from C(O), CH.sub.2, CHF, and CF.sub.2; R.sub.2 is chosen
from phenyl and 6-membered monocyclic heteroaryl, either of which
may be optionally substituted; R.sub.3 is optionally substituted
bicyclic heteroaryl; R.sub.4 is chosen from hydrogen, (O), and (S);
R.sub.14 is optionally substituted monocyclic heterocycloalkyl.
32. The compound as recited in claim 31, wherein R.sub.3 is an
optionally substituted 5/6-fused bicyclic heteroaryl.
33. The compound as recited in claim 32, wherein Y.sub.4 is
CH.sub.2.
34. The compound as recited in claim 33, wherein R.sub.14 is
optionally substituted piperazinyl.
35. The compound as recited in claim compound chosen from Examples
1 to 167.
36. A compound as recited in claim 1 for use as a medicament.
37. A compound as recited in claim 1 for use as a medicament for
the treatment of an MLK-mediated disease.
38. The compound as recited in claim 37, for use as a medicament
for the treatment of an MLK3-mediated disease.
39. The compound as recited in claim 38, wherein said disease is
chosen from diabetes mellitus, hyperglycemia, retinopathy,
nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout
and diabetic foot disease, insulin resistance, metabolic syndrome,
hyperinsulinemia, hypertension, hyperuricemia, obesity, edema,
dyslipidemia, chronic heart failure, atherosclerosis, peripheral
inflammation, cancer and hepatitis.
40. The use of a compound as recited in claim 1 in the manufacture
of a medicament for the treatment of an MLK-mediated disease.
41. The use as recited in claim 40, wherein said MLK is MLK3.
42. The use as recited in claim 41, wherein said disease is chosen
from diabetes mellitus, hyperglycemia, retinopathy, nephropathy,
neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic
foot disease, insulin resistance, metabolic syndrome,
hyperinsulinemia, hypertension, hyperuricemia, obesity, edema,
dyslipidemia, chronic heart failure, atherosclerosis, peripheral
inflammation, cancer and hepatitis.
43. A pharmaceutical composition comprising a compound as recited
in claim 1 together with a pharmaceutically acceptable carrier.
44. A pharmaceutical composition comprising a compound as recited
in claim 43 together with a pharmaceutically acceptable
carrier.
45. A method of inhibition of MLK comprising contacting MLK with a
compound as recited in claim 1.
46. The method as recited in claim 45, wherein said MLK is
MLK3.
47. The method as recited in claim 46 wherein said inhibition is
selective over other kinases.
48. A method of treatment of a MLK-mediated disease comprising the
administration of a therapeutically effective amount of a compound
as recited in claim 1 to a patient in need thereof.
49. The method as recited in claim 48 wherein said disease is an
inflammatory disease or a metabolic disease.
50. The method as recited in claim 49 wherein said disease is
chosen from diabetes mellitus, hyperglycemia, retinopathy,
nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout
and diabetic foot disease, insulin resistance, metabolic syndrome,
hyperinsulinemia, hypertension, hyperuricemia, obesity, edema,
dyslipidemia, chronic heart failure, atherosclerosis, and
peripheral inflammation.
51. The method as recited in claim 50 wherein said disease is an
autoimmune disease.
52. The method as recited in claim 51 wherein said disease is
chosen from cancer and hepatitis.
53. A method of treatment of a MLK-mediated disease comprising the
administration of: a. a therapeutically effective amount of a
compound as recited in claim 1; and b. another therapeutic
agent.
54. A method of achieving an effect in a patient comprising the
administration of a therapeutically effective amount of a compound
as recited in claim 1 to a patient, wherein the effect is chosen
from: increased survival of heart cells; suppression of
neuroinflammation or peripheral inflammation; suppression of
activation of immune cells; suppression of proliferation of
hepatocytes following injury; and suppression of proliferation of
cancer cells.
55. The method as recited in claim 54, wherein said immune cells
are chosen from monocytes, macrophages and microglia.
56. A method of treatment of a neuropsychiatric disorder in a
patient, comprising the step of administering to said patient an
MLK inhibitor.
57. The method as recited in claim 56, wherein said MLK is
MLK3.
58. A method of treatment of a neuropsychiatric in a patient,
comprising the step of administering to said patient a compound as
recited in claim 1.
59. The method as recited in claim 58 wherein said disorder a
psychological disorder.
60. The method as recited in claim 59 wherein said disease is
chosen from depression, bipolar disorder, and post-traumatic stress
disorder (PTSD).
61. The method as recited in claim 58 wherein said disorder is a
traumatic brain injury.
62. The method as recited in claim 61 wherein said traumatic brain
injury is stroke.
63. The method as recited in claim 58 wherein said disorder is
chosen from Alzheimer's Disease (AD), Parkinson's Disease, and HIV
associated neurocognitive disorder (HAND).
64. The method as recited in claim 58 wherein said disorder is a
neurologic disorder of hearing or vision.
65. The method as recited in claim 64 wherein said disorder is
chosen from ototoxicity, hearing loss, acute injury to the inner
ear, acoustic trauma, and injury resulting from blast noise.
66. The method as recited in claim 2, additionally comprising the
administration of a second therapeutic agent.
67. The method as recited in claim 66 wherein said second
therapeutic agent is a selective serotonin reuptake inhibitor
(SSRI).
68. The method as recited in claim 66 wherein said second
therapeutic agent is CRP 1347.
69. A method of achieving an effect in a patient comprising the
administration of a therapeutically effective amount of a compound
as recited in claim 1 to a patient, wherein the effect is chosen
from: increased survival of cells of the nervous system, cochlear
cells, vestibular cells or retinal cells; promotion of
neurogenesis; promotion of synaptogenesis; prevention or reduction
of neuronal damage; and restoration or improvement of neuronal
function.
70. A method of achieving an effect in a patient comprising the
administration of a therapeutically effective amount of a compound
as recited in claim 1 to a patient, wherein the effect is chosen
from: increased survival of cells of the nervous system, cochlear
cells, vestibular cells or retinal cells; increased survival of
heart cells; promotion of neurogenesis; promotion of
synaptogenesis; prevention or reduction of neuronal damage;
restoration or improvement of neuronal function; suppression of
neuroinflammation or peripheral inflammation; suppression of
activation of immune cells; suppression of proliferation of
hepatocytes following injury; and suppression of proliferation of
cancer cells.
71. The method as recited in claim 70, wherein said immune cells
are chosen from monocytes, macrophages and microglia.
Description
[0001] This application claims the benefit of U.S. Provisional
Applications No. 61/117,950, filed Nov. 25, 2008, No. 61/148,755
filed Jan. 30, 2009, and No. 61/148,778 filed Jan. 30, 2009, all of
which are incorporated by reference as if written herein in their
entireties.
[0003] Mammalian protein kinases are involved in the regulation of
important cellular functions. Due to the fact that dysfunctions in
protein kinase activity have been associated with several diseases
and disorders, protein kinases are targets for drug
development.
[0004] Mixed lineage kinases (MLKs) are MAPK kinase kinases that
target JNK and p38 MAPK for activation in response to diverse
stimuli that stress cells. As a result, the MLKs regulate a broad
range of cellular processes. MLK3 is the most widely expressed MLK
family member and is present in neurons. It is activated by GTPases
of the Ras superfamily, such as Cdc42 and Rac, which trigger
protein dimerization via a leucine zipper interface, resulting in
auto-phosphorylation at Thr277 and Ser281 within the protein
activation loop and subsequent activation of the enzyme.
[0005] Preclinical studies of the mixed lineage kinase (MLK)
inhibitor CEP1347 have shown that this agent can protect neurons
against a considerable range of insults, including exposure to the
Alzheimer's peptide, A.beta.. Studies using the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsonism
have demonstrated the efficacy of CEP1347 in treating motor
deficits and neuronal degeneration, and CEP1347-mediated
neuroprotection has also been observed in an in vitro model for
Parkinson's Disease, using methamphetamine-exposed human
mesencephalic-derived neurons. This finding suggests that CEP1347
might also be protective in the context of neurologic complications
such as HIV-associated dementia (HAD). In fact, Bodner et al. have
shown that CEP1347 can protect primary rat hippocampal neurons as
well as dorsal root ganglion neurons from the otherwise lethal
effects of exposure to HIV-1 gp120. It has been determined that
CEP1347 mediates this effect by inhibiting the activity of the
mixed lineage kinase (MLK) family.
[0006] Maggirwar et al. recently examined the effect of Tat and
gp120 on MLK3. Tat and gp120 were shown to induce
autophosphorylation of MLK3 in primary rat neurons and this was
abolished by the addition of CEP1347. These studies suggest that
the normal function of MLK3 is compromised by HIV-1 neurotoxins,
resulting in the downstream signaling events that result in
neuronal death and monocyte activation (with release of
inflammatory cytokines). Most recently, Eggert et al. have
demonstrated that CEP1347 is neuroprotective in an in vivo model of
HIV-1 infection, reversing microglial activation and restoring
normal synaptic architecture, as well as restoring macrophage
secretory profiles to a trophic vs. toxic phenotype in response to
HIV-1 infection. Eggert, D., Gorantla, S., Poluekova, L., Dou, H.
Schifitto, G., Maggirwar, S. B., Dewhurst. S., Gelbard, H. A. and
H. E. Gendelman: "Neuroprotective Activities of CEP-1347 in Models
of HIV-1 Encephalitis," J. Immunol. (in press).]
[0007] Recently, MLK3 has been shown to drive the production of the
HIV virus. As a result, several lines of evidence now support that
an inhibitor of MLK3 could serve as a treatment for numerous
neurological conditions, including neuroAIDS. CEP1347 does not have
ideal pharmacokinetic properties, which could potentially affect
its ability to gain entry to the CNS. Other small molecule MLK3
inhibitors are needed that have improved pharmacokinetic and brain
penetrating properties.
[0008] An inhibitor of MLK3 could also find use in the treatment of
psychological disorders. Depression is a complex disease that has a
multifactorial etiology. This may include genetic factors, changes
in normal neuronal signaling, and reduced levels of certain
neurotrophins (such as brain-derived neurotrophic factor, BDNF)
within particular regions of the brain (Krishnan, V., and E. J.
Nestler. 2008. Nature 455:894-902). Treatments for depression
include drugs such as SSRIs, as well as cognitive and behavioral
therapy ("talk therapy") and other inventions such as exercise.
Interestingly, SSRIs and exercise share the common property that
they promote neurogenesis; this is thought to be related to their
anti-depressive effects because of effects on neuronal plasticity
and remodeling (Krishnan, supra).
[0009] Pharmacologic blockade of mixed lineage kinase 3 (MLK3) has
been shown to result in activation of neurotrophin-mediated
signaling pathways, and increased expression of neurotrophin
receptors--resulting in enhanced responsiveness to endogenous
neurotrophins, including BDNF (Wang, L. H., A. J. Paden, and E. M.
Johnson, Jr. 2005. J Pharmacol Exp Ther 312:1007-19). MLK3
inhibitors have also been shown to increase production of BDNF
itself (Conforti, P. et al. 2008. Mol Cell Neurosci 39:1-7).
[0010] Combined treatment with SSRIs and MLK3 inhibitors could
result in the synergistic promotion of neurogenesis, due to the
neurotrophin-sensitizing effects of MLK3 inhibitors and their
ability to directly upregulate BDNF (Wang and Conforti, supra).
Increase of the therapeutic effectiveness of SSRIs (and possibly
talk therapy and exercise also) could also result if the compounds
were coadministered.
[0011] Exposure to MLK3 inhibitors may also compensate for lowered
BDNF levels in hippocampus of persons with depression, thereby
alleviating depression (based on the "BDNF hypothesis") (Krishnan,
supra).
[0012] Disclosed herein are compounds having an inhibitory effect
on MLK1, MLK2, and MLK3. In a related aspect, also disclosed herein
are compounds of Formula I as described below. Thus, provided
herein are novel compounds that can be used for therapeutic methods
involving modulation of MLKs. Also provided are pharmaceutical
compositions, methods of preparing the compounds, synthetic
intermediates, and methods of using the compounds, independently or
in combination with other therapeutic agents, for treating diseases
and conditions affected by MLK inhibition.
[0013] In one aspect, the present invention provides for compounds
of Formula I:
##STR00001##
wherein:
[0014] dashed lines indicate that a second bond may alternatively
be present or absent;
[0015] X.sub.1 is chosen from CH and N;
[0016] X.sub.2 is chosen from C and N;
[0017] Y.sub.1 is
--(CR.sub.6aR.sub.6b).sub.m--Z.sub.1--(CR.sub.7aR.sub.7b).sub.n--;
[0018] Y.sub.2 is
--(CR.sub.8aR.sub.8b).sub.p--Z.sub.2--(CR.sub.9aR.sub.9b).sub.q--;
[0019] Y.sub.3 is
--(CR.sub.10aR.sub.10b).sub.r--Z.sub.3--(CR.sub.11aR.sub.11b).sub.s--;
[0020] Y.sub.4 is --(CH.sub.2).sub.1--Z.sub.4--;
[0021] Z.sub.1, Z.sub.2, and Z.sub.3, are each independently chosen
from a bond, O, S, S(O), S(O).sub.2, N(R.sub.12), C(O),
C(O)N(R.sub.12), N(R.sub.12)C(O), S(O).sub.2N(R.sub.12), and
N(R.sub.12)S(O).sub.2;
[0022] Z.sub.4 is chosen from a bond, 0, and N;
[0023] m, n, p, q, r, and s are each independently an integer from
0 to 6;
[0024] t is an integer from 0 to 2;
[0025] R.sub.1, R.sub.2, and R.sub.3 are independently chosen from
hydrogen, halo, lower alkyl, lower alkenyl, lower alkynyl, lower
haloalkyl, lower cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
acyl, amido, amino, alkoxy, hydroxy, cyano, and nitro, any of which
may be optionally substituted; or R.sub.1 and R.sub.2 may each
additionally be heteroalkyl, and may be joined together such that
R.sub.1 and R.sub.2 together form an alkylene, alkenylene, or
heteroalkyl bridge comprising from 3 to 5 atoms, which may be
optionally substituted;
[0026] R.sub.4 is chosen from hydrogen, (O), (S), halogen, hydroxy,
cyano, nitro, lower alkyl, lower alkenyl, lower alkynyl, lower
cycloalkyl, lower cycloalkyloxy, lower thioalkoxy, lower
heterocycloalkyl, aryl, lower aralkyl, lower heteroaryl, lower
heteroaralkyl, amido, acyl, amino, and lower alkoxy, any of which
may be optionally substituted; or R.sub.3 and R.sub.4 may each
additionally be heteroalkyl, and may be joined together such that
R.sub.1 and R.sub.2 together form an alkylene, alkenylene, or
heteroalkyl bridge comprising from 3 to 5 atoms, which may be
optionally substituted;
[0027] R.sub.5 and R.sub.13 are each independently chosen from
hydrogen, halogen, hydroxy, cyano, nitro, lower alkyl, lower
alkene, lower alkyne, lower aryl, lower arylalkyl, lower
cycloalkyl, lower cycloalkylalkyl, lower heteroaryl, lower
heteroarylalkyl, lower heterocycloalkyl, lower
heterocycloalkylalkyl, and lower alkoxy, any of which may be
optionally substituted; and additionally, R.sub.13 and R.sub.3 may
be joined together to form a lower spiro-cycloalkyl or spiro-phenyl
comprising from 3 to 6 atoms, which may be optionally
substituted;
[0028] R.sub.6a, R.sub.6b, R.sub.7a, R.sub.7b, R.sub.8a, R.sub.8b,
R.sub.9a, R.sub.9b, R.sub.10a, R.sub.10b, R.sub.11a, R.sub.11b, and
R.sub.12 are each independently chosen from a bond, hydrogen,
halogen, hydroxy, C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3 alkyl;
and
[0029] R.sub.14 is chosen from null, lower cycloalkyl, lower
heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be
optionally substituted.
[0030] When, for example, Y.sub.1 is
--(CR.sub.6aR.sub.6b).sub.m--Z.sub.1--(CR.sub.7R.sub.7b).sub.n--,
and m and n are both 0, and Z.sub.1 is a bond, then Y.sub.1
collapses to a direct bond linking the parent ring system with
R.sub.1. This applies to all similar constructions used herein,
including Y.sub.2 and Y.sub.3. Also, when for example Y.sub.1 is
--(CR.sub.6aR.sub.6b).sub.m--Z.sub.1--(CR.sub.7aR.sub.7b).sub.n--,
the rightmost portion of Y.sub.1 attaches to the parent
molecule.
[0031] In certain embodiments, Y.sub.1, Y.sub.2, Y.sub.3, and
Y.sub.4 are no more than 6 atoms in length.
[0032] In certain embodiments, R.sub.4 is chosen from hydrogen,
(O), and (S).
[0033] In certain embodiments, R.sub.4 is (O), the second bond
linking R.sub.4 and the fused bicyclic core is present, and the
second bond in the five-membered portion of the fused bicyclic core
is absent.
[0034] In certain embodiments, R.sub.4 is hydrogen, the second bond
linking R.sub.4 and the fused bicyclic core is absent, and the
second bond in the five-membered portion of the fused bicyclic core
is present.
[0035] In certain embodiments,
[0036] X.sub.1 is CH; and
[0037] X.sub.2 is C.
[0038] In certain embodiments,
[0039] X.sub.1 is N; and
[0040] X.sub.2 is N.
[0041] In certain embodiments,
[0042] X.sub.1 is CH; and
[0043] X.sub.2 is N.
[0044] In certain embodiments,
[0045] X.sub.1 is N; and
[0046] X.sub.2 is C.
[0047] In certain embodiments,
[0048] m and n are both 0;
[0049] Z.sub.1 is a bond; and
[0050] R.sub.1 and R.sub.5 are both hydrogen.
[0051] In certain embodiments,
[0052] p and r are each independently an integer from 0 to 3;
[0053] q and s are each 0; and
[0054] Z.sub.2 and Z.sub.3 are each independently chosen from a
bond and 0.
[0055] In certain embodiments, R.sub.6a, R.sub.6b, R.sub.7a,
R.sub.7b, R.sub.8a, R.sub.8b, R.sub.9a, R.sub.9b, R.sub.10a,
R.sub.10b, R.sub.11a, R.sub.11b, and R.sub.12 are all hydrogen.
[0056] In certain embodiments, compounds have structural Formula
II
##STR00002##
[0057] wherein:
[0058] dashed lines indicate that a second bond may alternatively
be present or absent;
[0059] X.sub.1 is chosen from CH and N;
[0060] X.sub.2 is chosen from C and N;
[0061] Y.sub.1, Y.sub.2, and Y.sub.3 are independently chosen from
a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
[0062] Y.sub.4 is chosen from --(CH.sub.2).sub.m, C(O),
--(CH.sub.2).sub.mO--, and --(CH.sub.2).sub.mN--;
[0063] m is an integer from 0 to 2;
[0064] R.sub.1, R.sub.2, and R.sub.3 are independently chosen from
lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, lower
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, acyl, amido, amino,
alkoxy, hydroxy, cyano, and nitro, any of which may be optionally
substituted; or R.sub.1 and R.sub.2 may each additionally be
heteroalkyl, and may be joined together such that R.sub.1 and
R.sub.2 together form an alkylene, alkenylene, or heteroalkyl
bridge comprising from 3 to 5 atoms, which may be optionally
substituted;
[0065] R.sub.4 is chosen from hydrogen, (O), and (S);
[0066] R.sub.5 is chosen from hydrogen, hydroxy, cyano, lower
alkyl, lower cycloalkyl, and lower alkoxy, any of which may be
optionally substituted;
[0067] R.sub.13 is chosen from hydrogen, halogen, hydroxy, cyano,
nitro, lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, and
lower alkoxy, any of which may be optionally substituted; and
additionally, R.sub.13 and R.sub.3 may be joined together to form a
lower spiro-cycloalkyl or spiro-phenyl comprising from 3 to 6
atoms, which may be optionally substituted; and
[0068] R.sub.14 is chosen from null, lower cycloalkyl, lower
heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be
optionally substituted.
[0069] In certain embodiments, compounds have structural Formula
III
##STR00003##
wherein:
[0070] dashed lines indicate that a second bond may alternatively
be present or absent;
[0071] X.sub.1 and X.sub.2 are independently chosen from CH and
N;
[0072] Y.sub.3 is chosen from a bond, lower alkyl, lower carboxyl,
and lower heteroalkyl;
[0073] Y.sub.4 is chosen from C(O), --(CH.sub.2).sub.m--,
--(CH.sub.2).sub.mO--, and --(CH.sub.2).sub.mN--;
[0074] m is an integer from 0 to 1;
[0075] R.sub.2 and R.sub.3 are independently chosen from lower
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, any of which may be
optionally substituted;
[0076] R.sub.4 is chosen from hydrogen, (O), and (S);
[0077] R.sub.13 is chosen from hydrogen, lower alkyl, lower
cycloalkyl, lower cycloalkylalkyl, and lower alkoxy, any of which
may be optionally substituted;
[0078] R.sub.14 is chosen from null, lower cycloalkyl, lower
heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be
optionally substituted.
[0079] In certain embodiments, compounds have a structural Formula
chosen from Formula IV and Formula V:
##STR00004##
wherein:
[0080] X.sub.1 and X.sub.2 are independently chosen from CH and
N;
[0081] Y.sub.3 is chosen from a bond, lower alkyl, lower carboxyl,
and lower heteroalkyl;
[0082] Y.sub.4 is chosen from C(O), --(CH.sub.2).sub.m--,
--(CH.sub.2).sub.mO--, and --(CH.sub.2).sub.mN--;
[0083] m is an integer from 0 to 1;
[0084] R.sub.2 and R.sub.3 are independently chosen from lower
cycloalkyl, lower heterocycloalkyl, lower aryl, and lower
heteroaryl, any of which may be optionally substituted; and
[0085] R.sub.14 is chosen from null, lower cycloalkyl, lower
heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be
optionally substituted.
[0086] In certain embodiments, compounds have a structural Formula
chosen from Formula VI, Formula VII, Formula VIII, and Formula
IX:
##STR00005##
wherein
[0087] Y.sub.3 is chosen from a bond, lower alkyl, lower carboxyl,
and lower heteroalkyl;
[0088] Y.sub.4 is chosen from C(O), --(CH.sub.2).sub.m--,
--(CH.sub.2).sub.mO--, and --(CH.sub.2).sub.mN--;
[0089] m is an integer from 0 to 1;
[0090] R.sub.2 is chosen from phenyl, 6-membered monocyclic
heteroaryl, and 5/6-fused bicyclic heteroaryl, any of which may be
optionally substituted;
[0091] R.sub.3 is chosen from lower cycloalkyl, phenyl, and lower
heteroaryl, any of which may be optionally substituted;
[0092] R.sub.14 is chosen from null, lower cycloalkyl, lower
heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be
optionally substituted.
[0093] In certain embodiments, R.sub.2 and R.sub.3 are each
independently chosen from lower cycloalkyl, lower aryl, and
monocyclic or bicyclic heteroaryl, any of which may be optionally
substituted.
[0094] In certain embodiments, R.sub.2 is substituted with one or
more substituents chosen from halogen, hydroxy, lower amino,
C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3 alkyl.
[0095] In further embodiments, R.sub.2 is chosen from phenyl and
lower heteroaryl, any of which may be optionally substituted.
[0096] In further embodiments, R.sub.2 is chosen from phenyl,
6-membered monocyclic heteroaryl, and 5/6-fused bicyclic
heteroaryl, any of which may be optionally substituted.
[0097] In further embodiments, R.sub.2 is chosen from phenyl,
pyridinyl, pyrimidinyl, and indolyl, any of which may be optionally
substituted.
[0098] In further embodiments, R.sub.2 is substituted with one or
more substituents chosen from fluorine, hydroxy, NH.sub.2,
NH(CH.sub.3), N(CH.sub.3).sub.2, methoxy, and methyl.
[0099] In further embodiments, R.sub.2 is optionally substituted
phenyl.
[0100] In further embodiments, R.sub.2 is chosen from
##STR00006##
[0101] wherein
[0102] u is an integer from 0 to 3;
[0103] Y.sub.4 is chosen from C(O), --(CH.sub.2).sub.m--,
--(CH.sub.2).sub.mO--, and --(CH.sub.2).sub.mN--;
[0104] m is an integer from 0 to 1;
[0105] R.sub.14 is chosen from null, lower cycloalkyl, lower
heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be
optionally substituted; and
[0106] each R.sub.15 is independently chosen from halogen, hydroxy,
C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4
alkynyl, lower amino, lower amido, lower sulfonamido, and lower
sulfonyl.
[0107] In certain embodiments, R.sub.14 is chosen from piperazinyl,
pyrrolyl, and N(CH.sub.3).sub.2.
[0108] In certain embodiments, each R.sub.15 is independently
chosen from R.sub.15 is independently chosen from fluorine,
hydroxy, NH.sub.2, NH(CH.sub.3), N(CH.sub.3).sub.2,
NS(O).sub.2CH.sub.3, methoxy, and methyl.
[0109] In certain embodiments,
[0110] Y.sub.4 is --(CH.sub.2).sub.m--;
[0111] m is 0;
[0112] R.sub.14 is null;
[0113] u is an integer from 0 to 3; and
[0114] R.sub.15 is independently chosen from R.sub.15 is
independently chosen from fluorine, hydroxy, NH.sub.2,
NH(CH.sub.3), N(CH.sub.3).sub.2, NS(O).sub.2CH.sub.3, methoxy, and
methyl.
[0115] In certain embodiments, Y.sub.4 is chosen from C(O), O, N,
and --CH.sub.2--.
[0116] In certain embodiments, Y.sub.4 is --CH.sub.2--.
[0117] In certain embodiments, Y.sub.3 is chosen from a bond and
lower alkyl.
[0118] In certain embodiments, Y.sub.3 is chosen from a bond and
methyl.
[0119] In certain embodiments, Y.sub.3 is a bond.
[0120] In certain embodiments, R.sub.3 is chosen from lower
cycloalkyl, lower aryl, and monocyclic or bicyclic heteroaryl, any
of which may be optionally substituted.
[0121] In certain embodiments, R.sub.3 is substituted with one or
more substituents chosen from halogen, hydroxy, lower amino, lower
amido, lower phenylamido, lower phenylalkylamido, lower
heterocycloalkyl, lowerheterocycloalkyl,
loweralkylheterocycloalkyl, C.sub.1-C.sub.3 alkoxy and
C.sub.1-C.sub.3 alkyl.
[0122] In certain embodiments, R.sub.3 is chosen from
benzothiazolyl, pyrrolopyridinyl, indanyl, cyclopropyl,
cyclopentyl, phenyl, pyridinyl, pyrimidinyl, and indolyl, any of
which may be optionally substituted.
[0123] In certain embodiments, R.sub.3 is substituted with one or
more substituents chosen from fluorine, chlorine, hydroxy,
NH.sub.2, NH(CH.sub.3), N(CH.sub.3).sub.2, C(O)NH.sub.2,
C(O)NHCH.sub.3, morpholino, piperazinyl, methylpiperazinyl,
acetamido, methylacetamido, methylpropionamido,
phenylacetamidomethylene, benzamidomethylene,
phenylpropanamidomethylene, methoxy and methyl.
[0124] In certain embodiments are provided a compound of structural
Formula III
##STR00007##
or a salt thereof, wherein:
[0125] dashed lines indicate that a second bond may alternatively
be present or absent;
[0126] X.sub.1 and X.sub.2 are independently chosen from CH and
N;
[0127] Y.sub.3 is a bond;
[0128] Y.sub.4 is chosen from C(O), CH.sub.2, CHF, and
CF.sub.2;
[0129] R.sub.2 is chosen from phenyl and 6-membered monocyclic
heteroaryl, either of which may be optionally substituted;
[0130] R.sub.3 is optionally substituted bicyclic heteroaryl;
[0131] R.sub.4 is chosen from hydrogen, (O), and (S);
[0132] R.sub.14 is optionally substituted monocyclic
heterocycloalkyl.
[0133] In certain embodiments, R.sub.3 is an optionally substituted
5/6-fused bicyclic heteroaryl.
[0134] In certain embodiments, wherein Y.sub.4 is CH.sub.2.
[0135] In certain embodiments, R.sub.14 is optionally substituted
piperazinyl.
[0136] In certain embodiments, R.sub.2 is chosen from hydrogen,
halo, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.10 cycloalkyl,
C.sub.1-C.sub.4 alkyloxy, C.sub.3-C.sub.10 cycloalkyloxy, aryl,
cyano or nitro.
[0137] In certain embodiments, R.sub.1 and R.sub.2 together form a
butadienylene bridge.
[0138] In certain embodiments,
[0139] m and n are both 0;
[0140] Z.sub.1 is a bond;
[0141] R.sub.1, R.sub.5, and R.sub.4 are hydrogen; and
[0142] R.sub.2 and R.sub.3 are each independently chosen from aryl
and heteroaryl, either of which may be optionally substituted.
[0143] In certain embodiments,
[0144] m and n are both 0;
[0145] Z.sub.1 is a bond;
[0146] R.sub.1, R.sub.5, and R.sub.4 are hydrogen;
[0147] R.sub.2 is selected from the group consisting of aryl and
heteroaryl, either of which may be optionally substituted; and
[0148] R.sub.3 is chosen from 5-substituted-1H-indole,
5-substituted pyridine-2-amine, and 5-substituted
pyrimidine-2-amine.
[0149] In certain embodiments,
[0150] m is 0 or 1
[0151] n is 0:
[0152] Z.sub.1 is a bond;
[0153] R.sub.1, R.sub.5, and R.sub.4 are hydrogen; and
[0154] R.sub.1 is chosen from 5-substituted-1H-indole,
5-substituted pyridine-2-amine, and 5-substituted
pyrimidine-2-amine; and
[0155] R.sub.2 is chosen from
5-substituted-1,2,3-trimethoxybenzene,
4-substituted-1,2-dimethoxyphenyl, 5-substituted pyridine-2-amine,
and 5-substituted pyrimidine-2-amine
[0156] In certain embodiments,
[0157] R.sub.1, R.sub.5, and R.sub.4 are hydrogen; and
[0158] R.sub.2 and R.sub.3 are each independently chosen from aryl
and heteroaryl, either of which may be optionally substituted.
[0159] In certain embodiments of Formula I,
[0160] m and n are both 0;
[0161] Z.sub.1 is a bond;
[0162] R.sub.1, R.sub.5, and R.sub.4 are hydrogen,
[0163] R.sub.2 is chosen from aryl and heteroaryl, either of which
may be optionally substituted; and
[0164] R.sub.3 is chosen from 5-substituted-1H-indole,
5-substituted pyridine-2-amine, and 5-substituted
pyrimidine-2-amine, any of which may be optionally substituted.
[0165] In certain embodiments of Formula I,
[0166] m and n are both 0;
[0167] Z.sub.1 is a bond;
[0168] R.sub.1, R.sub.5, and R.sub.4 represent hydrogen,
[0169] R.sub.3 is chosen from 5-substituted-1H-indole,
5-substituted pyridine-2-amine, and 5-substituted
pyrimidine-2-amine; and
[0170] R.sub.2 is chosen from
5-substituted-1,2,3-trimethoxybenzene,
4-substituted-1,2-dimethoxybenzene, 5-substituted pyridine-2-amine,
and 5-substituted pyrimidine-2-amine
[0171] In certain embodiments,
[0172] R.sub.4 is (O), the second bond linking R.sub.4 and the
fused bicyclic core is present, and the second bond in the
five-membered portion of the fused bicyclic core is absent;
[0173] m and n are both 0;
[0174] Z.sub.1 is a bond;
[0175] R.sub.1 and R.sub.5 are each hydrogen; and
[0176] R.sub.2 and R.sub.3 are each independently chosen from aryl
and heteroaryl, either of which may be optionally substituted.
[0177] In certain embodiments,
[0178] R.sub.4 is (O), the second bond linking R.sub.4 and the
fused bicyclic core is present, and the second bond in the
five-membered portion of the fused bicyclic core is absent;
[0179] m and n are both 0;
[0180] Z.sub.1 is a bond;
[0181] R.sub.1 and R.sub.5 are each hydrogen; and
[0182] R.sub.2 is chosen from aryl and heteroaryl, either of which
may be optionally substituted; and
[0183] R.sub.3 is chosen from 5-substituted-1H-indole,
5-substituted pyridine-2-amine, and 5-substituted
pyrimidine-2-amine.
[0184] In certain embodiments,
[0185] R.sub.4 is (O), the second bond linking R.sub.4 and the
fused bicyclic core is present, and the second bond in the
five-membered portion of the fused bicyclic core is absent;
[0186] m and n are both 0;
[0187] Z.sub.1 is a bond;
[0188] R.sub.1 and R.sub.5 are each hydrogen;
[0189] R.sub.3 is chosen from 5-substituted-1H-indole,
5-substituted pyridine-2-amine, or 5-substituted
pyrimidine-2-amine; and
[0190] R.sub.4 is chosen from
5-substituted-1,2,3-trimethoxybenzene,
4-substituted-1,2-dimethoxybenzene, 5-substituted pyridine-2-amine,
and 5-substituted pyrimidine-2-amine
[0191] In certain embodiments, optionally substituted groups are
substituted with one or more substituent chosen from halogen,
hydroxy, C.sub.1-C.sub.3 alkoxy and C.sub.1-C.sub.3 alkyl.
[0192] In certain embodiments, R.sub.4 is mono- or poly-substituted
with fluorine.
[0193] In certain embodiments, R.sub.5 is mono- or poly-substituted
with fluorine.
[0194] In certain embodiments is provided a compound chosen from
Examples 1 to 167.
[0195] Also provided herein is a compound as disclosed herein for
use as a medicament.
[0196] Also provided herein is a compound as disclosed herein for
use as a medicament for the treatment of an MLK-mediated
disease.
[0197] Also provided herein is the use of a compound as disclosed
herein in the manufacture of a medicament for the treatment of an
MLK-mediated disease.
[0198] Also provided herein is a pharmaceutical composition
comprising a compound of Formula I together with a pharmaceutically
acceptable carrier.
[0199] Also provided is a pharmaceutical composition comprising a
compound chosen from Examples 1 to 167.
[0200] Also provided herein is a method of inhibition of MLK
comprising contacting MLK with a compound of Formula I.
[0201] In certain embodiments, said MLK is MLK3.
[0202] In certain embodiments, said inhibition is selective over
other kinases.
[0203] Also provided herein is a method of treatment of a
MLK-mediated disease comprising the administration of a
therapeutically effective amount of a compound of Formula I to a
patient in need thereof.
[0204] In certain embodiments, said disease is an inflammatory
disease or a metabolic disease.
[0205] In certain embodiments, said disease is chosen from diabetes
mellitus, hyperglycemia, retinopathy, nephropathy, neuropathy,
ulcers, micro- and macroangiopathies, gout and diabetic foot
disease, insulin resistance, metabolic syndrome, hyperinsulinemia,
hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic
heart failure, atherosclerosis, peripheral inflammation, and HIV
dementia.
[0206] Also provided herein is a method of treatment of a
MLK-mediated disease comprising the administration of:
[0207] a) a therapeutically effective amount of a compound of
Formula I; and
[0208] b) another therapeutic agent.
[0209] In certain embodiments, said disorder a psychological
disorder.
[0210] In certain embodiments, said disease is chosen from
depression, bipolar disorder, and post-traumatic stress disorder
(PTSD).
[0211] In certain embodiments, said disorder is a traumatic brain
injury.
[0212] In certain embodiments, said traumatic brain injury is
stroke.
[0213] In certain embodiments, said disorder is chosen from
Alzheimer's Disease (AD), Parkinson's Disease, HIV dementia and HIV
associated neurocognitive disorder (HAND).
[0214] In certain embodiments, said disorder is a neurologic
disorder of hearing or vision.
[0215] In certain embodiments, said disorder is chosen from
ototoxicity, hearing loss, acute injury to the inner ear, acoustic
trauma, and injury resulting from blast noise.
[0216] In certain embodiments the methods of treatment disclosed
herein additionally comprise the administration of a second
therapeutic agent, as part of a therapeutic regimen. The compounds
may be delivered in the same dosage form or separately, and further
may be taken concurrently or one subsequent to the other.
[0217] In certain embodiments, said second therapeutic agent is a
selective serotonin reuptake inhibitor (SSRI).
[0218] In certain embodiments, said second therapeutic agent is
CEP1347.
[0219] Also provided herein is a method of treatment of a
MLK-mediated disease comprising the administration of:
[0220] a) a therapeutically effective amount of a an MKL inhibitor;
and
[0221] b) another therapeutic agent.
[0222] In certain embodiments, said second therapeutic agent is a
selective serotonin reuptake inhibitor (SSRI).
[0223] In certain embodiments, said second therapeutic agent is
CEP1347.
[0224] Also provided herein is a method of achieving an effect in a
patient comprising the administration of a therapeutically
effective amount of a compound as disclosed herein to a patient,
wherein the effect is chosen from: [0225] increased survival of
cells of the nervous system, cochlear cells, vestibular cells or
retinal cells; [0226] increased survival of heart cells; [0227]
promotion of neurogenesis; [0228] promotion of synaptogenesis;
[0229] prevention or reduction of neuronal damage; [0230]
restoration or improvement of neuronal function; [0231] suppression
of neuroinflammation or peripheral inflammation; [0232] suppression
of activation of immune cells; [0233] suppression of proliferation
of hepatocytes following injury; and suppression of proliferation
of cancer cells.
[0234] In certain embodiments, the effect is chosen from: [0235]
increased survival of heart cells; [0236] suppression of
neuroinflammation or peripheral inflammation; [0237] suppression of
activation of immune cells; [0238] suppression of proliferation of
hepatocytes following injury; and [0239] suppression of
proliferation of cancer cells.
[0240] In certain embodiments, said immune cells are chosen from
monocytes, macrophages and microglia.
[0241] In certain embodiments, the effect is chosen from: [0242]
increased survival of cells of the nervous system, cochlear cells,
vestibular cells or retinal cells; [0243] increased survival of
heart cells; [0244] promotion of neurogenesis; [0245] promotion of
synaptogenesis; [0246] prevention or reduction of neuronal damage;
[0247] restoration or improvement of neuronal function; [0248]
suppression of neuroinflammation or peripheral inflammation; [0249]
suppression of activation of immune cells; [0250] suppression of
proliferation of hepatocytes following injury; and [0251]
suppression of proliferation of cancer cells.
[0252] In certain embodiments, said immune cells are chosen from
monocytes, macrophages and microglia.
[0253] In certain embodiments, the effect is chosen from: [0254]
increased survival of cells of the nervous system, cochlear cells,
vestibular cells or retinal cells; [0255] promotion of
neurogenesis; [0256] promotion of synaptogenesis; [0257] prevention
or reduction of neuronal damage; and [0258] restoration or
improvement of neuronal function.
[0259] As used herein, the terms below have the meanings
indicated.
[0260] When ranges of values are disclosed, and the notation "from
n.sub.1 . . . to n.sub.2" is used, where n.sub.1 and n.sub.2 are
the numbers, then unless otherwise specified, this notation is
intended to include the numbers themselves and the range between
them. This range may be integral or continuous between and
including the end values. By way of example, the range "from 2 to 6
carbons" is intended to include two, three, four, five, and six
carbons, since carbons come in integer units. Compare, by way of
example, the range "from 1 to 3 .mu.M (micromolar)," which is
intended to include 1 .mu.M 3 .mu.M, and everything in between to
any number of significant figures (e.g., 1.255 .mu.M, 2.1 .mu.M,
2.9999 .mu.M, etc.).
[0261] The term "about," as used herein, is intended to qualify the
numerical values which it modifies, denoting such a value as
variable within a margin of error. When no particular margin of
error, such as a standard deviation to a mean value given in a
chart or table of data, is recited, the term "about" should be
understood to mean that range which would encompass the recited
value and the range which would be included by rounding up or down
to that figure as well, taking into account significant
figures.
[0262] The term "acyl," as used herein, alone or in combination,
refers to a carbonyl attached to an alkenyl, alkyl, aryl,
cycloalkyl, heteroaryl, heterocycle, or any other moiety were the
atom attached to the carbonyl is carbon. An "acetyl" group refers
to a --C(O)CH.sub.3 group. An "alkylcarbonyl" or "alkanoyl" group
refers to an alkyl group attached to the parent molecular moiety
through a carbonyl group. Examples of such groups include
methylcarbonyl and ethylcarbonyl. Examples of acyl groups include
formyl, alkanoyl and aroyl.
[0263] The term "alkenyl," as used herein, alone or in combination,
refers to a straight-chain or branched-chain hydrocarbon radical
having one or more double bonds and containing from 2 to 20 carbon
atoms. In certain embodiments, said alkenyl will comprise from 2 to
6 carbon atoms. The term "alkenylene" refers to a carbon-carbon
double bond system attached at two or more positions such as
ethenylene [(--CH.dbd.CH--), (--C::C--)]. Examples of suitable
alkenyl radicals include ethenyl, propenyl, 2-propenyl,
2-methylpropenyl, butenyl, isobutenyl, 1,4-butadienyl, isoprenyl,
vinyl, and the like. Unless otherwise specified, the term "alkenyl"
may include "alkenylene" groups.
[0264] The term "alkoxy," as used herein, alone or in combination,
refers to an alkyl ether radical, wherein the term alkyl is as
defined below. Examples of suitable alkyl ether radicals include
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy,
sec-butoxy, tert-butoxy, and the like.
[0265] The term "alkyl," as used herein, alone or in combination,
refers to a straight-chain or branched-chain alkyl radical
containing from 1 to 20 carbon atoms. In certain embodiments, said
alkyl will comprise from 1 to 10 carbon atoms. In further
embodiments, said alkyl will comprise from 1 to 6 carbon atoms.
Alkyl groups may be optionally substituted as defined herein.
Examples of alkyl radicals include methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
iso-amyl, hexyl, octyl, noyl and the like. The term "alkylene," as
used herein, alone or in combination, refers to a saturated
aliphatic group derived from a straight or branched chain saturated
hydrocarbon attached at two or more positions, such as methylene
(--CH.sub.2--). Unless otherwise specified, the term "alkyl" may
include "alkylene" groups.
[0266] The term "alkylamino," as used herein, alone or in
combination, refers to an alkyl group attached to the parent
molecular moiety through an amino group. Suitable alkylamino groups
may be mono- or dialkylated, forming groups such as, for example,
N-methylamino, N-ethylamino, N,N-dimethylamino,
N,N-ethylmethylamino and the like.
[0267] The term "alkylidene," as used herein, alone or in
combination, refers to an alkenyl group in which one carbon atom of
the carbon-carbon double bond belongs to the moiety to which the
alkenyl group is attached.
[0268] The term "alkylthio," as used herein, alone or in
combination, refers to an alkyl thioether (R--S--) radical wherein
the term alkyl is as defined above and wherein the sulfur may be
singly or doubly oxidized. Examples of suitable alkyl thioether
radicals include methylthio, ethylthio, n-propylthio,
isopropylthio, n-butylthio, iso-butylthio, sec-butylthio,
tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.
[0269] The term "alkynyl," as used herein, alone or in combination,
refers to a straight-chain or branched chain hydrocarbon radical
having one or more triple bonds and containing from 2 to 20 carbon
atoms. In certain embodiments, said alkynyl comprises from 2 to 6
carbon atoms. In further embodiments, said alkynyl comprises from 2
to 4 carbon atoms. The term "alkynylene" refers to a carbon-carbon
triple bond attached at two positions such as ethynylene
(--C:::C--, --.ident.C--) Examples of alkynyl radicals include
ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, Butyn-2-yl,
pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, and the like. Unless
otherwise specified, the term "alkynyl" may include "alkynylene"
groups.
[0270] The terms "amido" and "carbamoyl," as used herein, alone or
in combination, refer to an amino group as described below attached
to the parent molecular moiety through a carbonyl group, or vice
versa. The term "C-amido" as used herein, alone or in combination,
refers to a --C(O)N(RR') group with R and R' as defined herein or
as defined by the specifically enumerated "R" groups designated.
The term "N-amido" as used herein, alone or in combination, refers
to a RC(O)N(R')-- group, with R and R' as defined herein or as
defined by the specifically enumerated "R" groups designated. The
term "acylamino" as used herein, alone or in combination, embraces
an acyl group attached to the parent moiety through an amino group.
An example of an "acylamino" group is acetylamino
(CH.sub.3C(O)NH--).
[0271] The term "amino," as used herein, alone or in combination,
refers to --NRR', wherein R and R' are independently chosen from
hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl,
and heterocycloalkyl, any of which may themselves be optionally
substituted. Additionally. R and R' may combine to form
heterocycloalkyl, either of which may be optionally
substituted.
[0272] The term "aryl," as used herein, alone or in combination,
means a carbocyclic aromatic system containing one, two or three
rings wherein such polycyclic ring systems are fused together. The
term "aryl" embraces aromatic groups such as phenyl, naphthyl,
anthracenyl, and phenanthryl.
[0273] The term "arylalkenyl" or "aralkenyl," as used herein, alone
or in combination, refers to an aryl group attached to the parent
molecular moiety through an alkenyl group.
[0274] The term "arylalkoxy" or "aralkoxy," as used herein, alone
or in combination, refers to an aryl group attached to the parent
molecular moiety through an alkoxy group.
[0275] The term "arylalkyl" or "aralkyl," as used herein, alone or
in combination, refers to an aryl group attached to the parent
molecular moiety through an alkyl group.
[0276] The term "arylalkynyl" or "aralkynyl," as used herein, alone
or in combination, refers to an aryl group attached to the parent
molecular moiety through an alkynyl group.
[0277] The term "arylalkanoyl" or "aralkanoyl" or "aroyl," as used
herein, alone or in combination, refers to an acyl radical derived
from an aryl-substituted alkanecarboxylic acid such as benzoyl,
naphthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl),
4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and
the like.
[0278] The term aryloxy as used herein, alone or in combination,
refers to an aryl group attached to the parent molecular moiety
through an oxy.
[0279] The terms "benzo" and "benz," as used herein, alone or in
combination, refer to the divalent radical C.sub.6H.sub.4=derived
from benzene. Examples include benzothiophene and
benzimidazole.
[0280] The term "carbamate," as used herein, alone or in
combination, refers to an ester of carbamic acid (--NRC(O)O--)
which may be attached to the parent molecular moiety from either
the nitrogen or acid end, and which may be optionally substituted
as defined herein. The term "O-carbamyl" as used herein, alone or
in combination, refers to a --OC(O)NRR' group; and the term
"N-carbamyl" as used herein, alone or in combination, refers to a
ROC(O)NR'-- group. R and R' are as defined herein, or as defined by
the specifically enumerated "R" groups designated.
[0281] The term "carbonyl," as used herein, when alone includes
formyl [--C(O)H] and in combination is a --C(O)-- group.
[0282] The term "carboxyl" or "carboxy." as used herein, refers to
--C(O)OH or the corresponding "carboxylate" anion, such as is in a
carboxylic acid salt. An "O-carboxy" group refers to a RC(O)O--
group, where R is as defined herein. A "C-carboxy" group refers to
a --C(O)OR groups where R is as defined herein.
[0283] The term "cyano," as used herein, alone or in combination,
refers to --CN.
[0284] The term "cycloalkyl," or, alternatively, "carbocycle," as
used herein, alone or in combination, refers to a saturated or
partially saturated monocyclic, bicyclic or tricyclic alkyl group
wherein each cyclic moiety contains from 3 to 12 carbon atom ring
members and which may optionally be a benzo fused ring system which
is optionally substituted as defined herein. In certain
embodiments, said cycloalkyl will comprise from 5 to 7 carbon
atoms. Examples of such cycloalkyl groups include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
tetrahydronaphthyl, indanyl, octahydronaphthyl,
2,3-dihydro-1H-indenyl, adamantyl and the like. "Bicyclic" and
"tricyclic" as used herein are intended to include both fused ring
systems, such as decahydronaphthalene, octahydronaphthalene as well
as the multicyclic (multicentered) saturated or partially
unsaturated type. The latter type of isomer is exemplified in
general by, bicyclo[1,1,1]pentane, camphor, adamantane, and
bicyclo[3,2,1]octane.
[0285] The term "ester," as used herein, alone or in combination,
refers to a carboxy group bridging two moieties linked at carbon
atoms.
[0286] The term "ether," as used herein, alone or in combination,
refers to an oxy group bridging two moieties linked at carbon
atoms.
[0287] The term "halo," or "halogen," as used herein, alone or in
combination, refers to fluorine, chlorine, bromine, or iodine.
[0288] The term "haloalkoxy," as used herein, alone or in
combination, refers to a haloalkyl group attached to the parent
molecular moiety through an oxygen atom. Haloalkoxy includes
perhaloalkoxy. The term "perhaloalkoxy" refers to an alkoxy group
where all of the hydrogen atoms are replaced by halogen atoms. An
example of perhaloalkoxy is perfluoromethoxy.
[0289] The term "haloalkyl," as used herein, alone or in
combination, refers to an alkyl radical having the meaning as
defined above wherein one or more hydrogens are replaced with a
halogen. Specifically embraced are monohaloalkyl, dihaloalkyl,
polyhaloalkyl, and perhaloalkyl radicals. A monohaloalkyl radical,
for one example, may have an iodo, bromo, chloro or fluoro atom
within the radical. Dihalo and polyhaloalkyl radicals may have two
or more of the same halo atoms or a combination of different halo
radicals. Examples of haloalkyl radicals include fluoromethyl,
difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,
trichloromethyl, pentafluoroethyl, heptafluoropropyl,
difluorochloromethyl, dichlorofluoromethyl, difluoroethyl,
difluoropropyl, dichloroethyl and dichloropropyl. "Haloalkylene"
refers to a haloalkyl group attached at two or more positions.
Examples of haloalkyl radicals include fluoromethyl,
difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,
trichloromethyl, pentafluoroethyl, heptafluoropropyl,
difluorochloromethyl, dichlorofluoromethyl, difluoroethyl,
difluoropropyl, dichloroethyl and dichloropropyl. "Haloalkylene"
refers to a haloalkyl group attached at two or more positions.
Examples include fluoromethylene (--CFH--), difluoromethylene
(--CF.sub.2--), chloromethylene (--CHCl--) and the like. The term
"perhaloalkyl" as used herein, alone or in combination, refers to
an alkyl group where all of the hydrogen atoms are replaced by
halogen atoms. Examples include perfluoromethyl.
[0290] The term "heteroalkyl," as used herein, alone or in
combination, refers to a stable straight or branched chain, or
cyclic hydrocarbon radical, or combinations thereof, fully
saturated or containing from 1 to 3 degrees of unsaturation,
consisting of the stated number of carbon atoms and from one to
three heteroatoms chosen from O, N, and S, and wherein the nitrogen
and sulfur atoms may optionally be oxidized and the nitrogen
heteroatom may optionally be quaternized. The heteroatom(s) O, N
and S may be placed at any interior position of the heteroalkyl
group. Up to two heteroatoms may be consecutive, such as, for
example, --CH.sub.2--NH--OCH.sub.3.
[0291] The term "heteroaryl," as used herein, alone or in
combination, refers to a 3 to 15 membered unsaturated
heteromonocyclic ring, or a fused monocyclic, bicyclic, or
tricyclic ring system in which at least one of the fused rings is
aromatic, which contains at least one atom chosen from O, S, and N.
Additionally, a heteroaryl may contain one or two C(O), S(O), or
S(O).sub.2 groups as ring members. In certain embodiments, said
heteroaryl will comprise from 5 to 10 atoms. In certain
embodiments, said heteroaryl will comprise from 5 to 7 atoms. In
certain embodiments, said heteroaryl will comprise from 1 to 4
heteroatoms as ring members. In further embodiments, said
heteroaryl will comprise from 1 to 2 heteroatoms as ring members.
The term also embraces fused polycyclic groups wherein heterocyclic
rings are fused with aryl rings, wherein heteroaryl rings are fused
with other heteroaryl rings, wherein heteroaryl rings are fused
with heterocycloalkyl rings, or wherein heteroaryl rings are fused
with cycloalkyl rings. Examples of heteroaryl groups include
pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl,
pyrazinyl, pyridazinyl, imidazolyl, triazinyl, triazolyl,
tetrazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl,
oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl,
isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl,
quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl,
benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl,
benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl,
chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl,
tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl,
furopyridinyl, pyrrolopyridinyl and the like. Exemplary tricyclic
heterocyclic groups include carbazolyl, benzidolyl,
phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl,
xanthenyl and the like.
[0292] The terms "heterocycloalkyl" and, interchangeably,
"heterocycle," as used herein, alone or in combination, each refer
to a saturated, partially unsaturated, or fully unsaturated
monocyclic, bicyclic, or tricyclic heterocyclic group containing at
least one heteroatom as a ring member, wherein each said heteroatom
may be independently chosen from N, O, and S. Additionally, a
heterocycloalkyl may contain one or two C(O), S(O), or S(O).sub.2
groups as ring members. In certain embodiments, said
hetercycloalkyl will comprise from 1 to 4 heteroatoms as ring
members. In further embodiments, said hetercycloalkyl will comprise
from 1 to 2 heteroatoms as ring members. In certain embodiments,
said hetercycloalkyl will comprise from 3 to 8 ring members in each
ring. In further embodiments, said hetercycloalkyl will comprise
from 3 to 7 ring members in each ring. In yet further embodiments,
said hetercycloalkyl will comprise from 5 to 6 ring members in each
ring. "Heterocycloalkyl" and "heterocycle" are intended to include
sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members,
and carbocyclic fused and benzo fused ring systems; additionally,
both terms also include systems where a heterocycle ring is fused
to an aryl group, as defined herein, or an additional heterocycle
group. Examples of heterocycle groups include aziridinyl,
azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl,
dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl,
dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl,
dihydroindolyl, dihy-dropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl,
1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl,
pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl,
and the like. The heterocycle groups may be optionally substituted
unless specifically prohibited.
[0293] The term "hydroxy," as used herein, alone or in combination,
refers to --OH.
[0294] The term "lower," as used herein, alone or in a combination,
where not otherwise specifically defined, means containing from 1
to and including 6 carbon atoms.
[0295] The term "lower alkyl," as used herein, alone or in a
combination, means C.sub.1-C.sub.6 straight or branched chain
alkyl. The term "lower alkenyl" means C.sub.2-C.sub.6 straight or
branched chain alkenyl. The term "lower alkynyl" means
C.sub.2-C.sub.6 straight or branched chain alkynyl.
[0296] The term "lower aryl," as used herein, alone or in
combination, means phenyl or naphthyl, either of which may be
optionally substituted as provided.
[0297] The term "lower heteroaryl," as used herein, alone or in
combination, means either 1) monocyclic heteroaryl comprising five
or six ring members, of which between one and four said members may
be heteroatoms chosen from O, S, and N, or 2) bicyclic heteroaryl,
wherein each of the fused rings comprises five or six ring members,
comprising between them one to four heteroatoms chosen from O, S,
and N.
[0298] The term "lower cycloalkyl," as used herein, alone or in
combination, means a monocyclic cycloalkyl having between three and
six ring members. Lower cycloalkyls may be unsaturated. Examples of
lower cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and
cyclohexyl.
[0299] The term "lower heterocycloalkyl," as used herein, alone or
in combination, means a monocyclic heterocycloalkyl having between
three and six ring members, of which between one and four may be
heteroatoms chosen from O, S, and N. Examples of lower
heterocycloalkyls include pyrrolidinyl, imidazolidinyl,
pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl. Lower
heterocycloalkyls may be unsaturated.
[0300] The term "lower amino," as used herein, alone or in
combination, refers to NRR', wherein R and R' are independently
chosen from hydrogen, lower alkyl, and lower heteroalkyl, any of
which may be optionally substituted. Additionally, the R and R' of
a lower amino group may combine to form a five- or six-membered
heterocycloalkyl, either of which may be optionally
substituted.
[0301] The term "nitro," as used herein, alone or in combination,
refers to --NO.sub.2.
[0302] The terms "oxy" or "oxa," as used herein, alone or in
combination, refer to --O--.
[0303] The term "oxo," as used herein, alone or in combination,
refers to .dbd.O.
[0304] The term "perhaloalkoxy" refers to an alkoxy group where all
of the hydrogen atoms are replaced by halogen atoms.
[0305] The term "perhaloalkyl" as used herein, alone or in
combination, refers to an alkyl group where all of the hydrogen
atoms are replaced by halogen atoms.
[0306] The terms "sulfonate." "sulfonic acid," and "sulfonic." as
used herein, alone or in combination, refer the --SO.sub.3H group
and its anion as the sulfonic acid is used in salt formation.
[0307] The term "N-sulfonamido" refers to a RS(.dbd.O).sub.2NR'--
group with R and R' as defined herein or as defined by the
specifically enumerated "R" groups designated.
[0308] The term "S-sulfonamido" refers to a --S(.dbd.O).sub.2NRR',
group, with R and R' as defined herein or as defined by the
specifically enumerated "R" groups designated.
[0309] The terms "thia" and "thio," as used herein, alone or in
combination, refer to a --S-- group or an ether wherein the oxygen
is replaced with sulfur. The oxidized derivatives of the thio
group, namely sulfinyl and sulfonyl, are included in the definition
of thia and thio. The term "sulfanyl," as used herein, alone or in
combination, refers to --S--. The term "sulfinyl," as used herein,
alone or in combination, refers to --S(O)--. The term "sulfonyl,"
as used herein, alone or in combination, refers to
--S(O).sub.2--.
[0310] The term "thiol," as used herein, alone or in combination,
refers to an --SH group.
[0311] The term "thiocarbonyl," as used herein, when alone includes
thioformyl --C(S)H and in combination is a --C(S)-- group.
[0312] Any definition herein may be used in combination with any
other definition to describe a composite structural group. By
convention, the trailing element of any such definition is that
which attaches to the parent moiety. For example, the composite
group alkylamido would represent an alkyl group attached to the
parent molecule through an amido group, and the term alkoxyalkyl
would represent an alkoxy group attached to the parent molecule
through an alkyl group.
[0313] When a group is defined to be "null," what is meant is that
said group is absent.
[0314] The term "optionally substituted" means the anteceding group
may be substituted or unsubstituted. When substituted, the
substituents of an "optionally substituted" group may include,
without limitation, one or more substituents independently selected
from the following groups or a particular designated set of groups,
alone or in combination: lower alkyl, lower alkenyl, lower alkynyl,
lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower
haloalkyl, lower haloalkenyl, lower haloalkynyl, lower
perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl,
aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy,
carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower
carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower
alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower
haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate,
sulfonic acid, trisubstituted silyl, N.sub.3, SH, SCH.sub.3,
C(O)CH.sub.3, CO.sub.2CH.sub.3, CO.sub.2H, pyridinyl, thiophene,
furanyl, lower carbamate, and lower urea. Two substituents may be
joined together to form a fused five-, six-, or seven-membered
carbocyclic or heterocyclic ring consisting of zero to three
heteroatoms, for example forming methylenedioxy or ethylenedioxy.
An optionally substituted group may be unsubstituted (e.g.,
--CH.sub.2CH.sub.3), fully substituted (e.g., --CF.sub.2CF.sub.3),
monosubstituted (e.g., --CH.sub.2CH.sub.2F) or substituted at a
level anywhere in-between fully substituted and monosubstituted
(e.g., --CH.sub.2CF.sub.3). Where substituents are recited without
qualification as to substitution, both substituted and
unsubstituted forms are encompassed. Where a substituent is
qualified as "substituted," the substituted form is specifically
intended. Additionally, different sets of optional substituents to
a particular moiety may be defined as needed; in these cases, the
optional substitution will be as defined, often immediately
following the phrase, "optionally substituted with."
[0315] The term R or the term R', appearing by itself and without a
number designation, unless otherwise defined, refers to a moiety
chosen from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl,
heteroaryl and heterocycloalkyl, any of which may be optionally
substituted. Such R and R' groups should be understood to be
optionally substituted as defined herein. Whether an R group has a
number designation or not, every R group, including R, R' and
R.sup.n where n=(1, 2, 3, . . . n), every substituent, and every
term should be understood to be independent of every other in terms
of selection from a group. Should any variable, substituent, or
term (e.g. aryl, heterocycle, R, etc.) occur more than one time in
a formula or generic structure, its definition at each occurrence
is independent of the definition at every other occurrence. Those
of skill in the art will further recognize that certain groups may
be attached to a parent molecule or may occupy a position in a
chain of elements from either end as written. Thus, by way of
example only, an unsymmetrical group such as --C(O)N(R)-- may be
attached to the parent moiety at either the carbon or the
nitrogen.
[0316] Asymmetric centers exist in the compounds disclosed herein.
These centers are designated by the symbols "R" or "S," depending
on the configuration of substituents around the chiral carbon atom.
It should be understood that the invention encompasses all
stereochemical isomeric forms, including diastereomeric,
enantiomeric, and epimeric forms, as well as d-isomers and
1-isomers, and mixtures thereof. Individual stereoisomers of
compounds can be prepared synthetically from commercially available
starting materials which contain chiral centers or by preparation
of mixtures of enantiomeric products followed by separation such as
conversion to a mixture of diastereomers followed by separation or
recrystallization, chromatographic techniques, direct separation of
enantiomers on chiral chromatographic columns, or any other
appropriate method known in the art. Compounds can be prepared
using diastereomers, enantiomers or racemic mixtures as starting
materials. Starting compounds of particular stereochemistry are
either commercially available or can be made and resolved by
techniques known in the art. Furthermore, diastereomer and
enantiomer products can be separated by chromatography, fractional
crystallization or other methods known to those of skill in the
art. Additionally, the compounds disclosed herein may exist as
geometric isomers. The present invention includes all cis, trans,
syn, anti, entgegen (E), and zusammen (Z) isomers as well as the
appropriate mixtures thereof. Additionally, compounds may exist as
tautomers; all tautomeric isomers are provided by this invention.
Solvates, hydrates, isomorphs, polymorphs are also provided.
Additionally, the compounds disclosed herein can exist in
unsolvated as well as solvated forms with pharmaceutically
acceptable solvents such as water, ethanol, and the like. In
general, the solvated forms are considered equivalent to the
unsolvated forms.
[0317] The term "bond" refers to a covalent linkage between two
atoms, or two moieties when the atoms joined by the bond are
considered to be part of larger substructure. A bond may be single,
double, or triple unless otherwise specified. A dashed line between
two atoms in a drawing of a molecule indicates that an additional
bond may be present or absent at that position. When, for example,
Y.sub.1 is
--(CR.sub.6aR.sub.6b).sub.m--Z.sub.1--(CR.sub.7aR.sub.7b).sub.n--,
and m and n are both 0, and Z.sub.1 is a bond, then Y.sub.1
collapses to a direct bond linking the parent ring system with
R.sub.1. This applies to all similar constructions used herein,
including Y.sub.2 and Y.sub.3. Or, for example, when either of
R.sub.6a and R.sub.6b of (CR.sub.6aR.sub.6b).sub.m are designated
to be "a bond," and m.gtoreq.1, then an additional bond forms
between a C of (CR.sub.6aR.sub.6b) and an adjacent atom. When
m.gtoreq.2, then (CR.sub.6aR.sub.6b).sub.m may form an alkene
(alkenylene) or alkyne (alkynylene).
[0318] As used herein, the terms "treating" and "treatment" refer
to delaying the onset of, retarding or reversing the progress of,
or alleviating or preventing either the disease or condition to
which the term applies, or one or more symptoms of such disease or
condition.
[0319] The term "patient" (and, equivalently, "subject") means all
mammals including humans. Examples of patients include humans,
cows, dogs, cats, goats, sheep, pigs, and rabbits. Preferably, the
patient is a human.
[0320] The term "disease" as used herein is intended to be
generally synonymous, and is used interchangeably with, the terms
"disorder," "syndrome," and "condition" (as in medical condition),
in that all reflect an abnormal condition of the human or animal
body or of one or more of its parts that impairs normal
functioning, is typically manifested by distinguishing signs and
symptoms, and/or causes the human or animal to have a reduced
duration or quality of life.
[0321] The term "neuropsychiatric disorder" includes, without
limitation, psychological, psychiatric, and neurological
disorders.
[0322] The term "HIV associated neurocognitive disorder (HAND)" is
related to, and is intended to be substantially synonymous with,
the terms HIV dementia, AIDS dementia, HIV encephalopathy, and
NeuroAIDS.
[0323] The term "combination therapy" means the administration of
two or more therapeutic agents to treat a therapeutic condition or
disorder described in the present disclosure. Such administration
encompasses co-administration of these therapeutic agents in a
substantially simultaneous manner, such as in a single capsule
having a fixed ratio of active ingredients or in multiple, separate
capsules for each active ingredient. In addition, such
administration also encompasses use of each type of therapeutic
agent in a sequential manner. In either case, the treatment regimen
will provide beneficial effects of the drug combination in treating
the conditions or disorders described herein.
[0324] As used herein, the term "administering" means oral
administration, administration as a suppository, topical contact,
intravenous, intraperitoneal, intramuscular, intralesional,
intranasal or subcutaneous administration, or the implantation of a
slow-release device, e.g., a mini-osmotic pump, to a subject.
Administration is by any route including parenteral, and
transmucosal (e.g., oral, nasal, vaginal, rectal, or transdermal).
Parenteral administration includes, e.g., intravenous,
intramuscular, intra-arteriole, intradermal, subcutaneous,
intraperitoneal, intraventricular, and intracranial. Other modes of
delivery include, but are not limited to, the use of liposomal
formulations, intravenous infusion, transdermal patches, and the
like.
[0325] As used herein, the term "prodrug" refers to a precursor
compound that, following administration, releases the biologically
active compound in vivo via some chemical or physiological process
(e.g., a prodrug on reaching physiological pH or through enzyme
action is converted to the biologically active compound).
[0326] The terms "controlled release," "sustained release,"
"extended release," and "timed release" are intended to refer
interchangeably to any drug-containing formulation in which release
of the drug is not immediate, i.e., with a "controlled release"
formulation, oral administration does not result in immediate
release of the drug into an absorption pool. The terms are used
interchangeably with "nonimmediate release" as defined in
Remington: The Science and Practice of Pharmacy, 21.sup.st Ed.,
Gennaro, Ed., Lippencott Williams & Wilkins (2003). As
discussed therein, immediate and nonimmediate release can be
defined kinetically by reference to the following equation:
Dosage Form .fwdarw. k r drug release Absorption Pool .fwdarw. k a
absorption Target Area .fwdarw. k e elimination ##EQU00001##
[0327] The "absorption pool" represents a solution of the drug
administered at a particular absorption site, and k.sub.r, k.sub.a
and k.sub.e are first-order rate constants for (1) release of the
drug from the formulation, (2) absorption, and (3) elimination,
respectively. For immediate release dosage forms, the rate constant
for drug release k.sub.r is far greater than the absorption rate
constant k.sub.a. For controlled release formulations, the opposite
is true, i.e., k.sub.r<<k.sub.a, such that the rate of
release of drug from the dosage form is the rate-limiting step in
the delivery of the drug to the target area.
[0328] The terms "sustained release" and "extended release" are
used in their conventional sense to refer to a drug formulation
that provides for gradual release of a drug over an extended period
of time, for example, 12 hours or more, and that preferably,
although not necessarily, results in substantially constant blood
levels of a drug over an extended time period.
[0329] As used herein, the term "delayed release" refers to a
pharmaceutical preparation that passes through the stomach intact
and dissolves in the small intestine.
[0330] "MLK3 inhibitor" is used herein to refer to a compound that
exhibits an IC.sub.50 with respect to MLK3 activity of no more than
about 100 .mu.M and more typically not more than about 50 .mu.M, as
measured in the MLK3 (assay name) described generally hereinbelow.
"IC.sub.50" is that concentration of inhibitor which reduces the
activity and/or expression of an enzyme (e.g., MLK or MLK3) to
half-maximal level. Certain compounds disclosed herein have been
discovered to exhibit inhibition against MLK3. In certain
embodiments, compounds will exhibit an IC50 with respect to MLK3 of
no more than about 10 .mu.M; in further embodiments, compounds will
exhibit an IC.sub.50 with respect to MLK3 of no more than about 5
.mu.M; in yet further embodiments, compounds will exhibit an
IC.sub.50 with respect to MLK3 of not more than about 1 .mu.M; in
yet further embodiments, compounds will exhibit an IC.sub.50 with
respect to MLK3 of not more than about 200 nM, as measured in the
MLK3 assay described herein.
[0331] The phrase "therapeutically effective" is intended to
qualify the amount of active ingredients used in the treatment of a
disease or disorder. This amount will achieve the goal of reducing
or eliminating the said disease or disorder.
[0332] The term "therapeutically acceptable" refers to those
compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.)
which are suitable for use in contact with the tissues of patients
without undue toxicity, irritation, and allergic response, are
commensurate with a reasonable benefit/risk ratio, and are
effective for their intended use.
[0333] The term "prodrug" refers to a compound that is made more
active in vivo. Certain compounds disclosed herein may also exist
as prodrugs, as described in Hydrolysis in Drug and Prodrug
Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard
and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003).
Prodrugs of the compounds described herein are structurally
modified forms of the compound that readily undergo chemical
changes under physiological conditions to provide the compound.
Additionally, prodrugs can be converted to the compound by chemical
or biochemical methods in an ex vivo environment. For example,
prodrugs can be slowly converted to a compound when placed in a
transdermal patch reservoir with a suitable enzyme or chemical
reagent. Prodrugs are often useful because, in some situations,
they may be easier to administer than the compound, or parent drug.
They may, for instance, be bioavailable by oral administration
whereas the parent drug is not. The prodrug may also have improved
solubility in pharmaceutical compositions over the parent drug. A
wide variety of prodrug derivatives are known in the art, such as
those that rely on hydrolytic cleavage or oxidative activation of
the prodrug. An example, without limitation, of a prodrug would be
a compound which is administered as an ester (the "prodrug"), but
then is metabolically hydrolyzed to the carboxylic acid, the active
entity. Additional examples include peptidyl derivatives of a
compound.
[0334] Prodrugs of compounds of Formula I are provided herein.
Prodrugs of compounds provided herein include, but are not limited
to, carboxylate esters, carbonate esters, hemi-esters, phosphorus
esters, nitro esters, sulfate esters, sulfoxides, amides,
carbamates, azo compounds, phosphamides, glycosides, ethers,
acetals, and ketals. Prodrug esters and carbonates may be formed,
for example, by reacting one or more hydroxyl groups of compounds
of Formula I or Formula II with alkyl, alkoxy or aryl substituted
acylating reagents using methods known to those of skill in the art
to produce methyl carbonates, acetates, benzoates, pivalates and
the like. Illustrative examples of prodrug esters of the compounds
provided herein include, but are not limited to, compounds of
Formula I having a carboxyl moiety wherein the free hydrogen is
replaced by C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.7
alkanoyloxymethyl, 1-((C.sub.1-C.sub.5)alkanoyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.5)alkanoyloxy)-ethyl, C.sub.1-C.sub.5
alkoxycarbonyloxymethyl,
1-((C.sub.1-C.sub.5)alkoxycarbonyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.5)alkoxycarbonyloxy)ethyl,
N--((C.sub.1-C.sub.5)alkoxycarbonyl)aminomethyl,
1-(N--((C.sub.1-C.sub.5)alkoxycarbonyl)amino)ethyl, 3-phthalidyl,
4-crotonolactonyl, gamma-butyrolacton-4-yl,
di-N,N--(C.sub.1-C.sub.2)alkylamino(C.sub.2-C.sub.3)alkyl (e.g.,
beta-dimethylaminoethyl), carbamoyl-(C.sub.1-C.sub.2)alkyl,
N,N-di(C.sub.1-C.sub.2)alkylcarbamoyl-(C.sub.1-C.sub.2)alkyl and
piperidino-, pyrrolidino- or morpholino(C.sub.2-C.sub.3)alkyl.
Oligopeptide modifications and biodegradable polymer derivatives
(as described, for example, in Int. J. Pharm. 115, 61-67, 1995) are
within the scope of the present disclosure. Methods for selecting
and preparing suitable prodrugs are provided, for example, in the
following: T. Higuchi and V. Stella, "Prodrugs as Novel Delivery
Systems," Vol. 14, ACS Symposium Series, 1975; H. Bundgaard,
"Design of Prodrugs," Elsevier, 1985; and "Bioreversible Carriers
in Drug Design," ed. Edward Roche, American Pharmaceutical
Association and Pergamon Press, 1987.
[0335] The compounds disclosed herein can exist as therapeutically
acceptable salts. The present invention includes compounds
disclosed herein in the form of salts, including acid addition
salts. Suitable salts include those formed with both organic and
inorganic acids. Such acid addition salts will normally be
pharmaceutically acceptable. However, salts of non-pharmaceutically
acceptable salts may be of utility in the preparation and
purification of the compound in question. Basic addition salts may
also be formed and be pharmaceutically acceptable. For a more
complete discussion of the preparation and selection of salts,
refer to Pharmaceutical Salts: Properties, Selection, and Use
(Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).
[0336] The term "therapeutically acceptable salt," as used herein,
represents salts or zwitterionic forms of the compounds disclosed
herein which are water or oil-soluble or dispersible and
therapeutically acceptable as defined herein. The salts can be
prepared during the final isolation and purification of the
compounds or separately by reacting the appropriate compound in the
form of the free base with a suitable acid. Representative acid
addition salts include acetate, adipate, alginate, L-ascorbate,
aspartate, benzoate, benzenesulfonate (besylate), bisulfate,
butyrate, camphorate, camphorsulfonate, citrate, digluconate,
formate, fumarate, gentisate, glutarate, glycerophosphate,
glycolate, hemisulfate, heptanoate, hexanoate, hippurate,
hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate
(isethionate), lactate, maleate, malonate, DL-mandelate,
mesitylenesulfonate, methanesulfonate, naphthylenesulfonate,
nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate,
persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate,
propionate, pyroglutamate, succinate, sulfonate, tartrate,
L-tartrate, trichloroacetate, trifluoroacetate, phosphate,
glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and
undecanoate. Also, basic groups in the compounds disclosed herein
can be quaternized with methyl, ethyl, propyl, and butyl chlorides,
bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl
sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides,
and iodides; and benzyl and phenethyl bromides. Examples of acids
which can be employed to form therapeutically acceptable addition
salts include inorganic acids such as hydrochloric, hydrobromic,
sulfuric, and phosphoric, and organic acids such as oxalic, maleic,
succinic, and citric. Salts can also be formed by coordination of
the compounds with an alkali metal or alkaline earth ion. Hence,
the present invention contemplates sodium, potassium, magnesium,
and calcium salts of the compounds disclosed herein, and the
like.
[0337] Basic addition salts can be prepared during the final
isolation and purification of the compounds by reacting a carboxy
group with a suitable base such as the hydroxide, carbonate, or
bicarbonate of a metal cation or with ammonia or an organic
primary, secondary, or tertiary amine. The cations of
therapeutically acceptable salts include lithium, sodium,
potassium, calcium, magnesium, and aluminum, as well as nontoxic
quaternary amine cations such as ammonium, tetramethylammonium,
tetraethylammonium, methylamine, dimethylamine, trimethylamine,
triethylamine, diethylamine, ethylamine, tributylamine, pyridine,
N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine,
dicyclohexylamine, procaine, dibenzylamine,
N,N-dibenzylphenethylamine, 1-ephenamine, and
N,N-dibenzylethylenediamine. Other representative organic amines
useful for the formation of base addition salts include
ethylenediamine, ethanolamine, diethanolamine, piperidine, and
piperazine.
[0338] Also provided herein are isotopically-substituted or
-labeled compounds of Formula I, wherein one or more atoms are
replaced by one or more atoms having specific atomic mass or mass
numbers. Examples of isotopes that can be incorporated into
compounds disclosed herein include, but are not limited to,
isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur,
and chlorine (such as .sup.2H, .sup.3H, .sup.13C, .sup.14C,
.sup.15N, .sup.18O, .sup.17O, .sup.18F, .sup.35S and .sup.36Cl).
Isotopically-labeled compounds of Formula I and prodrugs thereof,
as well as isotopically-labeled, pharmaceutically acceptable salts
of compounds of Formula I and prodrugs thereof, are herein
disclosed. Isotopically-labeled compounds are useful in assays of
the tissue distribution of the compounds and their prodrugs and
metabolites; preferred isotopes for such assays include .sup.3H and
.sup.14C. In addition, in certain circumstances substitution with
heavier isotopes, such as deuterium (.sup.2H), can provide
increased metabolic stability, which offers therapeutic advantages
such as increased in vivo half-life or reduced dosage requirements.
Isotopically-labeled compounds and prodrugs thereof can generally
be prepared according to the methods described herein by
substituting an isotopically-labeled reagent for a non-isotopically
labeled reagent.
[0339] In other aspects, provided herein are intermediates and
processes useful for preparing the intermediates below as well as
the compounds of Formula I, and pharmaceutically acceptable salts
and prodrugs thereof.
[0340] In a similar manner, the present invention provides methods
of preparing compounds of Formula I, that are based on the
synthetic protocols outlined in Schemes 1 through 21 as well as
methods well known by persons skilled in the art, and the more
detailed particular examples presented below in the experimental
section describing the examples. By following the general
preparative methods discussed below, or employing variations or
alternative methods, the compounds can be readily prepared by the
use of chemical reactions and procedures known to those of skill in
the art. Unless otherwise specified, the variables (e.g., R groups)
denoting groups in the general methods described below have the
meanings as hereinbefore defined.
[0341] Those of skill in the art will recognize that compounds with
each described functional group are generally prepared using slight
variations of the below-listed general methods. Within the scope of
each method, functional groups which are suitable to the reaction
conditions are used. Functional groups which might interfere with
certain reactions are presented in protected forms where necessary,
and the removal of such protective groups is completed at
appropriate stages by methods well known to those skilled in the
art.
[0342] In certain cases compounds can be prepared from other
compounds disclosed herein by elaboration, transformation, exchange
and the like of the functional groups present. Such elaboration
includes, but is not limited to, hydrolysis, reduction, oxidation,
alkylation, acylation, esterification, amidation and dehydration.
Such transformations can in some instances require the use of
protecting groups by the methods disclosed in T. W. Greene and P.
G. M. Wuts, Protective Groups in Organic Synthesis; Wiley: New
York, (1999), and incorporated herein by reference. Such methods
would be initiated after synthesis of the desired compound or at
another place in the synthetic route that would be readily apparent
to one skilled in the art.
[0343] In another aspect, provided herein are synthetic
intermediates useful for preparing the compounds of Formula I, and
pharmaceutically acceptable salts and prodrugs thereof, according
to the general preparative methods discussed below and other
processes known to those of skill in the art.
[0344] When the following abbreviations and acronyms are used
throughout the disclosure, they have the following meanings:
CDCl.sub.3, chloroform-d; CH.sub.2Cl.sub.2, methylene chloride;
CH.sub.3CN, acetonitrile; DIPEA, N,N-diisopropylethylamine; DMAP,
4-dimethylaminopyridine; DMF, N,N-dimethylformamide; DMSO,
dimethylsulfoxide; Et, ethyl; Et.sub.3N, triethylamine; EtOAc (or
AcOEt), ethyl acetate; EtOH, ethanol; h, hour; HCl, hydrochloric
acid; .sup.1H NMR, proton nuclear magnetic resonance;
H.sub.2SO.sub.4, sulfuric acid; HPLC, high performance liquid
chromatography; K.sub.2CO.sub.3, potassium carbonate; KOH,
potassium hydroxide; LC-MS, liquid chromatography--mass
spectroscopy; Me, methyl; MeOH, methanol; min, minute; MS ESI, mass
spectroscopy with electrospray ionization; MsOH, methanesulfonic
acid; NaH, sodium hydride; NaHCO.sub.3, sodium bicarbonate; NaOH,
sodium hydroxide; Na.sub.2SO.sub.4, sodium sulfate; NBS,
N-bromosuccinimide; NCS, N-chlorosuccinimide; NH.sub.3, ammonia;
NIS, N-iodosuccinimide; Pd/C, palladium on carbon;
Pd(PPh.sub.3).sub.4, tetrakis(triphenylphosphine)palladium(0);
R.sub.f, retention factor; TBAF, tetrabutylammonium fluoride; TBAI,
tetrabutylammonium iodide; TBDMS, t-butyldimethylsilyl; Tf.sub.2O,
trifluoromethanesulfonic anhydride; TFA, trifluoroacetic acid; THF,
tetrahydrofuran; TLC, thin layer chromatography; TMS,
trimethylsilyl; TMSCN, trimethylsilyl cyanide; TsOH,
toluenesulfonic acid.
[0345] While it may be possible for compounds to be administered as
the raw chemical, it is also possible to present them as a
pharmaceutical formulation. Accordingly, provided herein are
pharmaceutical formulations which comprise one or more of certain
compounds disclosed herein, or one or more pharmaceutically
acceptable salts, esters, prodrugs, amides, or solvates thereof,
together with one or more pharmaceutically acceptable carriers
thereof and optionally one or more other therapeutic ingredients.
The carrier(s) must be "acceptable" in the sense of being
compatible with the other ingredients of the formulation and not
deleterious to the recipient thereof. Proper formulation is
dependent upon the route of administration chosen. Any of the
well-known techniques, carriers, and excipients may be used as
suitable and as understood in the art; e.g., in Remington: The
Science and Practice of Pharmacy, 21.sup.st Ed., Gennaro, Ed.,
Lippencott Williams & Wilkins (2003). The pharmaceutical
compositions disclosed herein may be manufactured in any manner
known in the art, e.g., by means of conventional mixing,
dissolving, granulating, dragee-making, levigating, emulsifying,
encapsulating, entrapping or compression processes.
[0346] A compound as provided herein can be incorporated into a
variety of formulations for therapeutic administration, including
solid, semi-solid, liquid or gaseous forms. The formulations
include those suitable for oral, parenteral (including
subcutaneous, intradermal, intramuscular, intravenous,
intraarticular, and intramedullary), intraperitoneal, transmucosal,
transdermal, rectal and topical (including dermal, buccal,
sublingual and intraocular) administration although the most
suitable route may depend upon for example the condition and
disorder of the recipient. The formulations may conveniently be
presented in unit dosage form and may be prepared by any of the
methods well known in the art of pharmacy. Typically, these methods
include the step of bringing into association a compound or a
pharmaceutically acceptable salt, ester, amide, prodrug or solvate
thereof ("active ingredient") with the carrier which constitutes
one or more accessory ingredients. In general, the formulations are
prepared by uniformly and intimately bringing into association the
active ingredient with liquid carriers or finely divided solid
carriers or both and then, if necessary, shaping the product into
the desired formulation.
[0347] Formulations of the compounds disclosed herein suitable for
oral administration may be presented as discrete units such as
capsules, cachets or tablets each containing a predetermined amount
of the active ingredient; as a powder or granules; as a solution or
a suspension in an aqueous liquid or a non-aqueous liquid; or as an
oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The
active ingredient may also be presented as a bolus, electuary or
paste.
[0348] Pharmaceutical preparations which can be used orally include
tablets, push-fit capsules made of gelatin, as well as soft, sealed
capsules made of gelatin and a plasticizer, such as glycerol or
sorbitol. Tablets may be made by compression or molding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared by compressing in a suitable machine the active ingredient
in a free-flowing form such as a powder or granules, optionally
mixed with binders, inert diluents, or lubricating, surface active
or dispersing agents. Molded tablets may be made by molding in a
suitable machine a mixture of the powdered compound moistened with
an inert liquid diluent. The tablets may optionally be coated or
scored and may be formulated so as to provide slow or controlled
release of the active ingredient therein. All formulations for oral
administration should be in dosages suitable for such
administration. The push-fit capsules can contain the active
ingredients in admixture with filler such as lactose, binders such
as starches, and/or lubricants such as talc or magnesium stearate
and, optionally, stabilizers. In soft capsules, the active
compounds may be dissolved or suspended in suitable liquids, such
as fatty oils, liquid paraffin, or liquid polyethylene glycols. In
addition, stabilizers may be added.
[0349] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses. Also provided are oral
formulations in the form of powders and granules containing one or
more compounds disclosed herein.
[0350] The compounds may be formulated for parenteral
administration by injection, e.g., by bolus injection or continuous
infusion. Formulations for injection may be presented in unit
dosage form, e.g., in ampoules or in multi-dose containers, with an
added preservative. The compositions may take such forms as
suspensions, solutions or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. The formulations may be presented in
unit-dose or multi-dose containers, for example sealed ampoules and
vials, and may be stored in powder form or in a freeze-dried
(lyophilized) condition requiring only the addition of the sterile
liquid carrier, for example, saline or sterile pyrogen-free water,
immediately prior to use. Extemporaneous injection solutions and
suspensions may be prepared from sterile powders, granules and
tablets of the kind previously described.
[0351] Formulations for parenteral administration include aqueous
and non-aqueous (oily) sterile injection solutions of the active
compounds which may contain antioxidants, buffers, bacteriostats
and solutes which render the formulation isotonic with the blood of
the intended recipient; and aqueous and non-aqueous sterile
suspensions which may include suspending agents and thickening
agents. Suitable lipophilic solvents or vehicles include fatty oils
such as sesame oil, or synthetic fatty acid esters, such as ethyl
oleate or triglycerides, or liposomes. Aqueous injection
suspensions may contain substances which increase the viscosity of
the suspension, such as sodium carboxymethyl cellulose, sorbitol,
or dextran. Optionally, the suspension may also contain suitable
stabilizers or agents which increase the solubility of the
compounds to allow for the preparation of highly concentrated
solutions.
[0352] In addition to the formulations described previously, the
compounds may also be formulated as a depot preparation. Such long
acting formulations may be administered by implantation (for
example subcutaneously or intramuscularly) or by intramuscular
injection. Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0353] For buccal or sublingual administration, the compositions
may take the form of tablets, lozenges, pastilles, or gels
formulated in conventional manner. Such compositions may comprise
the active ingredient in a flavored basis such as sucrose and
acacia or tragacanth.
[0354] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, e.g., containing
conventional suppository bases such as cocoa butter, polyethylene
glycol, or other glycerides.
[0355] Certain compounds disclosed herein may be administered
topically, that is by non-systemic administration. This includes
the application of a compound disclosed herein externally to the
epidermis or the buccal cavity and the instillation of such a
compound into the ear, eye and nose, such that the compound does
not significantly enter the blood stream. In contrast, systemic
administration refers to oral, intravenous, intraperitoneal and
intramuscular administration.
[0356] Formulations suitable for topical administration include
liquid or semi-liquid preparations suitable for penetration through
the skin to the site of inflammation such as gels, liniments,
lotions, creams, ointments or pastes, and drops suitable for
administration to the eye, ear or nose. The active ingredient for
topical administration may comprise, for example, from 0.001% to
10% w/w (by weight) of the formulation. In certain embodiments, the
active ingredient may comprise as much as 10% w/w. In other
embodiments, it may comprise less than 5% w/w. In certain
embodiments, the active ingredient may comprise from 2% w/w to 5%
w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of
the formulation.
[0357] For administration by inhalation, compounds may be
conveniently delivered from an insufflator, nebulizer pressurized
packs or other convenient means of delivering an aerosol spray.
Pressurized packs may comprise a suitable propellant such as
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of a pressurized aerosol, the dosage unit may be
determined by providing a valve to deliver a metered amount.
Alternatively, for administration by inhalation or insufflation,
the compounds may take the form of a dry powder composition, for
example a powder mix of the compound and a suitable powder base
such as lactose or starch. The powder composition may be presented
in unit dosage form, in for example, capsules, cartridges, gelatin
or blister packs from which the powder may be administered with the
aid of an inhalator or insufflator.
[0358] In one embodiment, a compound is prepared for delivery in a
sustained-release, controlled release, extended-release,
timed-release or delayed-release formulation, for example, in
semipermeable matrices of solid hydrophobic polymers containing the
therapeutic agent. Various types of sustained-release materials
have been established and are well known by those skilled in the
art. Current extended-release formulations include film-coated
tablets, multiparticulate or pellet systems, matrix technologies
using hydrophilic or lipophilic materials and wax-based tablets
with pore-forming excipients (see, for example, Huang, et al. Drug
Dev. Ind. Pharm. 29:79 (2003); Pearnchob, et al. Drug Dev. Ind.
Pharm. 29:925 (2003); Maggi, et al. Eur. J. Pharm. Biopharm. 55:99
(2003); Khanvilkar, et al., Drug Dev. Ind. Pharm. 228:601 (2002);
and Schmidt, et al., Int. J. Pharm. 216:9 (2001)).
Sustained-release delivery systems can, depending on their design,
release the compounds over the course of hours or days, for
instance, over 4, 6, 8, 10, 12, 16, 20, 24 hours or more. Usually,
sustained release formulations can be prepared using
naturally-occurring or synthetic polymers, for instance, polymeric
vinyl pyrrolidones, such as polyvinyl pyrrolidone (PVP);
carboxyvinyl hydrophilic polymers; hydrophobic and/or hydrophilic
hydrocolloids, such as methylcellulose, ethylcellulose,
hydroxypropylcellulose, and hydroxypropylmethylcellulose; and
carboxypolymethylene.
[0359] The sustained or extended-release formulations can also be
prepared using natural ingredients, such as minerals, including
titanium dioxide, silicon dioxide, zinc oxide, and clay (see, U.S.
Pat. No. 6,638,521, herein incorporated by reference). Exemplified
extended release formulations that can be used in delivering a
compound include those described in U.S. Pat. Nos. 6,635,680;
6,624,200; 6,613,361; 6,613,358, 6,596,308; 6,589,563; 6,562,375;
6,548,084; 6,541,020; 6,537,579; 6,528,080 and 6,524,621, each of
which is hereby incorporated herein by reference. Controlled
release formulations of particular interest include those described
in U.S. Pat. Nos. 6,607,751; 6,599,529; 6,569,463; 6,565,883;
6,482,440; 6,403,597; 6,319,919; 6,150,354; 6,080,736; 5,672,356;
5,472,704; 5,445,829; 5,312,817 and 5,296,483, each of which is
hereby incorporated herein by reference. Those skilled in the art
will readily recognize other applicable sustained release
formulations.
[0360] Systemic administration can also be by transmucosal or
transdermal means. For transmucosal or transdermal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. For topical administration, the agents can be
formulated into ointments, creams, salves, powders or gels. In one
embodiment, the transdermal delivery agent can be DMSO. Transdermal
delivery systems can include, e.g., patches. For transmucosal
administration, penetrants appropriate to the barrier to be
permeated are used in the formulation. Such penetrants are
generally known in the art. Exemplified transdermal delivery
formulations that can find use with the compounds disclosed herein
include those described in U.S. Pat. Nos. 6,589,549; 6,544,548;
6,517,864; 6,512,010; 6,465,006; 6,379,696; 6,312,717 and
6,310,177, each of which are hereby incorporated herein by
reference.
[0361] The precise amount of compound administered to a patient
will be the responsibility of the attendant physician. The specific
dose level for any particular patient will depend upon a variety of
factors including the activity of the specific compound employed,
the age, body weight, general health, sex, diets, time of
administration, route of administration, rate of excretion, drug
combination, the precise disorder being treated, and the severity
of the indication or condition being treated. Also, the route of
administration may vary depending on the condition and its
severity. The dosage can be increased or decreased over time, as
required by an individual patient. A patient initially may be given
a low dose, which is then increased to an efficacious dosage
tolerable to the patient. Typically, a useful dosage for adults may
be from 5 to 2000 mg, but have been known to range from 0.1 to 500
mg/kg per day. By way of example, a dose may range from 1 to 200
mg, when administered by oral route; or from 0.1 to 100 mg or, in
certain embodiments, 1 to 30 mg, when administered by intravenous
route; in each case administered, for example, from 1 to 4 times
per day. When a compound is administered in combination with
another therapeutic agent, a useful dosage of the combination
partner may be from 20% to 100% of the normally recommended dose,
since, as discussed below, even doses of a given drug which would
be subtherapeutic if administered on its own may be therapeutic
when used in combination with another agent.
[0362] Dosage amount and interval can be adjusted individually to
provide plasma levels of the active compounds which are sufficient
to maintain therapeutic effect. In certain embodiments,
therapeutically effective serum levels will be achieved by
administering single daily doses, but efficacious multiple daily
dose schedules may be used as well. In cases of local
administration or selective uptake, the effective local
concentration of the drug may not be related to plasma
concentration. One having skill in the art will be able to optimize
therapeutically effective local dosages without undue
experimentation. Additionally, applicable methods for determining
an appropriate dose and dosing schedule for administration of
compounds such as those disclosed herein are described, for
example, in Goodman and Gilman's The Pharmacological Basis of
Therapeutics, 11.sup.th Ed., Brunton, Lazo and Parker, Eds.,
McGraw-Hill (2006), and in Remington: The Science and Practice of
Pharmacy, 21.sup.st Ed., Gennaro, Ed. Lippencott Williams &
Wilkins (2003), both of which are hereby incorporated herein by
reference.
[0363] In certain instances, it may be appropriate to administer at
least one of the compounds described herein (or a pharmaceutically
acceptable salt, ester, or prodrug thereof) in combination with
another therapeutic agent. By way of example only, if one of the
side effects experienced by a patient upon receiving one of the
compounds herein is hypertension, then it may be appropriate to
administer an anti-hypertensive agent in combination with the
initial therapeutic agent. Or, by way of example only, the
therapeutic effectiveness of one of the compounds described herein
may be enhanced by administration of an adjuvant (i.e., by itself
the adjuvant may only have minimal therapeutic benefit, but in
combination with another therapeutic agent, the overall therapeutic
benefit to the patient is enhanced). Or, by way of example only,
the benefit of experienced by a patient may be increased by
administering one of the compounds described herein with another
therapeutic agent (which also includes a therapeutic regimen) that
also has therapeutic benefit. By way of example only, in a
treatment for HIV dementia involving administration of one of the
compounds described herein, increased therapeutic benefit may
result by also providing the patient with another therapeutic agent
for dementia or inflammation. In any case, regardless of the
disease, disorder or condition being treated, the overall benefit
experienced by the patient may simply be additive of the two
therapeutic agents or the patient may experience a synergistic
benefit.
[0364] Specific, non-limiting examples of possible combination
therapies include use of certain compounds disclosed herein with
compounds used for treating diseases and conditions which can be
affected by SGLT inhibition, such as antidiabetic agents,
lipid-lowering/lipid-modulating agents, agents for treating
diabetic complications, anti-obesity agents, antihypertensive
agents, antihyperuricemic agents, and agents for treating chronic
heart failure, atherosclerosis or related disorders.
[0365] In any case, the multiple therapeutic agents (at least one
of which is a compound disclosed herein) may be administered in any
order or even simultaneously. If simultaneously, the multiple
therapeutic agents may be provided in a single, unified form, or in
multiple forms (by way of example only, either as a single pill or
as two separate pills). One of the therapeutic agents may be given
in multiple doses, or both may be given as multiple doses. If not
simultaneous, the timing between the multiple doses may be any
duration of time ranging from a few minutes to four weeks.
[0366] Examples of agents to be used in combination with compounds
disclosed herein include lithium, valproate and other agents used
in neuroprotection, PAF receptor antagonists, antioxidants
including mitochondrially-targeted antioxidants, activators of
SIRTI and other sirtuins, inhibitors of indoleamine 2,3
dehydrogenase (IDO), agents which enhance trans-blood brain bather
(BBB) uptake of drugs, including compounds that inhibit drug pumps
at the BBB such as, for example, ritonavir; HAART drugs and other
agents for use in HIV treatment; agents for the treatment of
cardiovascular, heart, and metabolic disorders, such as HMG-CoA
reductase inhibitors including statins, insulin and insulin
mimetics, and glycogen synthase kinase-3 beta (GSK3.beta.)
inhibitors; agents which "normalize" mitochondrial function;
antiinflammatory agents including PAF receptor antagonists or PAF
acetylhydrolase, cyclooxygenase inhibitors (including COX-2
selective and nonselective) such as aspirin, ibuprofen, naproxen,
and celecoxib; and agents for blocking liver cell proliferation,
such as JNK inhibitors.
[0367] Also provided are combinations of multiple agents, such as
lithium plus a GSK3.beta. blocker, to be used in combination with
the compounds provided herein.
[0368] Additionally, agents for neuroprotection and/or neurogenesis
include selective serotonin reuptake inhibitors SSRIs and small
molecule agonists of neurotrophin receptors.
[0369] Any of the aforementioned agents may be combined with viral
vectors that express genes intended to induce neural progenitor
cells, as well.
[0370] Treatment with the compounds disclosed here in may also be
effective when delivered along with deep-brain stimulation, such as
in Parkinsonism and HIV-associated dementia/HIV-associated
neurocognitive disorder.
[0371] Thus, in another aspect, certain embodiments provide methods
for treating MLK3-mediated disorders in a human or animal subject
in need of such treatment comprising administering to said subject
an amount of a compound disclosed herein effective to reduce or
prevent said disorder in the subject, in combination with at least
one additional agent for the treatment of said disorder that is
known in the art. In a related aspect, certain embodiments provide
therapeutic compositions comprising at least one compound disclosed
herein in combination with one or more additional agents for the
treatment of MLK3-mediated disorders.
[0372] Specific diseases to be treated by the compounds,
compositions, and methods disclosed herein include: metabolic
diseases such as type 1 and type 2 diabetes mellitus,
hyperglycemia, diabetic complications (such as retinopathy,
nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout
and diabetic foot disease), insulin resistance, metabolic syndrome
(Syndrome X), hyperinsulinemia, hypertension, hyperuricemia,
obesity, edema, dyslipidemia, hepatic steatosis, non-alcoholic
steatohepatitis (NASH), chronic heart failure, and
atherosclerosis.
[0373] Compounds disclosed herein may also be useful for the
treatment of inflammatory diseases such as bacterial sepsis, otitis
media, endotoxemia, mucosal hyperplasia, inflammatory bowel
disease, Crohn's disease, irritable bowel syndrome, and ulcerative
colitis; and respiratory diseases and conditions such as asthma,
chronic obstructive pulmonary disease (COPD), and acute
inhalation-induced lung injury.
[0374] Compounds disclosed herein may also be useful for the
treatment of autoimmune diseases such as multiple sclerosis,
rheumatoid arthritis, lupus and Crohn's disease.
[0375] Compounds disclosed herein may also be useful for the
treatment of proliferative disorders including cancers such as
liver cancer. Furthermore, Compounds disclosed herein may also be
useful for the treatment of hepatitis, including viral hepatitis,
and non-alcoholic steatohepatitis (NASH).
[0376] Compounds disclosed herein may also be useful for the
treatment of ischemic injury, including stroke, cerebral
ischemia/reperfusion, myocardial infarction, and ischemic heart
disease.
[0377] Compounds disclosed herein may also be useful for the
treatment of diseases and disorders of the nervous system such as
Alzheimer's Disease (AD), Parkinson's Disease, HIV dementia, HIV
associated neurocognitive disorder (HAND), neuroinflammatory
diseases, and neuropathies including drug-induced peripheral
neuropathy, and diabetic neuropathy, and HIV-associated neuropathy,
ototoxicity and hearing loss, acute insults to the inner ear,
including acoustic trauma, blast noise (for example, as experienced
by military personnel), exposure to ototoxic chemotherapeutic
agents for cancer therapy (such as cisplatin) and treatment with
aminoglycoside antibiotics. Compounds disclosed herein may also be
useful for the treatment of traumatic brain injury including
stroke.
[0378] Compounds disclosed herein may also be useful for the
treatment of pain including inflammatory pain, neuropathic pain,
back pain including discogenic pain, the pain of arthritis and
autoimmune disorders such as rheumatoid arthritis, and cancer pain
including pain due to bone metastasis.
[0379] Compounds disclosed herein may also be useful for the
treatment of psychological disorders including depression or major
depressive disorder (MDD), bipolar disorder, and post-traumatic
stress disorder.
[0380] Compounds disclosed herein may also be useful for
enhancement of stem-cell based therapies in the central nervous
system (CNS).
[0381] All publications and patent applications cited in this
specification are herein incorporated by reference as if each
individual publication or patent application were specifically and
individually indicated to be incorporated by reference. Although
the foregoing has been described in some detail by way of
illustration and example for purposes of clarity of understanding,
it will be readily apparent to those of ordinary skill in the art
in light of the teachings of this invention that certain changes
and modifications can be made thereto without departing from the
spirit or scope of the invention.
EXAMPLES
[0382] The invention is further illustrated by the following
examples, which are offered for illustrative purposes, and are not
intended to limit the invention in any manner. Those of skill in
the art will readily recognize a variety of noncritical parameters,
which can be changed or modified to yield essentially the same
results.
[0383] The structures of compounds synthesized in the examples
below were confirmed using the following procedures. LC-MS/UV/ELS
analysis was performed on instrumentation consisting of Shimadzu
LC-LOAD vp series HPLC pumps and dual wavelength IJV detector, a
Gilson 215 autosampler, a Sedex 75c evaporative light scattering
(ELS) detector, and a PE/Sciex API 150EX mass spectrometer. The ELS
detector was set to a temperature of 40.degree. C., a gain setting
of 7, and a N3 pressure of 3.3 atm. The Turbo IonSpray source was
employed on the API 150 with an ion spray voltage of 5 kV, a
temperature of 300.degree. C., and orifice and ring voltages of 5 V
and 175 V respectively. Positive ions were scanned in Q1 from 160
to 650 m/z. 5.0 .mu.L injections were performed for each sample, on
a Phenomenex Gemini 5 .mu.m C18 column. Mobile phases consisted of
0.05% formic acid in both HPLC grade water (A) and HPLC grade
acetonitrile (B). 5.0 injections were performed for each sample,
using gradient elution from 5% B to 100% B in 4 min at a flow rate
of 2.0 mL/min with a final hold at 100% B of 1.8 min UV and ELS
data is collected for 4.5 min Routine one-dimensional NMR
spectroscopy was performed on a 300 MHz Varian Mercury-Plus
spectrometer. The samples were dissolved in deuterated solvents
obtained from Cambridge Isotope Laboratories, Inc., and transferred
to 5 mm ID NMR tubes. The spectra were acquired at 293 K. The
chemical shifts were recorded on the ppm scale and were referenced
to the appropriate solvent signals, such as 2.49 ppm for DMSO-d6,
1.93 ppm for CD.sub.3CN, 3.30 ppm for CD.sub.3OD, 5.32 ppm for
CD.sub.3Cl.sub.3 and 7.26 ppm for CDCl.sub.3 for .sup.1H
spectra.
[0384] Other equipment and techniques standard in the art of
chemical analysis and characterization may be used.
Example L
##STR00008##
[0385] Preparation of
5-bromo-3-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine (Intermediate
A)
##STR00009##
[0387] To a stirred solution of
5-bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine (0.70 g, 2.2 mmol) in 15
mL of anhydrous THF cooled to 0.degree. C. with an ice bath was
added NaH [60% dispersion in mineral oil] (0.13 g, 3.3 mmol). The
reaction mixture was stirred for 20 min at 0.degree. C., after
which p-toluenesulfonyl chloride (0.47 g, 2.4 mmol) was added. The
resulting mixture was stirred at 0.degree. C. for 1.5 hr, after
which cold 0.5 M HCl (20 mL) was added. The mixture was partitioned
between EtOAc and 0.5 M HCl, after which the organic layer was
separated, dried over MgSO.sub.4, filtered, and evaporated in vacuo
to yield a residue that was triturated with 20% CH.sub.2Cl.sub.2 in
hexanes to yield the title compound (0.84 g, 81%) as a light yellow
powder. .sup.1H NMR (DMSO-d6, 300 MHz) .delta. 8.51 (d, J=2.1 Hz,
1H), 8.22 (s, 1H), 8.02 (d, J=1.2 Hz, 1H), 8.00 (d, J=5.1 Hz, 2H),
7.44 (dd, J=8.7 Hz, 0.6 Hz, 2H), 2.35 (s, 3H); MS ESI (m/z):
477.0/479.0 (M+1).sup.+, calc. 476.
Preparation of
5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine
(Intermediate B)
##STR00010##
[0389] To a stirred suspension of
5-bromo-3-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine (0.35 g, 0.73
mmol) and 1H-indol-5-ylboronic acid (0.14 mg, 0.88 mmol) in
CH.sub.3CN (10 mL) was added 1 M Na.sub.2CO.sub.3 (10 mL) followed
by bis(triphenylphosphine)palladium(II) dichloride (0.050 g, 0.071
mmol). The resulting mixture was stirred overnight at 60.degree. C.
After the mixture was evaporated to dryness in vacuo, it was
dissolved in DMF (3 m, absorbed onto Celite, and dried. The residue
was purified via silica gel chromatography using CH.sub.2Cl.sub.2
as the eluent to obtain the title compound (0.26 g, 76%). .sup.1H
NMR (CDCl.sub.3, 300 MHz): .delta. 8.48 (d, J=2.1 Hz, 1H), 8.27
(bs, 1H), 8.26 (d, J=2.4 Hz, 1H), 8.08 (d, J=8.1 Hz), 7.85 (s, 1H),
7.81 (m, 1H), 7.50 (d, J=8.7 Hz, 1H), 7.37 (dd, J=1.8, 8.4 Hz),
7.30 (m, 3H), 6.63 (m, 1H), 2.39 (s, 3H); MS ESI (m/z): 466.2/468.2
(M+1).sup.+, calc. 465.
Preparation of
3-(1H-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridine
(Compound C)
##STR00011##
[0391] To a solution of
5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (65 mg,
0.14 mmol) in CH.sub.3CN (1 mL) in a Personal Chemistry microwave
reaction vial was added 3,4,5-trimethoxyphenylboronic acid (30 mg,
0.14 mmol), bis(triphenylphosphine)-palladium(II) dichloride (7.0
mg, 0.010 mmol), and 1 M Na.sub.2CO.sub.3 (1 mL). The resulting
mixture was de-gassed with Ar for 10 min, after which it was heated
at 150.degree. C. for 10 min in a Personal Chemistry Optimizer. The
organic layer was separated, filtered, and concentrated in vacuo.
The residue was dissolved in MeOH (3 mL) and acetone (2 mL), and 2
M NaOH (1.5 mL) was added. The resulting mixture was stirred at
65.degree. C. for 30 min, after which it was partitioned between
EtOAc and 1 M NaOH. The organic layer was separated, dried over
MgSO.sub.4, filtered, and stripped to give a residue purified via
preparatory HPLC to give the title compound as a white solid.
.sup.1H NMR (DMSO-d6, 300 MHz): .delta. 11.78 (s, 1H), 11.03 (s,
1H), 8.51 (d, J=2.1 Hz, 1H), 8.36 (d, J=1.8 Hz, 1H), 7.86 (s, 1H),
7.72 (d, J=2.4 Hz, 1H). 7.45 (s, 2H), 7.32 (m, 1H), 6.92 (s, 2H),
6.45 (m, 1H), 3.85 (s, 6H), 3.70 (s, 3H); HPLC retention time: 2.04
minutes; MS ESI (m/z): 400.4 (M+1).sup.+, calc. 399.
Example 2
Preparation of
5-(3,4-dimethoxyphenyl)-3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridine
(Compound D)
##STR00012##
[0393] Compound D was prepared by a method analogous to that
described in Example 1 by substituting 3,4-dimethoxyphenylboronic
acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 2.33 minutes. MS ESI (m/z):
370.2 (M+H).sup.+, calc. 369.
Example 3
Preparation of
N-(4-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)acetamide
(Compound E)
##STR00013##
[0395] Compound E was prepared by a method analogous to that
described in Example 1 by substituting 4-acetamidophenylboronic
acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 1.86 minutes. MS ESI (m/z):
367.4 (M+H).sup.+, calc. 366.
Example 4
Preparation of
5-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-amine
(Compound F)
##STR00014##
[0397] Compound F was prepared by a method analogous to that
described in Example 1 by substituting
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for
3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. .sup.1H NMR (DMSO-d6, 300 MHz): .delta. 11.73 (d,
J=1.8 Hz, 1H), 11.05 (s, 1H), 8.43 (d, J=2.4 Hz, 1H), 8.29 (d,
J=1.8 Hz, 1H), 8.27 (d, J=2.1 Hz, 1H), 7.88 (s, 1H), 7.76 (dd,
J=2.4, 8.4 Hz, 1H), 7.46 (s, 2H), 7.33 (m, 1H), 6.55 (dd, J=0.6,
8.7 Hz, 1H), 6.46 (m, 1H), 5.99 (s, 2H). HPLC retention time: 1.10
minutes. MS ESI (m/z): 326.2 (M+H).sup./, calc. 325.
Example 5
Preparation of
4-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-methoxyaniline
(Compound G)
##STR00015##
[0399] Compound G was prepared by a method analogous to that
described in Example 1 by substituting
4-amino-3-methoxyphenylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 1.54 minutes. MS ESI (m/z):
355.4 (M+H).sup.+, calc. 354.
Example 6
Preparation of
3-(1H-indol-5-yl)-5-(6-methoxypyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine
(Compound H)
##STR00016##
[0401] Compound H was prepared by a method analogous to that
described in Example 1 by substituting 6-methoxypyridin-3-ylboronic
acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 2.16 minutes. MS ESI (m/z):
341.4 (M+H).sup.+, calc. 340.
Example 7
Preparation of
3-(1H-indol-5-yl)-5-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-pyrrolo[2-
,3-b]pyridine (Compound I)
##STR00017##
[0403] Compound I was prepared by a method analogous to that
described in Example 1 by substituting
2-(4-methylpiperazin-1-yl)pyridin-4-ylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 1.37 minutes. MS ESI (m/z):
409.4 (M+H).sup.+, calc. 408.
Example 8
Preparation of
4-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)aniline
(Compound J)
##STR00018##
[0405] Compound J was prepared by a method analogous to that
described in Example 1 by substituting 4-aminophenylboronic acid
for 3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 1.47 minutes. MS ESI (m/z):
325.4 (M+H).sup.+, calc. 324.
Example 9
Preparation of
5-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-amine
(Compound K)
##STR00019##
[0407] Compound K was prepared by a method analogous to that
described in Example 1 by substituting 2-aminopyrimidin-5-ylboronic
acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 1.81 minutes. MS ESI (m/z):
327.2 (M+H).sup.+, calc. 326.
Example 10
Preparation of
3-(1H-indol-5-yl)-5-(6-(piperazin-1-yl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyr-
idine (Compound L)
##STR00020##
[0409] Compound L was prepared by a method analogous to that
described in Example 1 by substituting
6-(piperazin-1-yl)pyridin-3-ylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 1.15 minutes. MS ESI (m/z)
395.4 (M+H).sup.+, calc. 394.
Example 11
Preparation of
N-(4-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)methanesulfo-
namide (Compound M)
##STR00021##
[0411] Compound M was prepared by a method analogous to that
described in Example 1 by substituting
4-(methylsulfonamido)phenylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 1.99 minutes. MS ESI (m/z):
403.4 (M+H)+, talc. 402.
Example 12
Preparation of 3,5-di(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridine
(Compound N)
##STR00022##
[0413] Compound N was prepared by a method analogous to that
described in Example 1 by substituting 1H-indol-5-ylboronic acid
for 3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 2.01 minutes. MS ESI (m/z):
349.2 (M+H)+, talc. 348.
Example 13
Preparation of
5-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylpyridin-2-
-amine (Compound O)
##STR00023##
[0415] Compound O was prepared by a method analogous to that
described in Example 1 by substituting
6-(dimethylamino)pyridin-3-ylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 1.58 minutes. MS ESI (m/z):
354.4 (M+H).sup.+, calc. 353.
Example 14
Preparation of 3-(1H-indol-5-yl)-5-phenyl-1H-pyrrolo[2,3-b]pyridine
(Compound P)
##STR00024##
[0417] Compound P was prepared by a method analogous to that
described in Example 1 by substituting phenylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate B. HPLC retention time: 2.49 minutes. MS ESI (m/z):
310.2 (M+H).sup.+, calc. 309.
Example 15
Preparation of
4-(5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)aniline
(Compound Q)
##STR00025##
[0419] Compound Q was prepared by a method analogous to that
described in Example 1 by substituting 4-aminophenylboronic acid
for 1H-indol-5-ylboronic acid in the reaction with Intermediate A.
HPLC retention time: 1.45 minutes. MS ESI (m/z): 376.4 (M+H).sup.+,
calc. 375.
Example 16
Preparation of
N-(4-(5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)ace-
tamide (Compound R)
##STR00026##
[0421] Compound R was prepared by a method analogous to that
described in Example 1 by substituting 4-acetamidophenylboronic
acid for 1H-indol-5-ylboronic acid in the reaction with
Intermediate A. HPLC retention time: 1.98 minutes. MS ESI (m/z):
418.6 (M+H).sup.+, calc. 417.
Example 17
Preparation of
5-(5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-a-
mine (Compound S)
##STR00027##
[0423] Compound S was prepared by a method analogous to that
described in Example 1 by substituting 2-aminopyrimidin-5-ylboronic
acid for 1H-indol-5-ylboronic acid in the reaction with
Intermediate A. HPLC retention time: 1.98 minutes. MS ESI (m/z):
378.4 (M+H).sup.+, calc. 377.
Example 18
Preparation of
5-(5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2-ami-
ne (Compound T)
##STR00028##
[0425] Compound T was prepared by a method analogous to that
described in Example 1 by substituting
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for
1H-indol-5-ylboronic acid in the reaction with Intermediate A.
.sup.1H NMR (DMSO-d6, 300 MHz): .delta. 11.82 (s, 1H), 8.53 (d,
J=1.8 Hz, 1H), 8.31 (d, J=1.8, 1 H), 8.28 (d, J=1.5 Hz), 7.76 (dd,
J=2.1, 8.4 Hz, 1H), 7.70 (d, J=2.4 Hz, 1H), 6.95 (s, 2H), 6.54 (d,
J=8.4 Hz, 1H), 5.87 (s, 2H), 3.86 (s, 6H), 3.68 (s, 3H); HPLC
retention time: 1.10 minutes. MS ESI (m/z): 377.4 (M+H).sup.+,
calc. 376.
Example 19
Preparation of
N,N-dimethyl-5-(5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-
pyridin-2-amine (Compound U)
##STR00029##
[0427] Compound U was prepared by a method analogous to that
described in Example 1 by substituting
6-(dimethylamino)pyridin-3-ylboronic acid for 1H-indol-5-ylboronic
acid in the reaction with Intermediate A. HPLC retention time: 1.43
minutes. MS ESI (m/z): 405.6 (M+H).sup.+, calc. 404.
Example 20
Preparation of
5,5'-(1H-pyrrolo[2,3-b]pyridine-3,5-diyl)dipyrimidin-2-amine
(Compound W)
##STR00030##
[0429] Compound W was prepared by a method analogous to that
described in Example 1 by substituting 2-aminopyrimidin-5-ylboronic
acid for 1H-indol-5-ylboronic acid in the reaction with
Intermediate A and 2-aminopyrimidin-5-ylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
Intermediate B. HPLC retention time: 1.17 minutes. MS ESI (m/z):
305.2 (M+H).sup.+, calc. 304.
Example 21
Preparation of
5,5'-(1H-pyrrolo[2,3-b]pyridine-3,5-diyl)bis(N,N-dimethylpyridin-2-amine)
(Compound X)
##STR00031##
[0431] Compound X was prepared by a method analogous to that
described in Example 1 by substituting
6-(dimethylamino)pyridin-3-ylboronic acid for 1H-indol-5-ylboronic
acid in the reaction with Intermediate A and
6-(dimethylamino)pyridin-3-ylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
Intermediate B. HPLC retention time: 1.17 minutes. MS ESI (m/z):
359.4 (M+H) calc. 358.
Example 22
Preparation of
5-(3-(3-chloro-4-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethy-
lpyridin-2-amine (Compound Y)
##STR00032##
[0433] Compound Y was prepared by a method analogous to that
described in Example 1 by substituting
3-chloro-4-fluorophenylboronic acid for 1H-indol-5-ylboronic acid
in the reaction with Intermediate A and
6-(dimethylamino)pyridin-3-ylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
Intermediate B. HPLC retention time: 1.73 minutes. MS ESI (m/z):
367.2 (M+H).sup.+, calc. 366.
Example 23
Preparation of
5-(3-(4-aminophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-amine
(Compound Z)
##STR00033##
[0435] Compound Z was prepared by a method analogous to that
described in Example 1 by substituting 4-aminophenylboronic acid
for 1H-indol-5-ylboronic acid in the reaction with Intermediate A
and 6-aminopyridin-3-ylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
Intermediate B. HPLC retention time: 0.68 minutes. MS ESI (m/z):
302.4 (M+H)+, talc. 301.
Example 24
Preparation of
3-(1-methyl-1H-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]py-
ridine (Compound AA)
##STR00034##
[0437] Compound AA was prepared by a method analogous to that
described in Example 1 by substituting
1-methyl-1H-indol-5-ylboronic acid for 1H-indol-5-ylboronic acid in
the reaction with Intermediate A. HPLC retention time: 2.29
minutes. MS ESI (m/z): 414.4 (M+H) talc. 413.
Example 25
Preparation of
4-(5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzamide
(Compound AB)
##STR00035##
[0439] Compound AB was prepared by a method analogous to that
described in Example 1 by substituting 4-carbamoylphenylboronic
acid for 1H-indol-5-ylboronic acid in the reaction with
Intermediate A. HPLC retention time: 1.64 minutes. MS ESI (m/z):
404.6 (M+H).sup.+, calc. 403.
Example 26
Preparation of
4-(5-(3,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzamide
(Compound AC)
##STR00036##
[0441] Compound AC was prepared by a method analogous to that
described in Example 1 by substituting 4-carbamoylphenylboronic
acid for 1H-indol-5-ylboronic acid in the reaction with
Intermediate A and 3,4-dimethoxyphenylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
Intermediate B. HPLC retention time: 1.60 minutes. MS ESI (m/z):
374.2 (M+H).sup.+, calc. 373.
Example 27
Preparation of
4-(5-(4-amino-3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzamide
(Compound AD)
##STR00037##
[0443] Compound AD was prepared by a method analogous to that
described in Example 1 by substituting 4-carbamoylphenylboronic
acid for 1H-indol-5-ylboronic acid in the reaction with
Intermediate A and 4-amino-3-methoxyphenylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
Intermediate B. HPLC retention time: 1.46 minutes. MS ESI (m/z):
359.2 (M+H).sup.+, calc. 358.
Example 28
Preparation of
4-(5-(6-aminopyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzamide
(Compound AE)
##STR00038##
[0445] Compound AE was prepared by a method analogous to that
described in Example 1 by substituting 4-carbamoylphenylboronic
acid for 1H-indol-5-ylboronic acid in the reaction with
Intermediate A and
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for
3,4,5-trimethoxyphenylboronic acid in the reaction with
Intermediate B. HPLC retention time: 1.13 minutes. MS ESI (m/z):
330.4 (M+H).sup.+, calc. 329.
Example 29
Preparation of
5-(3-(3-chloro-4-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-am-
ine (Compound AF)
##STR00039##
[0447] Compound AF was prepared by a method analogous to that
described in Example 1 by substituting
3-chloro-4-fluorophenylboronic acid for 1H-indol-5-ylboronic acid
in the reaction with Intermediate A and
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for
3,4,5-trimethoxyphenylboronic acid in the reaction with
Intermediate B. HPLC retention time: 1.47 minutes. MS ESI (m/z):
339.4 (M+H).sup.+, calc. 338.
Example 30
##STR00040##
[0448] Preparation of
5-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methylpyridin-2-ami-
ne (Compound AH)
##STR00041##
[0450] To a solution of
5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (40 mg,
0.09 mmol) in CH.sub.3CN (1 mL) in a Personal Chemistry microwave
reaction vial was added 6-fluoropyridin-3-ylboronic acid (12 mg,
0.09 mmol), bis(triphenylphosphine)-palladium(II) dichloride (5.0
mg, 0.007 mmol), and 1 M Na.sub.2CO.sub.3 (1 mL). The resulting
mixture was de-gassed with Ar for 10 min, after which it was heated
at 150.degree. C. for 10 min in a Personal Chemistry Optimizer. The
organic layer was separated, filtered, and concentrated in vacuo to
give intermediate Q. The residue was dissolved in DMSO (0.5 mL) and
methyl amine hydrochloride salt (29 mg, 0.43 mmol), and
K.sub.2CO.sub.3 (95 mg, 0.70 mmol) were added. The resulting
mixture was stirred at 80.degree. C. for 48 hr, after which it was
diluted with DMF (0.5 mL), filtered, and subjected to preparative
HPLC to yield the title compound (6.0 mg, 21%). .sup.1H NMR
(DMSO-d6, 300 MHz): .delta. 11.77 (s, 1H), 11.07 (s, 1H), 8.46 (d,
J=2.1 Hz, 1H), 8.34 (dd, J=2.4, 9.3 Hz, 1H), 7.90 (s, 1H), 7.86 (m,
1H), 7.74 (d, J=2.7 Hz, 1H), 7.47 (s, 2H), 7.35 (s, 1H), 6.80 (s,
1H), 6.63 (d, J=8.4 Hz, 1H), 6.48 (m, 1H), 2.84 (d, J=4.5 Hz, 1H).
HPLC retention time: 1.10 minutes; HPLC retention time: 1.56
minutes; MS ESI (m/z): 340.2 (M+1).sup.+, calc. 339.
Example 31
Preparation of
5-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-(2-(pyrrolidin-1-yl-
)ethyl)pyridin-2-amine (Compound AI)
##STR00042##
[0452] Compound AI was prepared by a method analogous to that
described in Example 15 by substituting
2-(pyrrolidin-1-yl)ethanamine for methylamine hydrochloride salt in
the reaction with intermediate Q. HPLC retention time: 1.58 minutes
MS ESI (m/z): 354.4 (M+H).sup.+, calc. 353.
Example 32
##STR00043##
[0453] Preparation of
4-(3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)benzaldehyde
(Intermediate AJ)
##STR00044##
[0455] To a solution of
5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine
[Intermediate B] (0.20 g, 0.43 mmole) in CH.sub.3CN (4 mL) in a
Personal Chemistry microwave reaction vial was added
4-formylphenylboronic acid (64 mg, 0.43 mmol),
bis(triphenylphosphine)-palladium(II) dichloride (40 mg, 0.057
mmol), and 1 M Na.sub.2CO.sub.3 (2 mL). The resulting mixture was
de-gassed with Ar for 10 min, after which it was heated at
150.degree. C. for 10 min in a Personal Chemistry Optimizer. The
organic layer was separated, filtered, and partitioned between
EtOAc and brine. The organic layer was dried over MgSO.sub.4,
filtered, and concentrated in vacuo to give Intermediate AJ. HPLC
retention time: 3.01 minutes. MS ESI (m/z): 492.4 (M+H).sup.+,
calc. 491.
Preparation of
3-(1H-indol-5-yl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrrolo-
[2,3-b]pyridine (Compound AK)
##STR00045##
[0457] To a solution of
4-(3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)benzaldehyde
[Intermediate AJ] (0.11 g, 0.214 mmol) in CH.sub.2Cl.sub.2 (3 mL)
was added 1-methylpiperazine (40 .mu.L, 0.40 mmol) and sodium
triacetoxyborohydride (68 mg, 0.32 mmol). The reaction mixture was
stirred for 1 hr at room temperature, after which it was
partitioned between CH.sub.2Cl.sub.2 and 1 M NaOH. The organic
layer was separated, dried over MgSO.sub.4, and concentrated in
vacuo. The residue was dissolved in 3:2 MeOH:acetone (5 mL), and 2
M NaOH (1.5 mL) was added. The resulting mixture was stirred at
65.degree. C. for 30 min, after which it was partitioned between
EtOAc and 1 M NaOH. The organic layer was separated, dried over
MgSO.sub.4, filtered, and stripped to provide a residue that was
subjected to preparatory HPLC to yield the title compound. HPLC
retention time: 1.63 minutes; MS ESI (m/z) 422.4 (M+1).sup.+, calc.
421.
Example 33
Preparation of
1-(4-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)-N,N-dimethy-
lmethanamine (Compound AL)
##STR00046##
[0459] Compound AL was prepared by a method analogous to that
described in Example 33 by substituting dimethylamine (2 M solution
in THF) for 1-methylpiperazine in the reaction with intermediate T.
HPLC retention time: 1.66 minutes. MS ESI (m/z): 367.4 (M+H).sup.+,
calc. 366.
Example 34
##STR00047## ##STR00048##
[0460] Preparation of
1-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)et-
hyl)piperazine (Intermediate AM)
##STR00049##
[0462] To a solution of 2-(piperazin-1-yl)ethanol (0.78 mL, 6.0
mmol) and triphenylphosphine (1.6 g, 6.0 mmol) in anhydrous THF (20
mL) at 0.degree. C. was added diethyl azodicarboxylate (0.95 mL,
6.0 mmol), followed by
2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
(1.0 g, 4.0 mmol). After stirring for 4 h at rt, additional
triphenylphosphine (1.6 g, 6.0 mmol) and diethyl azodicarboxylate
(0.95 mL, 6.0 mmol) were added. After stirring for an additional 2
h, the resulting mixture was evaporated to dryness in vacuo and the
residue was purified via silica gel chromatography eluting with 15%
MeOH in CH.sub.2Cl.sub.2 to yield a yellow oil (1.89 g) which
contained approximately 60% of the title compound by HPLC analysis.
HPLC retention time: 1.01 minutes. MS ESI (m/z): 363.6 (M+H).sup.+,
calc. 362.
Preparation of
3-(1H-indol-5-yl)-5-(3-methoxy-4-(2-(piperazin-1-yl)ethoxy)phenyl)-1H-pyr-
rolo[2,3-b]pyridine (Compound AO)
##STR00050##
[0464] To a solution of
5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine
(Intermediate B) (92 mg, 0.20 mmol) in CH.sub.3CN (2 mL) in a
Personal Chemistry microwave reaction vial was added
1-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)et-
hyl)piperazine (Intermediate AM) (72 mg, 0.20 mmol),
bis(triphenylphosphine)-palladium(II) dichloride (20 mg, 0.028
mmol), and 1 M Na.sub.2CO.sub.3 (2 mL). The resulting mixture was
de-gassed with Ar for 10 min, after which it was heated at
150.degree. C. for 25 min in a Personal Chemistry Optimizer. The
organic layer was separated, filtered, and concentrated in vacuo to
give Intermediate AN. The residue was dissolved in MeOH (3 mL) and
acetone (2 mL), and 2 M NaOH (1.5 mL) was added. The resulting
mixture was stirred at 50.degree. C. for 2 h, after which it was
partitioned between EtOAc and 1 M NaOH. The organic layer was
separated, dried over MgSO.sub.4, filtered, and stripped to give a
residue that was subjected to preparatory HPLC to yield the title
compound. HPLC retention time: 1.29 minutes; MS ESI (m/z) 468.6
(M+1).sup.+, calc. 467.
Example 35
Preparation of
2-(4-(3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-methoxyphenoxy)--
N,N-dimethylethanamine (Compound AP)
##STR00051##
[0466] Compound AP was prepared by a method analogous to that
described in Example 36 by substituting 2-(dimethylamino)ethanol
for 2-(piperazin-1-yl)ethanol in the reaction with
2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol.
HPLC retention time: 1.20 minutes. MS ESI (m/z): 427.2 (M+H).sup.+,
calc. 426.
Example 36
##STR00052## ##STR00053##
[0467] Preparation of
5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine (Intermediate
AQ)
##STR00054##
[0469] To a solution of 3,5-dibromopyrazin-2-amine (10 g, 40 mmol),
copper(I) iodide (0.91 g, 4.7 mmol), diisopropylethylamine (53 mL,
0.55 mol), and tetrakis(triphenylphosphine)-palladium(0) (2.3 g,
1.9 mmol) in DMF (120 mL) that was de-gassed with Ar was added
trimethylsilylacetylene (6.7 mL, 48 mmol). The resulting mixture
was stirred under an Ar atmosphere for 1 h at 120.degree. C., after
which it was evaporated to dryness in vacuo. The residue was
subjected to silica gel chromatography eluting with 35% EtOAc in
hexanes to give a brown oil that was triturated with hexanes to
give the title compound (5.0 g, 47%). .sup.1H NMR (CDCl.sub.3, 300
MHz): .delta. 8.04 (s, 1H), 5.10 (s, 2H), 0.28 (s, 9H). HPLC
retention time: 2.75 minutes. MS ESI (m/z): 270.0, 272.0
(M+H).sup.+, talc. 269.
Preparation of
N-(5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-yl)acetamide
(Intermediate AR)
##STR00055##
[0471] To a solution of
5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine (5.0 g, 19 mmol)
and pyridine (3.8 ml, 46 mmol) in anhydrous THF (75 mL) was added
acetyl chloride (1.6 mL, 23 mmol) in a drop-wise manner. After
stirring for 48 hr at rt, additional acetyl chloride (0.4 mL 6
mmol) was added and the mixture was stirred for an additional 48 hr
at rt. The solvent was removed in vacuo, and the residue was
diluted with 30% EtOAc in hexanes. The mixture was filtered, and
the filtrate was purified via silica gel chromatography eluting
with 30% EtOAc in hexanes to give a yellow-brown solid (1.8 g,
31%). .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. 8.34 (s, 1H), 8.08
(s, 1H), 2.46 (s, 3H), 0.32 (s, 9H). HPLC retention time: 2.29
minutes MS ESI (m/z): 312.2, 314.2 (M+H)+, talc. 311.
Preparation of 2-bromo-5H-pyrrolo[3,2-b]pyrazine (Intermediate
AS)
##STR00056##
[0473] A solution of
N-(5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-yl)acetamide
[Intermediate AR] (2.6 g, 8.4 mmol) and tetrabutylammonium fluoride
[1 M in THF] (18 mL, 18 mmol) in anhydrous THF (26 mL) was heated
at 75.degree. C. for 20 h, after which it was partitioned between
EtOAc and H.sub.2O. The organic layer was washed with brine, dried
over Na.sub.2SO.sub.4, and evaporated in vacuo to yield a residue
that was purified via silica gel chromatography eluting with 30%
EtOAc in hexanes to give the title compound as a tan solid (0.69 g,
42%). .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. 8.88 (bs, 1H),
8.34 (s, 1H), 7.62 (t, 0.1=3.3 Hz, 1H), 6.71 (dd, 0.1=3.6 Hz, 3.9
Hz, 1H). HPLC retention time: 1.73 minutes. MS ESI (m/z): 198.2,
200.2 (M+H).sup.+, calc. 197.
Preparation of 2-bromo-7-iodo-5H-pyrrolo[3,2-b]pyrazine
(Intermediate AT)
##STR00057##
[0475] To a solution of 2-bromo-5H-pyrrolo[3,2-b]pyrazine
[Intermediate AS] (0.68 g, 3.4 mmol) in acetone (17 mL) was added
N-iodosuccinimide (0.82 g, 3.6 mmol) and the resulting mixture was
stirred for 4 h at rt. The mixture was evaporated in vacuo to yield
a residue that was purified via silica gel chromatography eluting
with 40% THF in hexanes to give the title compound as a yellow
solid (0.99 g, 89%). .sup.1H NMR (DMSO-d6, 300 MHz): .delta. 12.82
(s, 1H), 8.42 (s, 1H), 8.20 (s, 1H). HPLC retention time: 2.23
minutes. MS ESI (m/z): 324.0, 326.0 (M+H).sup.+, calc. 323.
Preparation of 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[3,2-b]pyrazine
(Intermediate AU)
##STR00058##
[0477] To a stirred solution of
2-bromo-7-iodo-5H-pyrrolo[3,2-b]pyrazine [Intermediate AT] (1.1 g,
3.5 mmol) in anhydrous THF (20 mL) cooled to 0.degree. C. was added
NaH [60% dispersion in mineral oil] (0.17 g, 4.3 mmol). The
reaction mixture was stirred for 20 min at 0.degree. C., after
which p-toluenesulfonyl chloride (0.73 g, 3.8 mmol) in THF (8 mL)
was added. The resulting mixture was stirred at rt for 3 hr. after
which it was diluted with EtOAc and washed with H.sub.2O and brine.
The organic layer was separated, dried over Na.sub.2SO.sub.4,
filtered, and evaporated in vacuo to yield a residue that was
triturated with hexanes to yield the title compound (1.6 g, 94%) as
a light yellow powder. .sup.1H NMR (DMSO-d6, 300 MHz) 6.8.62 (d,
J=7.5 Hz, 2H), 8.03 (s, 1H), 8.00 (s, 1H), 7.47 (d, J=8.1 Hz, 2H),
2.37 (s, 3H). HPLC retention time: 2.84 minutes. MS ESI (m/z):
478.0/480.0 (M+H).sup.+, calc. 477.
Preparation of
2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine
(Intermediate AV)
##STR00059##
[0479] To a stirred suspension of
2-bromo-7-iodo-5-tosyl-5H-pyrrolo[3,2-b]pyrazine [Intermediate AU]
(0.25 g, 0.52 mmol) and 1H-indol-5-ylboronic acid (0.10 mg, 0.62
mmol) in CH.sub.3CN (20 mL) was added 1 M Na.sub.2CO.sub.3 (20 mL)
followed by bis(triphenylphosphine)-palladium(II) dichloride (60
mg, 0.086 mmol). The resulting mixture was stirred for 2 h at
60.degree. C. The title compound was isolated as a yellow solid via
filtration from the CH.sub.3CN layer (0.23 g, 94%). HPLC retention
time: 3.23 minutes. MS ESI (m/z): 467.2/469.2 (M+H).sup.+, calc.
466.
Preparation of
7-(1H-indol-5-yl)-2-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[3,2-b]pyrazine
(Compound AW)
##STR00060##
[0481] To a solution of
2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine
[Intermediate AV] (65 mg, 0.14 mmol) in CH.sub.3CN (1 mL) in a
Personal Chemistry microwave reaction vial was added
3,4,5-trimethoxyphenylboronic acid (30 mg, 0.14 mmol),
bis(triphenylphosphine)-palladium(II) dichloride (7.0 mg, 0.010
mmol), and 1 M Na.sub.2CO.sub.3 (1 mL). The resulting mixture was
de-gassed with Ar for 10 min, after which it was heated at
150.degree. C. for 10 min in a Personal Chemistry Optimizer. The
organic layer was separated, filtered, and concentrated in vacuo.
The residue was dissolved in MeOH (3 mL) and acetone (2 mL), and 2
M NaOH (1.5 mL) was added. The resulting mixture was stirred at
65.degree. C. for 30 min, after which it was partitioned between
EtOAc and 1 M NaOH. The organic layer was separated, dried over
MgSO.sub.4, filtered, and stripped to give a residue which was
purified by preparatory HPLC to give the title compound as a yellow
solid. HPLC retention time: 2.25 minutes; MS ESI (m/z) 401.2
(M+1).sup.+, calc. 400.
Example 37
Preparation of
2-(3,4-dimethoxyphenyl)-7-(1H-indol-5-yl)-5H-pyrrolo[3,2-b]pyrazine
(Compound AX)
##STR00061##
[0483] Compound AX was prepared by a method analogous to that
described in Example 38 by substituting 3,4-dimethoxyboronic acid
for 3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate AV. HPLC retention time: 2.45 minutes. MS ESI (m/z):
371.2 (M+H).sup.+, calc. 370.
Example 38
Preparation of
4-(7-(1H-indol-5-yl)-5H-pyrrolo[3,2-b]pyrazin-2-yl)-2-methoxyaniline
(Compound AY)
##STR00062##
[0485] Compound AY was prepared by a method analogous to that
described in Example 38 by substituting
4-amino-3-methoxyphenylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with
intermediate AV. HPLC retention time: 2.07 minutes. MS ESI (m/z):
356.4 (M+H).sup.+, calc. 355.
Example 39
Preparation of
4-(2-(4-(7-(1H-indol-5-yl)-5H-pyrrolo[3,2-b]pyrazin-2-yl)-2-methoxyphenox-
y)ethyl)morpholine (Compound AZ)
##STR00063##
[0487] Compound AZ was prepared by a method analogous to that
described in Example 36 by substituting
4-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)et-
hyl)morpholine for
1-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)et-
hyl)piperazine and
2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine for
intermediate B. HPLC retention time: 1.59 minutes. MS ESI (m/z):
470.4 (M+H).sup.+, calc. 469.
Example 40
##STR00064##
[0488] Preparation of 3,5-dibromopyrazin-2-amine (Intermediate
BA)
##STR00065##
[0490] To a stirred solution of aminopyrazine (8.21 g, 86.4 mmol)
in anhydrous methylene chloride (215 mL) cooled to 0.degree. C. was
added N-bromosuccinimide (32.3 g, 181 mmol) in portions over a six
hour period, during which time the temperature of the reaction was
kept below 0.degree. C. The resulting mixture was stored at
4.degree. C. overnight, after which it was stirred vigorously and
quenched with H.sub.2O (100 mL). The organic layer was separated,
after which it was washed with saturated aqueous NaHCO.sub.3,
washed with brine, dried over MgSO.sub.4, filtered, and evaporated
in vacuo to yield a residue that was triturated with 20% EtOAc in
hexanes to yield the title compound (10.3 g, 47%) as a yellow/brown
powder. .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 8.02 (s, 1H),
5.05 (bs, 2H); HPLC retention time: 1.99 minutes; MS ESI (m/z):
252.0/254.0/256.2 (M+1).sup.+, calc. 251.
Preparation of 6-bromo-N.sup.2-(1H-indol-5-yl)pyrazine-2,3-diamine
(Intermediate BB)
##STR00066##
[0492] To a stirred suspension of 3,5-dibromopyrazin-2-amine (3.48
g, 13.7 mmol) and 1H-indol-5-amine (2.00 g, 15.0 mmol) in EtOH (3.5
mL) was added diisopropylethylamine [DIEA] (2.60 mL, 15.0 mmol).
The resulting mixture was stirred for 48 hr at 80.degree. C., after
which it was partitioned between EtOAc and H.sub.2O. The organic
layer was separated, after which it was washed with brine, dried
over Na.sub.2SO.sub.4, filtered, and evaporated in vacuo to yield a
residue that was purified via silica gel chromatography eluting
with 1:1 EtOAc:hexanes to yield the title compound (1.75 g, 42%) as
a red/brown solid. .sup.1H NMR (DMSO-d6, 300 MHz): .delta. 10.98
(s, 1H), 8.22 (s, 1H), 7.83 (s, 1H), 7.31-7.28 (m, 3H), 7.19 (d,
J=8.7 Hz, 1H), 6.43 (s, 2H), 6.36 (s, 1H); HPLC retention time:
2.07 minutes; MS ESI (m/z): 304.2/306.2 (M+1).sup.+, calc. 303.
Preparation of
6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
(Intermediate BC)
##STR00067##
[0494] To a solution of
6-bromo-N.sup.2-(1H-indol-5-yl)pyrazine-2,3-diamine (0.450 g, 1.48
mmol) in THF (5 mL) was added carbonyldiimidazole (1.20 g, 7.40
mmol). The resulting mixture was heated at 65.degree. C. for 48 hr,
after which it was concentrated in vacuo and partitioned between
EtOAc and H.sub.2O. The organic layer was separated, dried over
MgSO.sub.4, filtered, and concentrated in vacuo to yield a residue
that was purified via silica gel chromatography eluting with EtOAc
to yield the title compound (0.20 g, 41%). HPLC retention time:
2.07 minutes; MS ESI (m/z): 330.2/332.2 (M+1).sup.+, calc. 329.
Preparation of
1-(1H-indol-5-yl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2(3-
H)-one (Compound BD)
##STR00068##
[0496] To a solution of
6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one (27
mg, 0.08 mmol) in CH.sub.3CN (1 mL) in a Personal Chemistry
microwave reaction vial was added 3,4,5-trimethoxyphenylboronic
acid (17 mg, 0.08 mmol), bis(triphenylphosphine)-palladium(II)
dichloride (6.0 mg, 0.008 mmol), and 1 M Na.sub.2CO.sub.3 (1 mL).
The resulting mixture was de-gassed with Ar for 10 min, after which
it was heated at 150.degree. C. for 10 min in a Personal Chemistry
Optimizer. The organic layer was separated, filtered, and
concentrated in vacuo. The residue was purified by preparatory HPLC
to yield the title compound (6.5 mg, 19%). .sup.1H NMR (DMSO-d6,
300 MHz): .delta. 12.18 (s, 1H), 11.28 (s, 1H), 8.57 (s, 1H), 7.83
(d, J=1.8 Hz, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.42 (m, 1H), 7.37 (dd,
J=1.8, 8.4 Hz, 1H). 7.20 (s, 2H), 6.51 (m, 1H), 3.78 (s, 6H), 3.66
(s, 3H); HPLC retention time: 2.30 minutes; MS ESI (m/z): 418.4
(M+1).sup.+, calc. 417.
Example 41
Preparation of
1-(1-methyl-1H-indol-5-yl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]py-
razin-2(3H)-one (Compound BE)
##STR00069##
[0498] Compound BE was prepared by a method analogous to that
described in Example 1 by substituting 1-methyl-1H-indol-5-amine
for 1H-indol-5-amine in the reaction with Intermediate BA. 4.0 mg
recovered. .sup.1H NMR (DMSO-d6, 300 MHz): .delta. 12.22 (s, 1H),
8.57 (s, 1H), 7.85 (d, J=1.8 Hz, 1H), 7.57 (d, J=8.7 Hz, 1H), 7.45
(d, J=1.8 Hz), 7.41 (m, 2H), 7.20 (s, 2H), 6.50 (d, J=3.0 Hz, 1H),
3.84 (s, 3H), 3.78 (s, 6H), 3.66 (s, 3H); HPLC retention time: 2.50
minutes. MS EST (m/z): 432.4 (M+H).sup.+, calc. 431.
Example 42
Preparation of
6-(4-hydroxyphenyl)-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2-
(3H)-one (Compound BF)
##STR00070##
[0500] Compound BE was prepared by a method analogous to that
described in Example 1 by substituting 1-methyl-1H-indol-5-amine
for 1H-indol-5-amine in the reaction with Intermediate BA to
prepare
6-bromo-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one.
In a procedure similar to that used to synthesize Compound D,
4-hydroxyphenylboronic acid was substituted for
3,4,5-trimethoxyphenylboronic acid and
6-bromo-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
was substituted for
6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one to
obtain the title compound. 2.2 mg recovered. HPLC retention time:
2.18 minutes. MS ESI (m/z): 358.2 (M+H).sup.+, calc. 357.
Example 43
Preparation of
6-(3,5-dimethylphenyl)-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazi-
n-2(3H)-one (Compound BG)
##STR00071##
[0502] Compound BG was prepared by a method analogous to that
described in Example 3 by substituting 3,5-dimethylphenylboronic
acid for 4-hydroxyphenylboronic acid in the reaction with
6-bromo-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one.
1.6 mg recovered. HPLC retention time: 3.04 minutes MS ESI (m/z):
370.2 (M+H).sup.+, calc. 369.
Example 44
Preparation of
1-(1H-indol-5-yl)-6-(pyridin-4-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
(Compound BH)
##STR00072##
[0504] Compound BH was prepared by a method analogous to that
described in Example 1 by substituting pyridin-4-ylboronic acid for
3,4,5-trimethoxyphenylboronic acid in the reaction with Compound
BC. 1.6 mg recovered. HPLC retention time: 1.10 minutes. MS ESI
(m/z): 329.4 (M+H).sup.+, calc. 328.
Example 45
Preparation of
6-(4-hydroxyphenyl)-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
(Compound BI)
##STR00073##
[0506] Compound BI was prepared by a method analogous to that
described in Example 1 by substituting by substituting
4-hydroxyphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid
in the reaction with Compound BC. 13.7 mg recovered. .sup.1H NMR
(DMSO-d6, 300 MHz): .delta. 12.07 (s, 1H), 11.30 (s, 1H), 9.61 (s,
1H), 8.38 (s, 1H), 7.69 (m, 2H), 7.52 (d, J=8.4 Hz, 1H), 7.44 (m,
1H), 7.26 (dd, J=1.8, 8.7 Hz), 6.76 (dd, J=2.4, 12.9 Hz), 6.52 (m,
1H); HPLC retention time: 1.99 minutes. MS ESI (m/z): 344.2
(M+H).sup.+, calc. 343.
Example 46
Preparation of
6-(3,5-dimethylphenyl)-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-o-
ne (Compound BJ)
##STR00074##
[0508] Compound BJ was prepared by a method analogous to that
described in Example 1 by substituting 3,5-dimethylphenylboronic
acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with
Compound BC. 4.3 mg recovered. HPLC retention time: 2.80 minutes.
MS ESI (m/z): 356.2 (M+H).sup.+, calc. 355.
Examples 47-119
[0509] Examples 47-119, shown in Table 3 below, were synthesized in
parallel according to procedures given below in Schemes 7 and 8,
using the reagents in Tables 1 and 2.
Examples 47-67
##STR00075##
[0510] Preparation of 1H-imidazo[4,5-b]pyrazin-2(3H)-one compounds
in Table 1
[0511] To a solution of
6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one (27
mg, 0.08 mmol) in CH.sub.3CN (1 mL) in a Personal Chemistry
microwave reaction vial was added 3,4,5-trimethoxyphenylboronic
acid (17 mg, 0.08 mmol), bis(triphenylphosphine)-palladium(II)
dichloride (6.0 mg, 0.008 mmol), and 1 M Na.sub.2CO.sub.3 (1 mL).
The resulting mixture was de-gassed with Ar for 10 min, after which
it was heated at 150.degree. C. for 10 min in a Personal Chemistry
Optimizer. The organic layer was separated, filtered, and
concentrated in vacuo. The residue was purified by preparatory HPLC
to yield the title compounds (>3 mg) in table 1, isolated as
amorphous solids.
TABLE-US-00001 TABLE 1 Ex. Boronic Acid Purified Compound Isolated
47 3,4-dimethoxyphenyl 6-(3,4-dimethoxyphenyl)-1-(1H-indol-5-
boronic acid yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 48
3,5-dichlorophenyl boronic 6-(3,5-dichlorophenyl)-1-(1H-indol-5-
acid yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 49
3-fluoro-4-methoxyphenyl 6-(3-fluoro-4-methoxyphenyl)-1-(1H-
boronic acid indol-5-yl)-1H-imidazo[4,5-b]pyrazin- 2(3H)-one 50
3-amino-4-methoxyphenyl 6-(3-amino-4-methoxyphenyl)-1-(1H- boronic
acid indol-5-yl)-1H-imidazo[4,5-b]pyrazin- 2(3H)-one 51
4-methoxy-3,5- 1-(1H-indol-5-yl)-6-(4-methoxy-3,5- dimethylphenyl
boronic dimethylphenyl)-1H-imidazo[4,5- acid b]pyrazin-2(3H)-one 52
4-morpholinophenyl 1-(1H-indol-5-yl)-6-(4- boronic acid
morpholinophenyl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 53
Indole-5-boronic acid 1,6-di(1H-indol-5-yl)-1H-imidazo[4,5-
b]pyrazin-2(3H)-one 54 3-hydroxyphenyl boronic
6-(3-hydroxyphenyl)-1-(1H-indol-5-yl)- acid
1H-imidazo[4,5-b]pyrazin-2(3H)-one 55 4-hydroxy-3-
6-(4-hydroxy-3-methoxyphenyl)-1-(1H- methoxyphenyl
indol-5-yl)-1H-imidazo[4,5-b]pyrazin- 2(3H)-one 56 indole-6-boronic
1-(1H-indol-5-yl)-6-(1H-indol-6-yl)-1H-
imidazo[4,5-b]pyrazin-2(3H)-one 57 3-methoxy-4-(2-
1-(1H-indol-5-yl)-6-(3-methoxy-4-(2- morpholinoethoxy)phenyl
morpholinoethoxy)phenyl)-1H- boronic acid
imidazo[4,5-b]pyrazin-2(3H)-one 58 2,5-difluoro-4-
6-(2,5-difluoro-4-hydroxyphenyl)-1-(1H- hydroxyphenyl boronic
indol-5-yl)-1H-imidazo[4,5-b]pyrazin- acid 2(3H)-one 59
3,5-difluoro-4- 6-(3,5-difluoro-4-hydroxyphenyl)-1-(1H-
hydroxyphenyl boronic indol-5-yl)-1H-imidazo[4,5-b]pyrazin- acid
2(3H)-one 60 4-amino-3-methoxyphenyl
6-(4-amino-3-methoxyphenyl)-1-(1H- boronic acid
indol-5-yl)-1H-imidazo[4,5-b]pyrazin- 2(3H)-one 61
3,5-difluorophenyl 6-(3,5-difluorophenyl)-1-(1H-indol-5- boronic
acid yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 62 4-hydroxy-3,5-
6-(4-hydroxy-3,5-dimethoxyphenyl)-1- dimethoxyphenyl
(1H-indol-5-yl)-1H-imidazo[4,5- boronic acid b]pyrazin-2(3H)-one 63
2,3- 6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-
dihydrobenzo[b][1,4]dioxin- 1-(1H-indol-5-yl)-1H-imidazo[4,5-
6-boronic acid b]pyrazin-2(3H)-one 64 4-hydroxy-3,5-
6-(4-hydroxy-3,5-dimethylphenyl)-1- dimethylphenyl boronic
(1H-indol-5-yl)-1H-imidazo[4,5- acid b]pyrazin-2(3H)-one 65
3,5-dimethoxyphenyl 6-(3,5-dimethoxyphenyl)-1-(1H-indol-5- boronic
acid yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 66
2-(4-methylpiperazin-1- 1-(1H-indol-5-yl)-6-(2-(4-
yl)pyridin-4-boronic acid methylpiperazin-1-yl)pyridin-4-yl)-1H-
imidazo[4,5-b]pyrazin-2(3H)-one 67 (3-methoxy-4-(2-
1-(1H-indol-5-yl)-6-(3-methoxy-4-(2- (piperazin-1-
(piperazin-1-yl)ethoxy)phenyl)-1H- yl)ethoxy)phenyl
imidazo[4,5-b]pyrazin-2(3H)-one
Examples 68-118
##STR00076##
[0512] Preparation of Intermediates 2BB
[0513] To a stirred suspension of 3,5-dibromopyrazin-2-amine (3.48
g, 13.7 mmol) and the corresponding alkyl, aryl, or heteroaryl
amine (15.0 mmol) in EtOH (3.5 mL) was added diisopropylethylamine
[DIEA] (2.60 mL, 15.0 mmol). The resulting mixture was stirred for
48 hr at 80.degree. C., after which it was partitioned between
EtOAc and H.sub.2O. The organic layer was separated, after which it
was washed with brine, dried over Na.sub.2SO.sub.4, filtered, and
evaporated in vacuo to yield a residue that was purified by
automated medium pressure silica gel chromatography eluting with
1:1 EtOAc:hexanes to yield the intermediates as amorphous
solids.
Preparation of Intermediates 2BC
[0514] Intermediates 2BB (0.450 g, 1.5 mmol) were dissolved in THF
(5 mL) and treated with carbonyldiimidazole (1.20 g, 7.40 mmol).
The resulting mixture was heated at 65.degree. C. for 48 hr, after
which it was concentrated in vacuo and partitioned between EtOAc
and H.sub.2O. The organic layer was separated, dried over
MgSO.sub.4, filtered, and concentrated in vacuo to yield a residue
that was purified via automated silica gel chromatography eluting
with hexane/EtOAc to yield the intermediates 2BC as amorphous
solids.
Preparation of 1H-Imidazo[4,5-b]Pyrazin-2(3H)-One Compounds in
Table 2
[0515] Individual solutions of intermediates 2BC (0.08 mmol) in
CH.sub.3CN (1 mL) in a Personal Chemistry microwave reaction vial
was added the corresponding Iboronic acid (0.08 mmol),
bis(triphenylphosphine)-palladium(II) dichloride (6.0 mg, 0.008
mmol), and 1 M Na.sub.2CO.sub.3 (1 mL). The resulting mixture was
de-gassed with Ar for 10 min, after which it was heated at
150.degree. C. for 10 min in a Personal Chemistry Optimizer. The
organic layer was separated, filtered, and concentrated in vacuo.
The residue was purified by preparatory HPLC to yield the title
compounds in table 2 (>3 mg) as amorphous solids.
TABLE-US-00002 Ex. Boronic Acid Amine Purified Compound Isolated 68
3,4,5- 4-methoxy- 1-(4-methoxyphenyl)-6- trimethoxyphenyl aniline
(3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin-
2(3H)-one 69 3,4- 4-methoxy- 6-(3,4-dimethoxyphenyl)-1-
dimethoxyphenyl aniline (4-methoxyphenyl)-1H- boronic acid
imidazo[4,5-b]pyrazin- 2(3H)-one 70 3,4- 4-methoxy-
6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl aniline
(4-methoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one
71 pyridin-4-boronic 4-methoxy- 1-(4-methoxyphenyl)-6- acid boronic
acid aniline (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 72
3,4,5- 2-methyl-5- 1-(2-methyl-1H-indol-5-yl)- trimethoxyphenyl
amino-indole 6-(3,4,5-trimethoxyphenyl)- boronic acid
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 73 3,5-dichlorophenyl
2-methyl-5- 6-(3,5-dichlorophenyl)-1-(2- boronic acid amino-indole
methyl-1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 74
3,4,5- 1-amino- 1-cyclopentyl-6-(3,4,5- trimethoxyphenyl
cyclopentane trimethoxyphenyl)-1H- boronic acid
imidazo[4,5-b]pyrazin- 2(3H)-one 75 3,4- 1-amino-
1-cyclopentyl-6-(3,4- dimethoxyphenyl cyclopentane
dimethoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one
76 4-hydroxyphenyl 1-amino- 1-cyclopentyl-6-(4- boronic acid
cyclopentane hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 77
pyridin-4-boronic 1-amino- 1-cyclopentyl-6-(pyridin-4- acid
cyclopentane yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 78 3,4,5-
Cyclopropane- 1-(cyclopropylmethyl)-6- trimethoxyphenyl methylamine
(3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin-
2(3H)-one 79 3,4- Cyclopropane- 1-(cyclopropylmethyl)-6-
dimethoxyphenyl methylamine (3,4-dimethoxyphenyl)-1H- boronic acid
imidazo[4,5-b]pyrazin- 2(3H)-one 80 3,5-dichlorophenyl
Cyclopropane- 1-(cyclopropylmethyl)-6- boronic acid methylamine
(3,5-dichlorophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 81
4-hydroxyphenyl Cyclopropane- 1-(cyclopropylmethyl)-6-(4- boronic
acid methylamine hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 82 4-aminopyridine Cyclopropane- 1-(cyclopropylmethyl)-6-
boronic acid methylamine (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 83 3,4,5- 1H-Indazol-5- 1-(1H-indazol-5-yl)-6-
trimethoxyphenyl amine (3,4,5-trimethoxyphenyl)- boronic acid
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 84 4-hydroxypheny 2-methyl-5-
6-(4-hydroxyphenyl)-1-(2- boronic acid amino-indole
methyl-1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 85
pyridin-4-boronic 2-methyl-5- 1-(2-methyl-1H-indol-5-yl)- acid
boronic acid amino-indole 6-(pyridin-4-yl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 86 4-morpholinophenyl
Cyclopropane- 1-(cyclopropylmethyl)-6-(4- boronic acid methylamine
morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 87 3,4-
1H-Indazol-5- 6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl amine
(1H-indazol-5-yl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one
88 4-aminopyridine 1H-Indazol-5- 1-(1H-indazol-5-yl)-6- boronic
acid amine (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 89
4-morpholinophenyl 1H-Indazol-5- 1-(1H-indazol-5-yl)-6-(4- boronic
acid amine morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one
90 3,4,5- 1H-Indazol-5- 1-(1H-indazol-6-yl)-6- trimethoxyphenyl
amine (3,4,5-trimethoxyphenyl)- boronic acid
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 91 3,4- 1H-Indazol-5-
6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl amine
(1H-indazol-6-yl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one
92 4-hydroxyphenyl 1H-Indazol-5- 6-(4-hydroxyphenyl)-1-(1H- boronic
acid amine indazol-6-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 93
4-aminopyridine 1H-Indazol-5- 1-(1H-indazol-6-yl)-6- boronic acid
amine (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 94 2,4,6-
1-amino- 1-cyclopentyl-6-(2,4,6- trimethoxyphenyl cyclopentane
trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 95
3,5-dimethylphenyl 1H-Indazol-5- 6-(3,5-dimethylphenyl)-1- boronic
acid amine (1H-indazol-6-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one
96 3,4,5- benzo[d]thiazol- 1-(benzo[d]thiazol-5-yl)-6-
trimethoxyphenyl 5-amine (3,4,5-trimethoxyphenyl)- boronic acid
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 97 4-hydroxyphenyl
benzo[d]thiazol- 1-(benzo[d]thiazol-5-yl)-6- boronic acid 5-amine
(4-hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 98
4-aminopyridine benzo[d]thiazol- 1-(benzo[d]thiazol-5-yl)-6-
boronic acid 5-amine (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 99 3,5-dimethylphenyl benzo[d]thiazol-
1-(benzo[d]thiazol-5-yl)-6- boronic acid 5-amine
(3,5-dimethylphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 100
4-morpholinophenyl benzo[d]thiazol- 1-(benzo[d]thiazol-5-yl)-6-
boronic acid 5-amine (4-morpholinophenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 101 3,4,5- 2,3-dihydro-1H-
1-(2,3-dihydro-1H-inden-1- trimethoxyphenyl inden-1-amine
yl)-6-(3,4,5- boronic acid trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 102 3,4,5- 1H-benzo[d]imidazol-
1-(1H-benzo[d]imidazol-5- trimethoxyphenyl 5-amine yl)-6-(3,4,5-
boronic acid trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one
103 3,4- 1H-benzo[d]imidazol- 1-(1H-benzo[d]imidazol-5-
dimethoxyphenyl 5-amine yl)-6-(3,4- boronic acid
dimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 104
4-morpholinophenyl 1H-benzo[d]imidazol- 1-(1H-benzo[d]imidazol-5-
boronic acid 5-amine yl)-6-(4-morpholinophenyl)-
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 105 3,4,5- aniline
1-phenyl-6-(3,4,5- trimethoxyphenyl trimethoxyphenyl)-1H- boronic
acid imidazo[4,5-b]pyrazin- 2(3H)-one 106 3,4- aniline
6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl phenyl-1H-imidazo[4,5-
boronic acid b]pyrazin-2(3H)-one 107 3-methoxy-4-(2- Cyclopropane-
1-(cyclopropylmethyl)-6-(3- morpholino- methylamine methoxy-4-(2-
ethoxy)phenyl morpholinoethoxy)phenyl)- boronic acid
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 108 3-methoxy-4-(2- 1-amino-
1-cyclopentyl-6-(3-methoxy- morpholino- cyclopentane 4-(2-
ethoxy)phenyl morpholinoethoxy)phenyl) - 1H-imidazo[4,5-b]pyrazin-
2(3H)-one 109 3,4,5- 6- 1-(6-morpholinopyridin-3- trimethoxyphenyl
morpholino- yl)-6-(3,4,5- boronic acid pyridin-3-amine
trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 110 3,4,5-
2,3-dihydro-1H- 1-(2,3-dihydro-1H-inden-2- trimethoxyphenyl
inden-2-amine yl)-6-(3,4,5- boronic acid trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 111 3,4- 1H-pyrrolo[2,3-
6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl b]pyridin-5-
(1H-pyrrolo[2,3-b]pyridin-5- boronic acid amine yl)-1H-imidazo[4,5-
b]pyrazin-2(3H)-one 112 3,4,5- 1H-pyrrolo[2,3-
1-(1H-pyrrolo[2,3-b]pyridin- trimethoxyphenyl b]pyridin-5-
5-yl)-6-(3,4,5- boronic acid amine trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 113 3,4,5- 1H-indol-6-
1-(1H-indol-6-yl)-6-(3,4,5- trimethoxyphenyl amine
trimethoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one
114 3,4,5- 4-aminophenol 1-(4-hydroxyphenyl)-6- trimethoxyphenyl
(3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin-
2(3H)-one 115 3,4- 4-aminophenol 6-(3,4-dimethoxyphenyl)-1-
dimethoxyphenyl (4-hydroxyphenyl)-1H- boronic acid
imidazo[4,5-b]pyrazin- 2(3H)-one 116 4-morpholinophenyl
4-aminophenol 1-(4-hydroxyphenyl)-6-(4- boronic acid
morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 117
6-aminopyridin-3- 1-amino- 6-(6-aminopyridin-3-yl)-1- boronic acid
cyclopentane cyclopentyl-1H-imidazo[4,5- b]pyrazin-2(3H)-one 118
4-amino-3- 1-amino- 6-(4-amino-3- methoxyphenyl cyclopentane
methoxyphenyl)-1- boronic acid cyclopentyl-1H-imidazo[4,5-
b]pyrazin-2(3H)-one
[0516] Examples 47-118 were physically characterized by
electrospray ionization mass spectrometry. Structures and molecular
masses are given below in Table 3.
TABLE-US-00003 TABLE 3 Ex. Structure IUPAC Name MW 47 ##STR00077##
6-(3,4-dimethoxyphenyl)-1- (1H-indol-5-yl)-1H
imidazo[4,5-b]pyrazin- 2(3H)-one 387.13 48 ##STR00078##
6-(3,5-dichlorophenyl)-1- (1H-indol-5-yl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 395.03 49 ##STR00079##
6-(3-fluoro-4- methoxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5-
b]pyrazin-2(3H)-one 375.11 50 ##STR00080## 6-(3-amino-4-
methoxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5-
b]pyrazin-2(3H)-one 372.13 51 ##STR00081## 1-(1H-indol-5-yl)-6-(4-
methoxy-3,5- dimethylphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one
371.40 52 ##STR00082## 1-(1H-indol-5-yl)-6-(4-
morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 412.45 53
##STR00083## 1,6-di(1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 366.39 54 ##STR00084## 6-(3-hydroxyphenyl)-1-(1H-
indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 343.35 55
##STR00085## 6-(4-hydroxy-3- methoxyphenyl)-1-(1H-
indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 373.37 56
##STR00086## 1-(1H-indol-5-yl)-6-(1H- indol-6-yl)-1H-imidazo[4,5-
b]pyrazin-2(3H)-one 366.39 57 ##STR00087## 1-(1H-indol-5-yl)-6-(3-
methoxy-4-(2- morpholinoethoxy)phenyl)- 1H-imidazo[4,5-b]pyrazin-
2(3H)-one 486.53 58 ##STR00088## 6-(2,5-difluoro-4-
hydroxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5-
b]pyrazin-2(3H)-one 379.33 59 ##STR00089## 6-(3,5-difluoro-4-
hydroxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5-
b]pyrazin-2(3H)-one 379.33 60 ##STR00090## 6-(4-amino-3-
methoxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5-
b]pyrazin-2(3H)-one 372.39 61 ##STR00091##
6-(3,5-difluorophenyl)-1- (1H-indol-5-yl)-1H-
imidazol-4,5-b]pyrazin- 2(3H)-one 363.33 62 ##STR00092##
6-(4-hydroxy-3,5- dimethoxyphenyl)-1-(1H-
indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 403.40 63
##STR00093## 6-(2,3- dihydrobenzo[b][1,4]dioxin-
6-yl)-1-(1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 385.39
64 ##STR00094## 6-(4-hydroxy-3,5- dimethylphenyl)-1-(1H-
indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 385.43 65
##STR00095## 6-(3,5-dimethoxyphenyl)-1- (1H-indol-5-yl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 387.40 66 ##STR00096##
1-(1H-indol-5-yl)-6-(2-(4- methylpiperazin-1- yl)pyridin-4-yl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 426.50 67 ##STR00097##
1-(1H-indol-5-yl)-6-(3- methoxy-4-(2-(piperazin-1-
yl)ethoxy)phenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 485.55 68
##STR00098## 1-(4-methoxyphenyl)-6- (3,4,5-trimethoxyphenyl)-
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 408.42 69 ##STR00099##
6-(3,4-dimethoxyphenyl)-1- (4-methoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 378.39 70 ##STR00100##
6-(4-hydroxyphenyl)-1-(4- methoxyphenyl)-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 334.34 71 ##STR00101## 1-(4-methoxyphenyl)-6-
(pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 319.33 72
##STR00102## 1-(2-methyl-1H-indol-5-yl)-
6-(3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one
431.45 73 ##STR00103## 6-(3,5-dichlorophenyl)-1-(2-
methyl-1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 410.27
74 ##STR00104## 1-cyclopentyl-6-(3,4,5- trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 370.41 75 ##STR00105##
1-cyclopentyl-6-(3,4- dimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 340.39 76 ##STR00106## 1-cyclopentyl-6-(4-
hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 296.33 77
##STR00107## 1-cyclopentyl-6-(pyridin-4- yl)-1H-imidazo[4,5-
b]pyrazin-2(3H)-one 281.32 78 ##STR00108## 1-(cyclopropylmethyl)-6-
(3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one
356.38 79 ##STR00109## 1-(cyclopropylmethyl)-6-
(3,4-dimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 326.36
80 ##STR00110## 1-(cyclopropylmethyl)-6- (3,5-dichlorophenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 335.20 81 ##STR00111##
1-(cyclopropylmethyl)-6-(4- hydroxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 282.30 82 ##STR00112##
1-(cyclopropylmethyl)-6- (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 267.29 83 ##STR00113## 1-(1H-indazol-5-yl)-6-
(3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one
418.42 84 ##STR00114## 6-(4-hydroxyphenyl)-1-(2-
methyl-1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 357.37
85 ##STR00115## 1-(2-methyl-1H-indol-5-yl)- 6-(pyridin-4-yl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 342.36 86 ##STR00116##
1-(cyclopropylmethyl)-6-(4- morpholinophenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 351.41 87 ##STR00117##
6-(3,4-dimethoxyphenyl)-1- (1H-indazol-5-yl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 388.39 88 ##STR00118##
1-(1H-indazol-5-yl)-6- (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 329.32 89 ##STR00119## 1-(1H-indazol-5-yl)-6-(4-
morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 413.44 90
##STR00120## 1-(1H-indazol-6-yl)-6- (3,4,5-trimethoxyphenyl)-
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 418.42 91 ##STR00121##
6-(3,4-dimethoxyphenyl)-1- (1H-indazol-6-yl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 388.39 92 ##STR00122##
6-(4-hydroxyphenyl)-1-(1H- indazol-6-yl)-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 344.34 93 ##STR00123## 1-(1H-indazol-6-yl)-6-
(pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 329.32 94
##STR00124## 1-cyclopentyl-6-(2,4,6- trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 370.41 95 ##STR00125##
6-(3,5-dimethylphenyl)-1- (1H-indazol-6-yl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 356.39 96 ##STR00126##
1-(benzo[d]thiazol-5-yl)-6- (3,4,5-trimethoxyphenyl)-
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 435.46 97 ##STR00127##
1-(benzo[d]thiazol-5-yl)-6- (4-hydroxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 361.38 98 ##STR00128##
1-(benzo[d]thiazol-5-yl)-6- (pyridin-4-yl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 346.37 99 ##STR00129##
1-(benzo[d]thiazol-5-yl)-6- (3,5-dimethylphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 373.44 100 ##STR00130##
1-(benzo[d]thiazol-5-yl)-6- (4-morpholinophenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 430.49 101 ##STR00131##
1-(2,3-dihydro-1H-inden-1- yl)-6-(3,4,5- trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 418.46 102 ##STR00132##
1-(1H-benzo[d]imidazol-5- yl)-6-(3,4,5- trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 418.42 103 ##STR00133##
1-(1H-benzo[d]imidazol-5- yl)-6-(3,4- dimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 388.39 104 ##STR00134##
1-(1H-benzo[d]imidazol-5- yl)-6-(4- morpholinophenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 413.44 105 ##STR00135##
1-phenyl-6-(3,4,5- trimethoxyphenyl)-1H- imidazo[4,5-b[pyrazin-
2(3H)-one 378.39 106 ##STR00136## 6-(3,4-dimethoxyphenyl)-1-
phenyl-1H-imidazo[4,5- b]pyrazin-2(3H)-one 348.36 107 ##STR00137##
1-(cyclopropylmethyl)-6-(3- methoxy-4-(2- morpholinoethoxy)phenyl)-
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 425.49 108 ##STR00138##
1-cyclopentyl-6-(3- methoxy-4-(2- morpholinoethoxy)phenyl)-
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 439.52 109 ##STR00139##
1-(6-morpholinopyridin-3- yl)-6-(3,4,5- trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 464.48 110 ##STR00140##
1-(2,3-dihydro-1H-inden-2- yl)-6-(3,4,5- trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 418.46 111 ##STR00141##
6-(3,4-dimethoxyphenyl)-1- (1H-pyrrolo[2,3-b]pyridin-
5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 388.39 112 ##STR00142##
1-(1H-pyrrolo[2,3- b]pyridin-5-yl)-6-(3,4,5- trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 418.42 113 ##STR00143##
1-(1H-indol-6-yl)-6-(3,4,5- trimethoxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 418.42 114 ##STR00144##
1-(4-hydroxyphenyl)-6- (3,4,5-trimethoxyphenyl)-
1H-imidazo[4,5-b]pyrazin- 2(3H)-one 394.50 115 ##STR00145##
6-(3,4-dimethoxyphenyl)-1- (4-hydroxyphenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 364.50 116 ##STR00146##
1-(4-hydroxyphenyl)-6-(4- morpholinophenyl)-1H-
imidazo[4,5-b]pyrazin- 2(3H)-one 389.50 117 ##STR00147##
6-(6-aminopyridin-3-yl)-1- cyclopentyl-1H- imidazo[4,5-b]pyrazin-
2(3H)-one 296.33 118 ##STR00148## 6-(4-amino-3- methoxyphenyl)-1-
cyclopentyl-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 325.37
Example 119
Preparation of
5-chloro-1-(cyclopropylmethyl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5--
b]pyrazin-2(3H)-one
##STR00149##
[0518] Example 119 was prepared by a method analogous to that
described in Examples 68-118 by substituting 6
chloro-3,5-dibromopyrazin-2-amine for 3,5-dibromopyrazin-2-amine in
the reaction with aminomethylcyclopropane. MS ESI (m/z): 390.83
calc
Example 120
##STR00150##
[0519] Preparation of
1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine
(Intermediate BK)
##STR00151##
[0521] To a stirred solution of 7-azaindole (1.18 g, 10.0 mmol) in
anhydrous dimethylformamide (10 mL) cooled to 0.degree. C. was
added NaH [60% dispersion in mineral oil] (0.480 g, 12.0 mmol) in
portions over 15 min. The resulting mixture was allowed to stir for
1 hr at 0.degree. C., after which
(2-(chloromethoxy)ethyl)trimethylsilane [SEM-Cl] (2.12 mL, 12.0
mmol) was added over 15 min. The resulting mixture was stirred for
1 hr, after which it was quenched with H.sub.2O (50 mL), and
pardoned between EtOAc and H.sub.2O. The organic layer was
separated, washed with brine, dried over MgSO.sub.4, filtered, and
evaporated in vacuo to yield a yellow oil (2.50 g, 100%). HPLC
retention time: 2.66 minutes; MS ESI (m/z): 249.4 (M+1).sup.+,
calc. 248.
Preparation of
3,3,5-tribromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyri-
din-2(3H)-one (Compound BL)
##STR00152##
[0523] To a solution of
1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine
(2.50 g, 10.0 mmol) in 1:1 tert-butanol/H.sub.2O (140 mL) at room
temperature was added bromine (6.40 mL, 126 mmol). After stirring
for 3.5 hr at room temperature, an additional portion of bromine
was added (6.40 mL, 126 mmol) and the resulting mixture was stirred
for 18 hr. The resulting mixture was concentrated in vacuo to yield
the title compound, which was used without any further
purification. HPLC retention time: 2.97 minutes; MS ESI (m/z):
441.0/443.0/445.2 (Fragment+1).sup.+, calc. 498.
Preparation of
5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3-
H)-one (Compound BM)
##STR00153##
[0525] To a solution of
3,3,5-tribromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyri-
din-2(3H)-one (4.98 g, 10.0 mmol) in AcOH (50 mL) was added zinc
dust (1.28 g, 20.0 mmol). The resulting mixture was stirred at room
temperature for 2 hr, after which it was filtered thru Celite and
concentrated in vacuo. The resulting residue was purified via
silica gel chromatography eluting with 1:1 Hexanes:EtOAc to yield
the title compound as a yellow oil (0.85 g, 25% over three steps).
HPLC retention time: 2.60 minutes; MS ESI (m/z): 287.2
(Fragment+1).sup.+, calc. 342.
Preparation of
5-(3,4,5-trimethoxyphenyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrro-
lo[2,3-b]pyridin-2(3H)-one (Compound BN)
##STR00154##
[0527] To a solution of
5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3-
H)-one (0.85 g, 2.5 mmol) in CH.sub.3CN (5 mL) was added
3,4,5-trimethoxyphenylboronic acid (525 mg, 2.5 mmol),
bis(triphenylphosphine)-palladium(II) dichloride (250 mg, 0.35
mmol), and 1 M Na.sub.2CO.sub.3 (5 mL). The resulting mixture was
de-gassed with Ar for 10 min, after which it was heated at
80.degree. C. for 2 hr. The reaction mixture was partitioned
between EtOAc and H.sub.2O, and the organic layer was separated,
filtered, and concentrated in vacuo. The residue was purified by
silica gel chromatography eluting with 3:1 EtOAc:Hexanes to yield
the title compound (640 mg, 60%). HPLC retention time: 2.51
minutes; MS ESI (m/z): 431.4 (M+1).sup.+, calc. 430.
Preparation of
3,3-dimethyl-5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-on-
e (Compound BO)
##STR00155##
[0529] To a solution of
5-(3,4,5-trimethoxyphenyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrro-
lo[2,3-b]pyridin-2(3H)-one (43 mg, 0.10 mmol) in DMF (2 mL) was
added cesium carbonate (0.17 g, 0.50 mmol) and methyl iodide (19
.mu.L, 0.30 mmol). The resulting solution was stirred for 48 hr at
room temperature, after which it was partitioned between EtOAc and
H.sub.2O. The organic layer was separated, dried over MgSO.sub.4,
filtered, and concentrated in vacuo. The residue was dissolved in 6
N HCl (10 mL) and MeOH (5 mL), and the resulting mixture was
stirred at room temperature overnight, after which it was
partitioned between EtOAc and H.sub.2O. The organic layer was
concentrated in vacuo, and the residue was dissolved in EtOH (2
mL). Potassium acetate (100 mg) was then added, and the reaction
was stirred for 2 hr. The resulting solution was purified via
preparatory HPLC to give the title compound (24 mg, 73%). .sup.1H
NMR (CDCl.sub.3, 300 MHz): .delta. 9.72 (s, 1H), 8.35 (d, J=2.1 Hz,
1H), 7.60 (d, J=1.8 Hz, 1H), 6.71 (s, 2H), 3.95 (s, 6H), 3.90 (s,
3H), 1.49 (s, 6H). HPLC retention time: 1.80 minutes; MS ESI (m/z):
329.4 (M+1).sup.+, calc. 328.
Example 121
##STR00156##
[0530] Preparation of
5'-(3,4,5-trimethoxyphenyl)spiro[cyclopentane-1,3'-pyrrolo[2,3-b]pyridin]-
-2'(1'H)-one (Compound BP)
##STR00157##
[0532] To a solution of
5-(3,4,5-trimethoxyphenyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrro-
lo[2,3-b]pyridin-2(3H)-one (Compound BN, 43 mg, 0.10 mmol) in DMF
(2 mL) was added cesium carbonate (0.17 g, 0.50 mmol) and
1,4-diiodobutane (13 .mu.L, 0.10 mmol). The resulting solution was
stirred for 4 hr at room temperature, after which it was
partitioned between EtOAc and H.sub.2O. The organic layer was
separated, dried over MgSO.sub.4, filtered, and concentrated in
vacuo. The residue was dissolved in 6 N HCl (10 mL) and MeOH (5
mL), and the resulting mixture was stirred at room temperature
overnight, after which it was partitioned between EtOAc and
H.sub.2O. The organic layer was concentrated in vacuo, and the
residue was dissolved in EtOH (2 mL). Potassium acetate (100 mg)
was then added, and the reaction was stirred for 2 hr. The
resulting solution was purified via preparatory HPLC to give the
title compound (18 mg, 51%). .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. 9.53 (s, 1H), 8.32 (d, J=2.1 Hz, 1H), 7.56 (s, 1H), 6.69
(s, 2H), 3.95 (s, 6H), 3.90 (s, 3H), 2.28 (m, 2H), 2.24 (m, 2H),
1.97 (m, 4H). HPLC retention time: 2.00 minutes; MS ESI (m/z):
355.4 (M+1).sup.+, calc. 354.
Examples 122 and 123
##STR00158##
[0533] Preparation of
3,3-bis(cyclopropylmethyl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]py-
ridin-2(3H)-one (Example 22, Compound BQ) and
3-(cyclopropylmethyl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-
-2(3H)-one (Example 23, Compound BR)
##STR00159##
[0535] To a solution of
5-(3,4,5-trimethoxyphenyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrro-
lo[2,3-b]pyridin-2(3H)-one (43 mg, 0.10 mmol) in DMF (2 mL) was
added cesium carbonate (0.17 g, 0.50 mmol),
(bromomethyl)cyclopropane (10 .mu.L, 0.10 mmol), and potassium
iodide (83 mg, 0.50 mmol). The resulting solution was stirred for 4
hr at room temperature, after which it was partitioned between
EtOAc and H.sub.2O. The organic layer was separated, dried over
MgSO.sub.4, filtered, and concentrated in vacuo. The residue was
dissolved in 6 N HCl (10 mL) and MeOH (5 mL), and the resulting
mixture was stirred at room temperature overnight, after which it
was partitioned between EtOAc and H.sub.2O. The organic layer was
concentrated in vacuo, and the residue was dissolved in EtOH (2
mL). Potassium acetate (100 mg) was then added, and the reaction
was stirred for 2 hr. The resulting solution was purified via
preparatory HPLC to give the Compound Q (11.4 mg) and Compound R
(4.1 mg). Compound BQ: .sup.1H NMR (CDCl.sub.3. 300 MHz): .delta.
8.37 (d, J=2.1 Hz. 1H), 7.71 (s, 1H), 6.72 (s, 2H), 3.96 (s, 6H),
3.91 (s, 3H), 2.04 (m, 2H), 1.69 (m, 2H), 1.26 (m, 2H), 0.88 (m,
2H), 0.40 (m, 2H), 0.29 (m, 2H), -0.07 (m, 2H). HPLC retention
time: 2.49 minutes; MS ESI (m/z): 409.4 (M+1).sup.+, calc. 408.
Compound BR: .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. 8.31 (s,
1H). 7.92 (s, 1H), 6.69 (s, 2H), 3.95 (s, 6H), 3.91 (s, 3H), 3.50
(m, 1H), 2.18 (m, 1H), 1.78 (m, 1H), 1.26 (m, 1H), 0.83 (m, 2H),
0.25 (m, 2H). HPLC retention time: 2.32 minutes; MS ESI (m/z):
355.0 (M+1).sup.+, calc. 354.
Example 124
##STR00160##
[0536] Preparation of
1-(1H-indol-5-yl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3-
H)-one (Compound BS)
[0537] Commercially available 5-bromopyridine-2,3-diamine 3 was
converted to 6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one via
treatment with carbonyl diimidazole in THF at 60.degree. C., which
was then protected as the monoethoxy carbonyl derivative 4 in a
fashion similar to that described in J. Org. Chem., 1995,
1565-1582. Intermediate 4 was subjected to an NOE analysis, and
interactions between the 7-position hydrogen and the carbamate
ethyl group were apparent, supporting the structure that is shown
above. Following protection of the 3-position amine with a
tert-butyl carboxylate group and deprotection of the ethyl
carboxylate group using isopropyl amine, intermediate 6 was coupled
to indole-5-boronic acid using copper acetate in a mixture of
DCM/pyridine, after which it was deprotected using
TFA/CH.sub.2Cl.sub.2. To the resulting
6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one in
CH.sub.3CN (1 mL) in a microwave reaction vial was added
3,4,5-trimethoxyphenylboronic acid (30 mg, 0.14 mmol),
bis(triphenylphosphine)-palladium(II) dichloride (7.0 mg, 0.010
mmol), and 1 M Na.sub.2CO.sub.3 (1 mL). The resulting mixture was
de-gassed with Ar for 10 min, after which it was heated at
150.degree. C. for 10 min in a Personal Chemistry Optimizer. The
resulting mixture was partitioned between EtOAc and 1 M NaOH. The
organic layer was separated, dried over MgSO.sub.4, filtered, and
stripped to give a residue that was purified via preparatory HPLC
to give 1.8 mg of the title compound. HPLC retention time: 2.36
minutes; MS ESI (m/z): 417.4 (M+1).sup.+, calc. 416.
Example 125
Preparation of
1-(cyclopropylmethyl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyridin-
-2(3H)-one
##STR00161##
[0539] Intermediate 5 from Example 124 was alkylated with
(bromomethyl)cyclopropane using K.sub.2CO.sub.3 in acetone, after
which it was deprotected using TFA/CH.sub.2Cl.sub.3. To the
resulting
6-bromo-1-(cyclopropylmethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one in
CH.sub.3CN (1 mL) in a microwave reaction vial was added
3,4,5-trimethoxyphenylboronic acid (30 mg, 0.14 mmol),
bis(triphenylphosphine)-palladium(II) dichloride (7.0 mg, 0.010
mmol), and 1 M Na.sub.2CO.sub.3 (1 mL). The resulting mixture was
de-gassed with Ar for 10 min, after which it was heated at
150.degree. C. for 10 min in a Personal Chemistry Optimizer. The
resulting mixture was partitioned between EtOAc and 1 M NaOH. The
organic layer was separated, dried over MgSO.sub.4, filtered, and
stripped to give a residue that was purified via preparatory HPLC
to give 3.7 mg of the title compound. HPLC retention time: 1.90
minutes; MS ESI (m/z): 356.2 (M+1).sup.+, calc. 355.
Example 126
##STR00162##
[0540] Preparation of
1-(1H-indol-5-yl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyrazine
(Compound BW)
##STR00163##
[0542] Following a method described in Pteridines, 2002, Vol. 13,
65-72, Intermediate BB was heated in anhydrous DMF at 175.degree.
C. for 15 min in a Personal Chemistry Optimizer. To the resulting
6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazine 1 in CH.sub.3CN
(1 mL) in a microwave reaction vial was added
3,4,5-trimethoxyphenylboronic acid (30 mg, 0.14 mmol),
bis(triphenylphosphine)-palladium(II) dichloride (7.0 mg, 0.010
mmol), and 1 M Na.sub.2CO.sub.3 (1 mL). The resulting mixture was
de-gassed with Ar for 10 min, after which it was heated at
150.degree. C. for 10 min in a Personal Chemistry Optimizer. The
resulting mixture was partitioned between EtOAc and 1 M NaOH. The
organic layer was separated, dried over MgSO.sub.4, filtered, and
stripped to give a residue that was purified via preparatory HPLC
to give 4.7 mg of the title compound. HPLC retention time: 2.43
minutes; MS ESI (m/z): 402.8 (M+1).sup.+, calc. 401.
Example 127
Preparation of
1-(cyclopropylmethyl)-6-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-b]pyrazin-
e-2(3H)-thione (Compound BX)
##STR00164##
[0544] Compound BX was prepared by reacting Example 78 with
Lawesson's reagent in refluxing toluene. The resulting mixture was
partitioned between EtOAc and 1 M NaHCO.sub.3. The organic layer
was separated, dried over MgSO.sub.4, filtered, and stripped to
give a residue that was purified via preparatory HPLC to give 2.0
mg of the title compound. HPLC retention time: 2.29 minutes; MS ESI
(m/z): 373.2 (M+1).sup.+, calc. 372.
Example 128
##STR00165##
[0545] Preparation of
3-pyridin-3-ylmethylene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2-
,3-b]pyridin-2-one
[0546] To a solution of
5-(3,4,5-trimethoxy-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1,3-dihyd-
ro-pyrrolo[2,3-b]pyridin-2-one (157 mg, 0.365 mmol) in toluene (2
mL) was added triethylamine (56 .mu.l, 0.365 mmol), molecular
sieves 4 .ANG. (100 mg), and 3-pyridinecarboxaldehyde (38 .mu.l,
0.401 mmol). The resulting mixture was stirred overnight at room
temperature, after which it was filtered and partitioned between
DCM and H.sub.2O. The organic layer was separated, dried over
MgSO.sub.4, filtered, and concentrated in vacuo. The residue was
purified by silica gel chromatography eluting with 40-70%
EtOAc:Hexanes to yield the SEM-protected precursor as a mixture of
cis and trans isomers (101 mg, 53%). 41 mg (0.079 mmol) of this
material was dissolved in MeOH (1.5 ml), 6 N HCl (3 ml) was added,
and the mixture was stirred for 3 hours at 45.degree. C. The
reaction was quenched with 1 N NaOH (15 ml), neutralized by the
addition of saturated NaHCO.sub.3 and extracted with DCM. Silica
gel chromatography eluting with 0-5% MeOH:DCM yielded the title
compound (22 mg, 72%) as a cis/trans-mixture. .sup.1H NMR
(CDCl.sub.3, 300 MHz): 9.15 (d, J=4.8 Hz, 1H), 9.11 (bs, 1H), 9.02
(d, J=1.2 Hz, 1H), 8.98 (d, J=1.1, 1H), 8.69 (dd, J=0.9, 2.9 Hz,
1H), 8.66 (dd, J=0.9, 2.8 Hz, 1H), 8.39 (d, J=1.2 Hz, 1H), 8.37 (d,
J=1.2 Hz, 1H), 7.95 (m, 1H), 7.93 (s, 1H), 7.87 (d, J=1.1 Hz, 1H),
7.44 (m, 1H), 6.75 (s, 2H), 6.59 (s, 2H), 3.97 (s, 6H), 3.91 (s,
3H), 3.90 (s, 6H), 3.86 (s, 3H).
Example 129
Preparation of (E)- and
(Z)-3-pyridin-4-ylmethylene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrro-
lo[2,3-b]pyridin-2-one
##STR00166##
[0548] (E)- and
(Z)-3-pyridin-4-ylmethylene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrro-
lo[2,3-b]pyridin-2-one were prepared by a method analogous to that
described in Example 128 by substituting 3-pyridinecarboxaldehyde
for 4-pyridinecarboxaldehyde in the reaction with Compound BN. The
isomers were separated using silica gel chromatography eluting with
0-5% MeOH:DCM. Assignment of stereochemistry is tentatively based
on the .sup.1H NMR spectra. .sup.1H NMR (CDCl.sub.3, 300 MHz):
E-isomer: .delta. 8.91 (s, 1H), 8.76 (d, (J=3.6 Hz, 1H), 8.39 (d,
J=1.2 Hz, 1H), 8.02 (d, J=3.7 Hz, 1H), 7.91 (d, J=1.2 Hz, 1H), 7.52
(s, 1H), 6.74 (s, 2H), 3.96 (s, 6H). 3.91 (s, 3H). Z-isomer:
.delta. 9.01 (s, 1H), 8.78 (d, (J=3.5 Hz, 1H), 8.38 (d, J=1.2 Hz,
1H), 7.87 (s, 1H), 7.81 (d, J=1.2 Hz, 1H), 7.52 (d, J=6.1 Hz, 1H),
6.56 (s, 2H), 3.89 (s, 6H), 3.88 (s, 3H).
Example 130
Preparation of
3-benzylidene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyrid-
in-2-one
##STR00167##
[0550]
3-Benzylidene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b-
]pyridin-2-one was prepared by a method analogous to that described
in Example 128 by substituting 3-pyridinecarboxaldehyde for
benzaldehyde in the reaction with Compound BN. 15 mg (33%) of the
title compound were obtained.
Example 131
Preparation of
4-[2-oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyridin-3--
ylidenemethyl]-benzamide
##STR00168##
[0552]
4-[2-Oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyri-
din-3-ylidenemethyl]-benzamideone was prepared by a method
analogous to that described in Example 128 by substituting
3-pyridinecarboxaldehyde for 4-formylbenzamide in the reaction with
Compound BN. 25 mg (50%) of the title compound were obtained.
Example 132
Preparation of
3-[2-oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyridin-3--
ylidenemethyl]-benzamide
##STR00169##
[0554]
3-[2-Oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyri-
din-3-ylidenemethyl]-benzamideone was prepared by a method
analogous to that described in Example 128 by substituting
3-pyridinecarboxaldehyde for 3-formylbenzamide in the reaction with
Compound BN. 26 mg (52%) of the title compound were obtained.
Example 133
##STR00170##
[0555] Preparation of
5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one
(Intermediate BY)
##STR00171##
[0557] A mixture of 5-bromo-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one
(200 mg, 0.939 mmol), 3,4,5-trimethoxyphenylboronic acid (239 mg,
1.127 mmol) and dichlorobis(triphenylphosphine)palladium (II) (33
mg, 0.047 mmol) in CH.sub.3CN (5 ml) and 1 M Na.sub.2CO.sub.3 (5
ml) was heated in a microwave reactor for 10 min at 150.degree. C.
The reaction mixture was filtered, evaporated, partitioned between
water and DCM and purified by silica gel chromatography with 0-10%
MeOH:DCM to obtain 85 mg (30%) of compound #. .sup.1H NMR
(CDCl.sub.3/DMSO-d.sub.6, 300 MHz): .delta. 10.19 (bs, 1H), 8.18
(d, J=1.1 Hz, 1H), 7.54 (s, 1H), 6.57 (s, 2H), 3.80 (s, 6H), 3.75
(s, 3H), 3.47 (s, 2H).
Preparation of
4-[2-oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyridin-3--
ylidenemethyl]-benzonitrile
##STR00172##
[0559] A mixture of
5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one
(Intermediate BY, 42 mg, 0.14 mmol), 4-cyanobenzaldehyde (22 mg,
0.168 mmol), triethylamine (22 .mu.l, 0.168 mmol) and molecular
sieves 4 .ANG. (100 mg) in toluene (2 ml) was reacted at 80.degree.
C. for 1 d. The mixture was partitioned between DCM and water, the
aqueous phase extracted with DCM, combined organic phases dried,
evaporated and purified by silica gel chromatography (0-5%
MeOH:DCM) to obtain 31 mg (54%) of the title compound as a mixture
of (E)- and (Z)-isomers.
Example 134
Preparation of
3-[2-oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyridin-3--
ylidenemethyl]-benzonitrile
##STR00173##
[0561]
3-[2-oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyri-
din-3-ylidenemethyl]-benzonitrile was prepared by a method
analogous to that described in Example 133 by substituting
4-cyanobenzaldehyde for 3-cyanobenzaldehyde in the reaction with
Intermediate BY. 36 mg (62%) of the title compound were obtained as
a mixture of cis- and trans-isomers.
Example 135
##STR00174##
[0562] Preparation of
3-pyridin-3-ylmethyl-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3--
b]pyridin-2-one
[0563] To a solution of
3-pyridin-4-ylmethylene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2-
,3-b]pyridin-2-one (50 mg, 0.128 mmol) in MeOH (4 ml) was added
ammonium formate (245 mg, 3.85 mmol) and Pd/C (10%, 30 mg). The
mixture was stirred at room temperature for 3 hrs after which it
was filtered, evaporated, and partitioned between water and DCM.
The title compound (33 mg, 66%) was obtained after silica gel
chromatography eluting with 0-10% MeOH:DCM. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. 10.05 (s, 1H), 8.60 (d, J=2.6 Hz,
1H). 8.45 (d, J=1.1 Hz, 1H), 8.38 (d, J=1.2 Hz, 1H), 7.62 (d, J=4.7
Hz, 1H), 7.35 (dd, J=2.9, 4.7 Hz, 1H), 6.53 (d, J=1.2 Hz, 1H), 6.38
(s, 1H), 3.95 (m, 1H), 3.90 (m, 1H), 3.85 (s, 6H), 3.84 (s, 3H),
3.84 (m, 1H).
Example 136
Preparation of
3-pyridin-4-ylmethyl-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3--
b]pyridin-2-one
##STR00175##
[0565]
3-Pyridin-4-ylmethyl-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrol-
o[2,3-b]pyridin-2-one was prepared by a method analogous to that
described in Example 135. The title compound (14 mg, 61%) was
obtained after silica gel chromatography eluting with 0-8%
MeOH:DCM. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. 9.52 (bs, 1H),
8.54 (d, J=3.5 Hz, 1H), 8.32 (d, J=1.1 Hz, 1H), 7.18 (d, J=3.6 Hz,
1H), 7.12 (m, 1H), 6.54 (s, 1H), 3.91 (s, 6H), 3.89 (m, 1H), 3.88
(s, 3H), 3.54 (dd, J=3.1, 8.3 Hz, 1H), 3.03 (dd, J=5.6, 8.3 Hz,
1H).
Example 137
##STR00176##
[0566] Preparation of
3-benzyl-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2--
one
[0567] To a solution of
3-benzylidene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyrid-
in-2-one (41 mg, 0.106 mmol) in a mixture of MeOH (2 ml), THF (1
ml) and water (0.3 ml) was added sodium borohydride (40 mg, 1.06
mmol). The reaction was stirred at room temperature for 10 min
after which it was quenched by the addition of 1 N HCl and
partitioned between water and DCM. The residue was purified by
preparatory HPLC to yield the title compound (5.2 mg, 13%).
Example 138
Preparation of
4-[2-oxo-5-(3,4,5-trimethoxy-phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-
-3-ylmethyl]-benzamide
##STR00177##
[0569]
4-[2-Oxo-5-(3,4,5-trimethoxy-phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]p-
yridin-3-ylmethyl]-benzamide was prepared from
4-[2-oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyridin-3--
ylidenemethyl]-benzamideone by a method analogous to that described
in Example 137. The title compound (12 mg, 54%) was obtained after
silica gel chromatography eluting with 0-10% MeOH:DCM. .sup.1H NMR
(DMSO-d6, 300 MHz): .delta. 11.06 (s, 1H), 8.34 (d, J=1.5 Hz, 1H),
7.88 (s, 1H), 7.75 (d, J=5.0 Hz, 2H), 7.41 (d, J=0.5 Hz, 1H), 7.30
(s, 1H), 7.28 (d, J=5.0 Hz, 2H), 6.74 (s, 2H), 4.03 (m, 1H), 3.82
(s, 6H), 3.67 (s, 3H), 3.44 (dd, J=3.4, 8.2 Hz, 1H), 3.11 (dd,
J=4.6, 8.2 Hz, 1H).
Example 139
Preparation of
3,3-dibenzyl-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridi-
n-2-one
##STR00178##
[0571]
5-(3,4,5-Trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one
(95 mg, 0.316 mmol) and TMEDA (96 .mu.l, 0.623 mmol) were dissolved
in anhydrous THF (4 ml) and cooled to -78.degree. C. n-BuLi (1.6 M
in hexanes, 415 .mu.l, 0.664 mmol) was added dropwise. After
completed addition stirring was continued for 1 hr at -78.degree.
C. Benzyl bromide (41.3 .mu.l, 0.348 mmol) was added dropwise as a
10% solution in anh. THF. After completed addition the reaction was
allowed to warm up to room temperature while stirring overnight.
The reaction was quenched by the addition of MeOH, evaporated and
partitioned between water and DCM. Silica gel chromatography
eluting with 0-50% EtOAc:Hexanes yielded the title compound (47 mg,
38%). .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. 8.83 (s, 1H), 8.18
(d, J=1.2 Hz, 1H), 7.19 (d, J=1.2 Hz, 1H), 7.14 (m, 6H), 6.99 (m,
4H), 6.61 (s, 2H), 3.96 (s, 6H), 3.90 (s, 3H), 3.30 (d, J=8.0 Hz,
2H), 3.26 (d, J=8.0 Hz, 2H).
Example 140
Preparation of
1-(4-{4-[3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-piperaz-
in-1-yl)-ethanone
##STR00179##
[0573]
2-(4-Bromomethyl-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
(100 mg, 0.337 mmol). N-acetylpiperazine (47 mg, 0.37 mmol) and
K.sub.2CO.sub.3 (93 mg, 0.675 mmol) were combined in DMF (2.5 ml)
and stirred overnight at room temperature. The reaction was
quenched by the addition of water, extracted with DCM and dried.
The residue was taken up in CH.sub.3CN (2 ml), Intermediate B (120
mg, 0.275 mmol) and dichlorobis(triphenylphosphine)palladium (II)
(10 mg, 0.013 mmol) were added and the reaction was heated to
150.degree. C. in a microwave reactor for 20 min. The mixture was
partitioned between water and DCM, the organic phase dried,
evaporated and purified by silica gel chromatography using 0-5%
MeOH:DCM. 53 mg (46%) of the title compound were obtained. MS ESI
(m/z): 450.4 (M+1).sup.+, calc. 449.
Example 141
Preparation of
4-{4-[3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-1-methyl-p-
iperazin-2-one
##STR00180##
[0575]
4-{4-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-1-me-
thyl-piperazin-2-one was prepared by a method analogous to that
described in Example 140 by substituting N-acetylpiperazine for
1-methyl-piperazin-2-one. The title compound (14 mg, 28%) was
obtained after silica gel chromatography eluting with 0-10%
MeOH:DCM. MS ESI (m/z): 435.9 (M+1).sup.+, calc. 435.
Example 142
Preparation of
4-{4-[3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-piperazin--
2-one
##STR00181##
[0577]
4-{4-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-pipe-
razin-2-one was prepared by a method analogous to that described in
Example 140 by substituting N-acetylpiperazine for piperazin-2-one.
The title compound (22 mg, 45%) was obtained after silica gel
chromatography eluting with 0-10% MeOH:DCM. MS ESI (m/z): 422.2
(M+1).sup.+, calc. 421.
Example 143
Preparation of
4-{3-[3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-1-methyl-p-
iperazin-2-one
##STR00182##
[0579]
4-{3-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-1-me-
thyl-piperazin-2-one was prepared by a method analogous to that
described in Example 140 by substituting N-acetylpiperazine for
1-methyl-piperazin-2-one and
2-(4-bromomethyl-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
for 3-(bromomethyl)phenylboronic acid. The title compound (22 mg,
45%) was obtained after silica gel chromatography eluting with
0-10% MeOH:DCM. MS ESI (m/z): 436.4 (M+1).sup.+, calc. 435.
Example 144
Preparation of
4-{4-[3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-piperazine-
-1-carboxylic acid tert-butyl ester
##STR00183##
[0581]
4-{4-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-pipe-
razine-1-carboxylic acid tert-butyl ester was prepared by a method
analogous to that described in Example 140 by substituting
N-acetylpiperazine for N-Boc-piperazine. The title compound (20 mg,
33%) was obtained after silica gel chromatography eluting with 0-3%
MeOH:DCM. MS ESI (m/z): 508.2 (M+1)+, calc. 507.
Example 145
##STR00184##
[0582] Preparation of
{4-[3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-phenyl}-(4-methyl-pi-
perazin-1-yl)-methanone
[0583] 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic
acid (100 mg, 0.403 mmol), EDCI (97 mg, 0.504 mmol) and DMAP
(catalytic amount) were combined in CH.sub.3CN, stirred for 10 min
and treated with N-methylpiperazine (54 .mu.l, 0.484 mmol). The
mixture was stirred overnight at room temperature. An aliquot of
650 .mu.l was taken, combined with Intermediate B (50 mg, 0.107
mmol) and dichlorobis(triphenylphosphine)palladium (II) (10 mg,
0.013 mmol) and heated to 150.degree. C. in a microwave reactor for
20 min. The mixture was partitioned between water and DCM, the
organic phase dried, evaporated and purified by silica gel
chromatography using 0-6% MeOH:DCM. 13 mg (28%) of the title
compound were obtained. .sup.1H NMR (DMSO-d6, 300 MHz): .delta.
11.88 (d, J=1.5 Hz, 1H), 11.08 (s, 1H), 8.57 (d, J=2.1 Hz, 1H),
8.45 (d, J=1.8 Hz, 1H). 7.90 (s, 1H), 7.82 (d, J=8.4 Hz, 1H), 7.77
(d, J=2.4 Hz, 1H), 7.47 (m, 4H), 7.34 (t, J=2.6 Hz, 1H), 6.47 (t,
J=2.4 Hz, 1H), 3.58 (bs, 4H), 2.3 (bs, 4H), 2.18 (s, 3H).
Example 146
Preparation of
1-(4-{4-[3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-pipera-
zin-1-yl)-ethanone
##STR00185##
[0585]
1-(4-{4-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}--
piperazin-1-yl)-ethanone was synthesized by a method analogous to
that described in Example 144 by substituting N-methylpiperazine
for N-acetylpiperazine. The title compound (13 mg, 26%) was
obtained after silica gel chromatography eluting with 0-5%
MeOH:DCM. MS ESI (m/z): 464.2 (M+1).sup.+, calc. 463.
Example 147
Preparation of
{3-[3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-phenyl}-(4-methyl-pi-
perazin-1-yl)-methanone
##STR00186##
[0587]
{3-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-phenyl}-(4-met-
hyl-piperazin-1-yl)-methanone was synthesized by a method analogous
to that described in Example 144 by substituting
4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid for
3-carboxyphenylboronic acid. The title compound (23 mg, 49%) was
obtained after silica gel chromatography eluting with 5-10%
MeOH:DCM. MS ESI (m/z): 436.4 (M+1).sup.+, calc. 435.
Example 148
##STR00187##
[0588] Preparation of
4-[5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzamid-
e (Intermediate CA)
##STR00188##
[0590]
5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine
(Intermediate BZ, 483 mg, 1.01 mmol), 4-aminocarbonylphenylboronic
acid (196 mg, 1.22 mmol) and
dichlorobis(triphenylphosphine)palladium (II) (71 mg, 0.1 mmol)
were combined in CH.sub.3CN (10 ml) and 1 M Na.sub.2CO.sub.3 (10
ml) and stirred at 60.degree. C. for 3 hrs. Water was added and the
mixture was extracted with DCM and purified by silica gel
chromatography using 0-30% EtOAc/Hexanes. The title compound was
obtained in 79% yield (373 mg). .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. 8.51 (d, J=1.2 Hz, 1H), 8.20 (d, J=1.2 Hz, 1H), 8.11 (d,
J=5.1 Hz, 2H), 7.96 (s, 1H), 7.93 (d, J=5.0 Hz, 2H), 7.64 (d, J=5.1
Hz, 2H), 7.31 (d, J=4.8 Hz, 2H), 6.1 (bs, 1H), 5.7 (bs, 1H), 2.39
(s, 3H).
Preparation of
4-{4-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-pipe-
razine-1-carboxylic acid tert-butyl ester
##STR00189##
[0592]
4-[5-Bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-be-
nzamide (Intermediate CA, 200 mg, 0.425 mmol),
4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-
-carboxylic acid tert-butyl ester (212 mmg, 0.51 mmol) and
dichlorobis(triphenylphosphine)palladium (II) (15 mg, 0.021 mmol)
were combined in CH.sub.3CN (5 ml) and 1 M Na.sub.2CO.sub.3 (5 ml)
and reacted in a microwave reactor at 150.degree. C. for 10 min.
The mixture was filtered, water was added, extracted with EtOAc and
purified by silica gel chromatography using 0-8% MeOH:DCM. The
title compound was obtained in 46% yield (102 mg). .sup.1H NMR
(DMSO-d6, 300 MHz): .delta. 12.2 (bs, 1H). 8.63 (d, J=1.1 Hz, 1H),
8.54 (d, J=1.1 Hz, 1H), 8.08 (s, 1H), 7.98 (bs, 1H), 7.96 (d, J=5.1
Hz, 2H), 7.89 (m, 4H), 7.54 (d, J=4.9 Hz, 2H), 7.32 (bs, 1H), 3.6
(bs, 2H), 3.4 (bs), 1.41 (s, 9H).
Example 149
Preparation of
4-{5-[4-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-be-
nzamide, hydrochloride salt
##STR00190##
[0594] A solution of
4-{4-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-pipe-
razine-1-carboxylic acid tert-butyl ester (100 mg, 0.19 mmol) in
MeOH (3 ml) was treated with 4 N HCl in dioxane (2.5 ml) and
stirred at room temperature for 1 hr. The mixture was evaporated,
taken up in MeOH and evaporated again. This was repeated twice to
give 102 mg (116%) of the title compound. MS ESI (m/z): MS ESI
(m/z): 426.4 (M+1).sup.+, calc. 425.
Example 150
Preparation of
4-{5-[4-(4-acetyl-piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-
-3-yl}-benzamide
##STR00191##
[0596] To a solution of
4-{5-[4-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-be-
nzamide, hydrochloride salt (19 mg, 0.041 mmol) in MeOH (2 ml) was
added triethylamine (400 .mu.l, 2.88 mmol) and acetic anhydride
(100 .mu.l, 1.06 mmol). The mixture was stirred for 1 hr at room
temperature. EtOAc was added and washed with saturated aqu.
NaHCO.sub.3, water, brine and dried and evacuated. Purification on
silica gel employing 0-10% MeOH:DCM provided 4.7 mg (25%) of the
title compound. MS ESI (m/z): 468.3 (M+1).sup.+, calc. 467.
Example 151
Preparation of
4-{3-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-pipe-
razine-1-carboxylic acid tert-butyl ester
##STR00192##
[0598]
4-{3-[3-(4-Carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl-
}-piperazine-1-carboxylic acid tert-butyl ester was prepared by a
method analogous to that described in Example 148 by substituting
4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-
-carboxylic acid tert-butyl ester for
4-[3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-
-carboxylic acid tert-butyl ester. The title compound (109 mg, 49%)
was obtained after silica gel chromatography eluting with 0-8%
MeOH:DCM. .sup.1H NMR (DMSO-d6, 300 MHz): .delta. 12.18 (bs, 1H),
8.61 (d, J=1.2 Hz, 1H), 8.52 (d, J=1.2 Hz, 1H), 8.07 (s, 1H), 7.96
(m, 3H). 7.89 (m, 3H). 7.80 (s, 1H), 7.57 (t, J=4.6 Hz, 1H), 7.41
(d, J=4.6 Hz, 1H), 7.32 (s, 1H). 3.63 (bs, 2H), 3.4 (bs, 2H), 1.40
(s, 9H).
Example 152
Preparation of
4-{5-[3-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-be-
nzamide, hydrochloride salt
##STR00193##
[0600] The hydrochloride salt of
4-{5-[3-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-be-
nzamide was prepared by a method analogous to that described in
Example 149 by substituting
4-{4-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-pipe-
razine-1-carboxylic acid tert-butyl ester for
4-{3-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-pipe-
razine-1-carboxylic acid tert-butyl ester. 105 mg (128%) of the
title compound were obtained. .sup.1H NMR (DMSO-d6, 300 MHz):
.delta. 12.32 (s, 1H), 9.52 (s, 2H), 8.66 (d, J=1.8 Hz, 1H), 8.59
(d, J=1.8 Hz, 1H), 8.11 (d, J=2.7 Hz, 1H), 7.95 (m, 5H), 7.60 (t,
J=7.8 Hz, 1H), 7.52 (d, J=7.2 Hz, 1H), 7.36 (bs, 1H), 3.6-4.0 (bs,
8H).
Example 153
Preparation of
4-{5-[3-(4-acetyl-piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-
-3-yl}-benzamide
##STR00194##
[0602]
4-{5-[3-(4-Acetyl-piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]p-
yridin-3-yl}-benzamide was prepared by a method analogous to that
described in Example 150 by substituting
4-{5-[4-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-be-
nzamide, hydrochloride salt for
4-{5-[3-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-be-
nzamide, hydrochloride salt. 3.1 mg (14%) of the title compound
were obtained. .sup.1H NMR (CD.sub.3OD, 300 MHz): .delta. 8.56 (d,
J=1.2 Hz, 1H), 8.55 (d, J=1.2 Hz, 1H), 7.99 (d, J=4.2 Hz, 2H), 7.86
(m, 4H), 7.81 (d, J=1.8 Hz, 1H), 7.62 (t, J=4.6 Hz, 1H), 7.47 (dd,
J=0.7, 3.8 Hz, 1H), 3.5-3.9 (m, 8H), 2.14 (bd, 3H).
Example 154
Preparation of
4-[7-oxy-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benza-
mide
##STR00195##
[0604]
4-[5-(3,4,5-Trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benza-
mide (50 mg, 0.124 mmol), magnesium monoperoxyphthalic acid (80%,
300 mg, 0.46 mmol) and acetic acid (10 drops were combined in EtOH
(3 ml) and stirred at 50.degree. C. for 1 hr. After adding EtOAc
the mixture was washed with saturated NaHCO.sub.3, dried and
purified by silica gel chromatography using 0-8% MeOH:DCM to
provide 18 mg (33%) of the title compound. .sup.1H NMR (DMSO-d6,
300 MHz): .delta. 12.9 (bs, 1H), 8.62 (s, 1H), 8.14 (s, 1H), 8.0
(bs, 2H), 7.97 (d, J=5.0 Hz, 2H), 7.89 (d, J=5.0 Hz, 2H), 7.34 (bs,
1H). 7.04 (s, 2H), 3.89 (s, 6H), 3.70 (s, 3H).
Example 155
Preparation of
4-{5-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin--
3-yl}-benzamide
##STR00196##
[0606]
4-{5-[4-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]py-
ridin-3-yl}-benzamide was prepared by a method analogous to that
described in Example 148 by substituting
4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-
-carboxylic acid tert-butyl ester for
1-methyl-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-pipe-
razine. The title compound (24 mg, 44%) was obtained by
precipitation from DCM. .sup.1H NMR (DMSO-d6, 300 MHz): .delta.
12.1 (s, 1H), 8.57 (d, J=1.2 Hz, 1H), 8.48 (d, J=1.2 Hz, 1H), 8.05
(d, J=1.3 Hz, 1H), 7.98 (bs, 1H), 7.96 (d, J=5.0 Hz, 2H), 7.88 (d,
J=5.1 Hz, 2H), 7.73 (d, J=4.5 Hz, 2H), 7.40 (d, J=4.5 Hz, 2H), 7.31
(bs, 1H), 3.50 (s, 2H), 2.2-2.45 (bs, 8H), 2.15 (s, 3H).
Example 156
Preparation of
4-{5-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin--
3-yl}-benzamide
##STR00197##
[0608]
4-{5-[3-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]py-
ridin-3-yl}-benzamide was prepared by a method analogous to that
described in Example 148 by substituting
4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-
-carboxylic acid tert-butyl ester for
1-methyl-4-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-pipe-
razine. The title compound (8 mg, 15%) was obtained by
precipitation from DCM. .sup.1H NMR (DMSO-d6, 300 MHz): .delta.
12.1 (s, 1H), 8.56 (d, J=1.2 Hz, 1H), 8.46 (d, J=1.2 Hz, 1H), 8.05
(d, J=1.3 Hz, 1H), 7.96 (m, 3H), 7.88 (d, J=5.1 Hz, 2H), 7.66 (m,
2H), 7.45 (m, 1H), 7.31 (m, 2H), 3.55 (s, 2H), 2.2-2.45 (bs, 8H),
2.14 (s, 3H).
Example 157
Preparation of
4-{5-[4-(4-acetyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin--
3-yl}-benzamide
##STR00198##
[0610]
4-{5-[4-(4-Acetyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]py-
ridin-3-yl}-benzamide was prepared by a method analogous to that
described in Example 140 by substituting Intermediate B with
Intermediate CA. Purification by silica gel chromatography using
4-5% MeOH:DCM yielded the title compound (13 mg, 30%). MS ESI
(m/z): 454.1 (M+1).sup.+, calc. 453.
Example 158
Preparation of
4-{5-[4-(4-methyl-3-oxo-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]py-
ridin-3-yl}-benzamide
##STR00199##
[0612]
4-{5-[4-(4-Methyl-3-oxo-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,-
3-b]pyridin-3-yl}-benzamide was prepared by a method analogous to
that described in Example 140 by substituting Intermediate B with
Intermediate CA and N-acetylpiperazine for
1-methyl-piperazin-2-one. Purification by silica gel chromatography
using 4-5% MeOH:DCM yielded the title compound (4 mg, 10%). MS ESI
(m/z): 440.3 (M+1).sup.+, calc. 439.
Example 159
##STR00200##
[0613] Preparation of
4-[5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzylam-
ine (Intermediate CB)
##STR00201##
[0615]
5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine
(200 mg, 0.419 mmol), 4-aminomethylphenylboronic acid hydrochloride
(95 mg, 0.503 mmol) and dichlorobis(triphenylphosphine)palladium
(II) (29 mg, 0.042 mmol) were combined in CH.sub.3CN (5 ml) and 1 M
Na.sub.2CO.sub.3 (5 ml) and stirred at 60.degree. C. for 3 hrs.
EtOAc was added, the organic phase was washed with water, dried and
evaporated, to yield 136 mg (71%) of the title compound. MS ESI
(m/z): 455.9/458.1 (M+1).sup.+, calc. 455/457.
Preparation of
N-{4-[5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzy-
l}-acetamide (Intermediate CC)
##STR00202##
[0617]
4-[5-Bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-be-
nzylamine (Intermediate CB, 45 mg, 0.1 mmol) was combined with
triethylamine (45 .mu.l, 0.3 mmol) and acetic anhydride (11 .mu.l,
0.11 mmol) in anh. DCM (2 ml). The mixture was stirred for 2 hrs,
EtOAc, was added and washed with 0.5 N HCl, saturated NaHCO.sub.3,
water and brine. Evaporation yielded the title compound (48 mg,
96%). MS ESI (m/z): 498.1/500.1 (M+1).sup.+, calc. 497/499.
Preparation of
N-{4-[5-(3,4,5-Trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzyl}--
acetamide
##STR00203##
[0619]
N-{4-[5-Bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-
-benzyl}-acetamide (Intermediate CC, 24 mg, 0.048 mmol),
3,4,5-trimethoxyphenyl boronic acid (13 mg, 0.058 mmol) and
dichlorobis(triphenylphosphine)palladium (II) (2 mg, 0.002 mmol)
were combined in CH.sub.3CN (1 ml) and 1 M Na.sub.7CO.sub.3 (2 ml)
and heated in a microwave reactor at 150.degree. C. for 20 min.
EtOAc was added, washed with water, dried and purified by silica
gel chromatography eluting with 0-4% MeOH:DCM to give 11 mg (53%)
of the title compound. MS ESI (m/z): 432.2 (M+1).sup.+, calc.
431.
Example 160
Preparation of
2-phenyl-N-{4-[5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-
-benzyl}-acetamide
##STR00204##
[0621]
2-Phenyl-N-{4-[5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-
-3-yl]-benzyl}-acetamide was prepared by a method analogous to that
described in Example 159 by substituting acetic anhydride for
phenacetyl chloride. Purification by silica gel chromatography
using 0-4% MeOH:DCM yielded the title compound (9 mg, 38%). MS ESI
(m/z): 508.3 (M+1).sup.+, calc. 507.
Example 161
Preparation of
3-phenyl-N-{4-[5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-
-benzyl}-propionamide
##STR00205##
[0623]
3-Phenyl-N-{4-[5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-
-3-yl]-benzyl}-propionamide was prepared by a method analogous to
that described in Example 159 by substituting acetic anhydride for
phenylpropionyl chloride. Purification by silica gel chromatography
using 0-4% MeOH:DCM yielded the title compound (13 mg, 54%). MS ESI
(m/z): 522.4 (M+1).sup.+, calc. 521.
Example 162
##STR00206##
[0624] Preparation of
5-bromo-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1-(toluene-4-sulfony-
l)-1H-pyrrolo[2,3-b]pyridine (Intermediate CD)
##STR00207##
[0626]
5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine
(200 mg, 0.419 mmol),
1-methyl-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-pipe-
razine (160 mg, 0.503 mmol) and
dichlorobis(triphenylphosphine)palladium (II) (30 mg, 0.042 mmol)
were combined in CH.sub.3CN (5 ml) and 1 M Na.sub.2CO.sub.3 (5 ml)
and stirred at 60.degree. C. for 2 hrs. EtOAc was added and the
organic phase was washed with water, dried and evaporated.
Purification by silica gel chromatography using 0-20% MeOH:DCM
yielded 235 mg (104%) of the title compound. MS ESI (m/z):
539.0/541.2 (M+1).sup.+, talc. 538/540.
Preparation of
4-{3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin--
5-yl}-benzamide
##STR00208##
[0628]
5-Bromo-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1-(toluene-4-s-
ulfonyl)-1H-pyrrolo[2,3-b]pyridine (Intermediate CD. 70 mg, 0.13
mmol), aminocarbonylphenylboronic acid (26 mg, 0.156 mmol) and
dichlorobis(triphenylphosphine)palladium (II) (5 mg, 0.0065 mmol)
were combined in CH.sub.3CN (2 ml) and 1 M Na.sub.2CO.sub.3 (2 ml)
and reacted in a microwave reactor for 20 min at 150.degree. C.
Water was added and the aqueous phase was extracted with DCM, dried
and evaporated. Purification by reversed phase chromatography using
0-100% MeOH:water yielded 6 mg (11%) of the title compound. MS ESI
(m/z): 426.7 (M+1).sup.+, calc. 425.
Example 163
Preparation of
5-(1H-indol-5-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo-
[2,3-b]pyridine
##STR00209##
[0630]
5-(1H-Indol-5-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-p-
yrrolo[2,3-b]pyridine was prepared by a method analogous to that
described in Example 162 by substituting aminocarbonylphenylboronic
acid for indole-5-boronic acid. Purification by silica gel
chromatography using 0-10% MeOH:DCM yielded the title compound (28
mg, 60%). MS ESI (m/z): 422.4 (M+1).sup.+, calc. 421.
Example 164
##STR00210##
[0631] Preparation of
4-[5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-N-methyl-
-benzamide (Intermediate CE)
##STR00211##
[0633]
5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine
(350 mg, 0.73 mmol), 4-(N-methylaminocarbonyl)phenylboronic acid
(160 mg, 0.88 mmol) and dichlorobis(triphenylphosphine)palladium
(11) (52 mg, 0.073 mmol) were combined in CH.sub.3CN (10 ml) and 1
M Na.sub.2CO.sub.3 (10 ml) and stirred at 60.degree. C. for 5 hrs.
Water was added and the mixture was extracted with DCM, combined
organic phases were dried and evaporated to yield 428 mg (121%) of
the title compound. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. 8.50
(d, J=1.3 Hz, 1H), 8.20 (d, J=1.2 Hz, 1H), 8.09 (d, J=5.1 Hz, 2H),
7.94 (s, 1H). 7.87 (d, J=5.1, 2H), 7.61 (d, J=5.0 Hz, 2H), 7.31 (d,
J=5.0 Hz, 2H), 6.21 (bd, J=2.5 Hz, 1H), 3.06, (d, J=2.9 Hz, 3H),
2.39 (s, 3H).
Preparation of
N-methyl-4-[5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-be-
nzamide
##STR00212##
[0635]
4-[5-Bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-N--
methyl-benzamide (Intermediate CE, 100 mg, 0.206 mmol),
3,4,5-trimethoxyphenylboronic acid (53 mg, 0.248 mmol) and
dichlorobis(triphenylphosphine)palladium (II) (9 mg, 0.012 mmol)
were combined in CH.sub.3CN (2 ml) and 1 M Na.sub.2CO.sub.3 (2 ml)
and reacted in a microwave reactor for 20 min at 150.degree. C.
Water was added, the aqueous phase was extracted with DCM and the
organic phase was dried and evaporated. Purification by silica gel
chromatography using 0-8% MeOH:DCM yielded 40 mg (47%) of the title
compound. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. 12.09 (s, 1H),
8.59 (d, J=1.2 Hz, 1H), 8.48 (d, J=1.2 Hz, 1H), 8.43 (q, J=2.7 Hz,
1H), 8.04 (s, 1H), 7.94 (d, J=4.0, 2H), 7.91 (d, J=4.0 Hz, 2H),
7.00 (s, 2H), 3.89 (s, 6H), 3.70 (s, 3H), 2.80, (d, J=4.5 Hz,
3H).
Example 165
Preparation of
N-methyl-4-{5-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b-
]pyridin-3-yl}-benzamide
##STR00213##
[0637]
N-Methyl-4-{5-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo-
[2,3-b]pyridin-3-yl}-benzamide was prepared by a method analogous
to that described in Example 164 by substituting
3,4,5-trimethoxyphenylboronic acid for
1-methyl-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-ben-
zyl]-piperazine. Purification by precipitation from hot DCM yielded
the title compound (46 mg, 51%). NMR (CDCl.sub.3, 300 MHz): .delta.
12.09 (s, 1H), 8.57 (d, J=1.2 Hz, 1H), 8.48 (d, J=1.2 Hz, 1H), 8.43
(q, J=2.7 Hz, 1H), 8.05 (d, J=1.5 Hz, 1H), 7.92 (d, J=5.2 Hz, 2H),
7.89 (d, J=5.2 Hz, 2H), 7.73 (d, J=4.9 Hz, 2H), 7.40 (d, J=4.9 Hz,
2H), 3.50 (s, 2H), 2.81, (d, J=2.7 Hz, 3H), 2.2-2.45 (bs, 8H), 2.15
(s, 3H).
Example 166
##STR00214##
[0638] Preparation of
5-bromo-3-(4-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyrid-
ine (Intermediate CF)
##STR00215##
[0640]
5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine (70
mg, 0.147 mmol), 4-fluorophenylboronic acid (25 mg, 0.176 mmol) and
dichlorobis(triphenylphosphine)palladium (II) (10 mg, 0.015 mmol)
were combined in CH.sub.3CN (2 ml) and 1 M Na.sub.2CO.sub.3 (2 ml)
and stirred at 60.degree. C. for 3 hrs. EtOAc was added and the
mixture was washed with water, dried and evaporated to yield 73 mg
(112%) of the title compound. MS ESI (m/z): 445.1/447.2
(M+1).sup.+, calc. 444/446.
Preparation of
3-(4-fluoro-phenyl)-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine
##STR00216##
[0642]
5-Bromo-3-(4-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b-
]pyridine (37 mg, 0.083 mmol), 3,4,5-trimethoxyphenylboronic acid
(21 mg, 0.1 mmol) and dichlorobis(triphenylphosphine)palladium (II)
(3 mg, 0.004 mmol) were combined in CH.sub.3CN (1.5 ml) and 1 M
Na.sub.2CO.sub.3 (2 ml) and reacted in a microwave reactor for 20
min at 150.degree. C. EtOAc was added and the mixture was washed
with water, dried, evaporated and purified by silica gel
chromatography using 0-2% MeOH:DCM to yield 9 mg (29%) of the title
compound. MS ESI (m/z): 379.2 (M+1).sup.+, calc. 378.
Example 167
##STR00217## ##STR00218##
[0643] Preparation of
2-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazole
(Intermediate CG)
##STR00219##
[0645] 2-(4-Bromo-phenyl)-1H-imidazole (300 mg, 1.3 mmol),
bis(pinacolato)diboron (376 mg, 1.48 mmol), KOAc (400 mg, 4.03
mmol) and PdCl.sub.2(dppf).CH.sub.2Cl.sub.2 (50 mg, 0.067 mmol)
were combined in DMSO (8 ml) and stirred t 80.degree. C. overnight.
EtOAc was added, washed with water, dried, evaporated and purified
by silica gel chromatography eluting with 0-5% MeOH:DCM to give 116
mg (36%) of the title compound. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. 7.86 (s, 4H), 7.18 (s, 2H), 1.36 (s, 12H).
Preparation of
5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine (Intermediate
CH)
##STR00220##
[0647] 5-Bromo-1H-pyrrolo[2,3-b]pyridine (1.54 g, 7.83 mmol).
3,4,5-trimethoxyphenylboronic acid (1.83 g, 8.61 mmol) and
dichlorobis(triphenylphosphine)palladium (II) (275 mg, 0.39 mmol)
were combined in CH.sub.3CN (10 ml) and 1 M Na.sub.2CO.sub.3 (10
ml) and reacted in a microwave reactor for min at 150.degree. C.
EtOAc was added and the mixture was washed with water, brine,
dried, evaporated and purified by silica gel chromatography using
0-2% MeOH:DCM to yield 1.86 g (84%) of the title compound. .sup.1H
NMR (CDCl.sub.3, 300 MHz): .delta. 9.9 (bs, 1H), 8.54 (d, J=2.1 Hz,
1H), 8.11 (d, J=2.1 Hz, 1H), 7.41 (t, J=2.1 Hz, 1H), 6.82 (s, 2H),
6.58 (t, J=1.5 Hz, 1H), 3.96 (s, 6H), 3.92 (s, 3H).
Preparation of
3-iodo-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine
(Intermediate CI)
##STR00221##
[0649] To a solution of
5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine (510 mg, 1.79
mmol) in acetone (100 ml) was added N-iodosuccinimide (444 mg, 1.97
mmol) under stirring. After 1 hr the mixture was evaporated and
purified by silica gel chromatography using 0-2% MeOH:DCM to give
the title compound (870 mg, 118%). MS ESI (m/z): 411.1 (M+1).sup.+,
calc. 410.
Preparation of
3-iodo-1-(toluene-4-sulfonyl)-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3--
b]pyridine (Intermediate CJ)
##STR00222##
[0651] A solution of
3-iodo-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine (870
mg, 2.12 mmol) in anh. THF (10 ml) was cooled to 0.degree. C. and
NaH (60% dispersion, 130 mg, 3.18 mmol) was added. After 20 min
tosyl chloride (450 mg, 2.33 mmol) was added and the mixture was
allowed to warm to room temperature. After 3 hrs the mixture was
cooled to 0.degree. C. and quenched by the addition of 0.5 N HCl.
The product was extracted with DCM and purified by silica gel
chromatography using DCM as an eluent affording 648 mg (54%).
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. 8.61 (d, J=2.4 Hz, 1H),
8.12 (d, J=8.4 Hz, 1H), 7.91 (s, 1H), 7.74 (d, J=2.1 Hz, 1H), 7.31
(d, J=8.4 Hz, 2H), 6.73 (s, 2H), 3.94 (s, 6H), 3.90 (s, 3H), 2.39
(s, 3H).
Preparation of
3-[4-(1H-imidazol-2-yl)-phenyl]-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,-
3-b]pyridine
##STR00223##
[0653]
3-Iodo-1-(toluene-4-sulfonyl)-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrol-
o[2,3-b]pyridine (Intermediate CJ, 30 mg, 0.053 mmol),
2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazole
(Intermediate CG, 18 mg, 0.064 mmol) and
dichlorobis(triphenylphosphine)palladium (II) (2 mg, 0.003 mmol)
were combined in CH.sub.3CN (1 ml) and 1 M Na.sub.2CO.sub.3 (1 ml)
and stirred at 60.degree. C. for 2 d. Additional Intermediate CG
(18 mg, 0.064 mmol) was added and stirring was continued for
another day. EtOAc was added and the mixture was washed with water,
dried, evaporated and purified by silica gel chromatography using
0-5% MeOH:DCM to yield 5 mg (22%) of the title compound. MS ESI
(m/z): 427.2 (M+1).sup.+, calc. 426.
Biological Activity
[0654] The activity of the compounds in Examples 1-138 as MLK
inhibitors is illustrated in the following assays. The other
compounds listed above, which have not yet been made and/or tested,
are predicted to have activity in these assays as well.
Radiometric Filter Plate MLK3 Assay
[0655] 200 ng (130 nM) MLK3 (Dundee, DU8313) was incubated with 1
.mu.M inactive MKK7b (Dundee, DU703) in the presence of 2 .mu.M
cold ATP (K.sub.m) and 0.5 .mu.Ci/assay .sup.33P ATP and
appropriate concentrations of compounds. After a twenty minute
incubation, the reactions were washed through filter plates and
read on a scintillation counter. Results are shown in Table 4
below, in which +++ indicates .ltoreq.0.1 .mu.M, ++ indicates
>0.1 .mu.M and .ltoreq.1 .mu.M, and + indicates >1 .mu.M.
TABLE-US-00004 TABLE 4 Ex. MK3 IC.sub.50 MW 1 ++ 399.45 2 ++ 369.43
3 +++ 366.50 4 +++ 325.50 5 +++ 354.50 6 ++ 340.39 7 +++ 408.50 8
+++ 324.50 9 +++ 326.36 10 ++ 394.48 11 +++ 402.50 12 ++ 348.41 13
++ 353.43 14 ++ 309.13 15 +++ 375.43 16 +++ 417.47 17 +++ 377.41 18
+++ 376.42 19 +++ 404.47 20 + 304.32 21 ++ 358.45 22 + 366.83 23 ++
301.35 24 +++ 413.48 25 +++ 403.44 26 +++ 373.14 27 ++ 358.14 28 ++
329.13 29 + 338.77 30 +++ 339.15 31 ++ 422.54 32 +++ 421.55 33 +++
366.47 34 +++ 467.58 35 + 426.52 36 +++ 400.44 37 +++ 370.41 38 +++
355.40 39 +++ 469.55 40 +++ 417.43 41 ++ 431.16 42 + 357.12 43 +
369.16 44 + 328.11 45 ++ 343.11 46 + 355.14 47 ++ 387.13 48 +
395.03 49 + 375.11 50 ++ 372.13 51 ++ 371.40 52 ++ 412.45 53 ++
366.39 54 ++ 343.35 55 +++ 373.37 56 + 366.39 57 +++ 486.53 58 ++
379.33 59 +++ 379.33 60 +++ 372.39 61 + 363.33 62 +++ 403.40 63 ++
385.39 64 + 385.43 65 + 387.40 66 + 426.50 67 ++ 485.55 68 ++
408.42 69 + 378.39 70 + 334.34 71 + 319.33 72 +++ 431.45 73 +
410.27 74 +++ 370.41 75 + 340.39 76 ++ 296.33 77 + 281.32 78 ++
356.38 79 ++ 326.36 80 + 335.20 81 + 282.30 82 + 267.29 83 ++
418.42 84 ++ 357.37 85 + 342.36 86 + 351.41 87 + 388.39 88 + 329.32
89 + 413.44 90 ++ 418.42 91 ++ 388.39 92 + 344.34 93 ++ 329.32 94 +
370.41 95 + 356.39 96 ++ 435.46 97 ++ 361.38 98 + 346.37 99 +
373.44 100 + 430.49 101 + 418.46 102 +++ 418.42 103 ++ 388.39 104
++ 413.44 105 ++ 378.39 106 ++ 348.36 107 ++ 425.49 108 ++ 439.52
109 + 464.48 110 +++ 418.46 111 ++ 388.39 112 +++ 418.42 113 +++
418.42 114 ++ 394.50 115 ++ 364.50 116 ++ 389.50 117 + 296.33 118
++ 325.37 119 + 390.83 120 ++ 328.37 121 ++ 354.41 122 + 413.40 123
++ 354.41 124 ++ 416.44 125 + 355.40 126 + 401.43 127 + 372.45 128
++ 389.40 129 + 389.40 130 + 388.42 131 ++ 431.44 132 + 431.44 133
+ 413.43 134 + 413.43 135 + 391.42 136 + 391.42 137 + 390.44 138 +
433.46 139 ++ 480.55 140 + 449.55 141 +++ 435.52 142 +++ 421.49 143
+++ 435.52 144 +++ 507.63 145 ++ 435.52 146 +++ 463.53 147 +++
435.52 148 +++ 525.60 149 +++ 425.48 150 ++ 467.52 151 +++ 525.60
152 ++ HCl-salt: 461.94 153 ++ 467.52 154 ++ 419.43 155 ++ 425.53
156 +++ 425.53 157 +++ 453.54 158 +++ 439.51 159 +++ 431.48 160 ++
507.58 161 ++ 521.61 162 +++ 425.53 163 + 421.54 164 + 417.46 165
+++ 439.55 166 ++ 378.40 167 ++ 426.47
Pharmacokinetic Studies
[0656] Compounds disclosed herein may be evaluated in
pharmacokinetic assays and models to determine absorption,
distribution, metabolism, and excretion parameters. The choice and
tailoring of in vitro and ex vivo assays and in vivo models will
vary according to the route of administration/formulation,
indication under study, properties of test compounds, etc., as well
as according to such factors as costs, availability of technology
and resources, etc. Such parameters are well known in the fields of
pharmacology and drug development. It is within the capacity of one
skilled in the art to design and carry out, such work, or to
outsource it to a capable third party.
Pharmacokinetic Evaluation in Mice
[0657] Several compounds disclosed herein were evaluated in a
standard murine pharmacokinetic model. Compounds were selected that
exhibited reasonable solubility and metabolic stability, and good
predicted blood brain barrier penetration, based on low molecular
weight, a low number of hydrogen bond donors, log D within a range
of 2-4, and low polar surface area.
[0658] Compounds were dissolved in either 5% DMSO, 40% PEG400, and
55% saline (pH=8) or % DMSO, 40% PEG400, and 55% (20% HP-.beta.-CD
in deionized water; pH=8) to yield a nominal concentration of 2
mg/mL for intravenous administration. Compounds were administered
via a single intravenous (IV) injection in CL57 BL/6 mice at 10
mg/kg in DMSO/PEG400 solution. Three mice in each group were used
for blood and brain collection at each time point. Blood samples
(300 .mu.L) were collected via the retro-orbital vein predose and
at 5 min, 0.25, 0.50, 1, 2, 4, 6, 8, and 24 hours postdose. Blood
samples were placed into tubes containing sodium heparin and
centrifuged under refrigerated conditions at 8000 rpm for 6 minutes
to separate plasma from the samples. The brain of each animal was
collected after the final blood collection. The whole tissue was
harvested, excised and rinsed by saline, dried by filter paper, and
then placed into one tube per tissue per animal. All samples were
stored at -20.degree. C. until bioanalysis.
[0659] Compound concentrations in plasma and brain homogenate were
determined using a high performance liquid chromatography/mass
spectrometry (HPLC/MS/MS) method (Agilent 1100 series HPLC, AB Inc.
API4000 triple-quadrupole with an ESI interface and Analyst 1.4
software).
[0660] Results in the form of area under the
time-versus-concentration curve (AUC) are given below in Table 5.
Additional compounds disclosed herein can be tested according to
this method and are expected to exhibit similar results.
TABLE-US-00005 TABLE 5 AUC Plasma AUC Brain + indicates
.gtoreq.1500 + indicates .gtoreq.500 Ex. - indicates <1500 -
indicates <500 1 + + 4 - - 9 + + 17 + - 18 + - 32 + +
Animal Models of Efficacy
[0661] Compounds disclosed herein may be tested in any number of
well-known and publicly available animal models of efficacy for
diseases in which MLK3 inhibition may play a therapeutic role. It
is within the capacity of one skilled in the art to select and
tailor such a model.
Testing of Compounds for Efficacy in Established HIV-1-Encephalitic
(HIVE) Mouse Model
[0662] For example, compounds disclosed herein can be ranked for in
vivo efficacy in a mouse model relevant to NeuroAids (D. Eggert,
The Journal of Immunology, in press, November 2009.) Test compounds
selected may be prioritized based on MLK3 potency and favorable
exposure in the brain, but this is not an absolute requirement.
Four-week-old male CB-17/IcrCrl-SCIDbr (CB17/SCID) mice may be
purchased from Charles River Laboratory. HIV-1ADA-infected MDM
(1.5.times.10.sup.5 cells infected at an MOI of 0.1 in 5 ml) is
stereotactically injected intracranially after 1 day of viral
infection and referred to as HIVE mice. The test compound is then
administered i.p. daily for 7 days at doses 0.5, 1.0, 1.5, 5.0, and
15.0 mg/kg/d (where, e.g., n=4 mice/treatment group). Vehicle only
serves as the control. CB17/SCID mice receive intracranial (i.c.)
injections of media (sham-operated) and serve as additional
controls. Animals are treated with vehicle or test compound (i.e.,
a compound as disclosed herein) starting 1 d post-i.c, injection
and for 7 d after MDM injections and test compound treatments.
Dosing parameters, number per group, etc. may be varied as needed,
and such variations are within the skill of one skilled in the
art.
Histopathology and Image Analysis
[0663] Brain tissue is collected at necropsy, fixed in 4%
phosphate-buffered paraformaldehyde, and embedded in paraffin.
Paraffin blocks are cut until the injection site of the human MDM
is identified. HIV-1 p24 Ag (cloneKal-1; Dako, Carpinteria, Calif.)
is used to test for virus-infected human MDM. For each mouse.
30-100 serial (5-mm-thick) sections are cut from the injection site
and three to seven sections (10 sections apart) analyzed. Abs to
vimentin intermediate filaments (clone VIM 3B4; Boehringer
Mannheim, Indianapolis, Ind.) are used for detection of human cells
in mouse brains. Mouse microglia are detected by Abs to Iba-1
(WAKO, Osaka, Japan), and astrocytes are detected by Abs for glial
fibrillaryacidic protein ([GFAP] Dako). NeuN, MAP-2 (both from
Chemicon International), and H chain (200 kDa) neurofilaments
(Dako) are used for detection of neurons. All sections are
counterstained with Mayer's hematoxylin. The numbers of human MDM
and HIV-1 p24 Ag-positive cells are counted with a Nikon
Microphot-FXA microscope. All obtained images are imported into
Image-Pro Plus, v. 4.0 (Media Cybernetics, Silver Spring, Md.) for
quantifying area (%) of GFAP, Iba-1, MAP-2, and NeuN positive
staining. Efficacious MLK inhibitors will exhibit a dose-dependent
reduction in microgliosis and restoration of normal synaptic
architecture relative to control animals. Compounds disclosed
herein can be tested according to this method and are expected to
exhibit similar results.
[0664] From the foregoing description, one skilled in the art can
easily ascertain the essential characteristics of this invention,
and without departing from the spirit and scope thereof, can make
various changes and modifications of the invention to adapt it to
various usages and conditions.
* * * * *